Modelling of the conformational flexibility of human immunodeficiency virus type 1 reverse transcriptase by Titmuss, Stephen James
University of Wollongong 
Research Online 
University of Wollongong Thesis Collection 
1954-2016 University of Wollongong Thesis Collections 
1998 
Modelling of the conformational flexibility of human immunodeficiency 
virus type 1 reverse transcriptase 
Stephen James Titmuss 
University of Wollongong 
Follow this and additional works at: https://ro.uow.edu.au/theses 
University of Wollongong 
Copyright Warning 
You may print or download ONE copy of this document for the purpose of your own research or study. The University 
does not authorise you to copy, communicate or otherwise make available electronically to any other person any 
copyright material contained on this site. 
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, 
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe 
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court 
may impose penalties and award damages in relation to offences and infringements relating to copyright material. 
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the 
conversion of material into digital or electronic form. 
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily 
represent the views of the University of Wollongong. 
Recommended Citation 
Titmuss, Stephen James, Modelling of the conformational flexibility of human immunodeficiency virus 
type 1 reverse transcriptase, Master of Science (Hons.) thesis, Department of Chemistry, University of 
Wollongong, 1998. https://ro.uow.edu.au/theses/2783 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Modelling of the 
Conformational Flexibility of 
Human Immunodeficiency Virus 
Type 1 Reverse Transcriptase 
A thesis submitted in (partial) fulfilment of the 
requirements for the award of the degree of 
Honours Master of Science 
from 
The University of Wollongong 
by 
Stephen James Titmuss, BSc, BCompSc 
Supervisors : Dr Renate Griffith 
Dr Paul A. Keller 
Department of Chemistry 
1998 
ACKNOWLEDGMENTS 
I would like to express my gratitude to my supervisors, Drs Renate Griffith and Paul 
Keller, for their invaluable advice, guidance, encouragement and patience, during this 
project. 
Thanks also to all members of the lab, particularly Adam, Glenn, Parisa, Sarah and Tien, 
for making my life bearable, and memorable, throughout the year. 
Sincere appreciation goes also to Jackie, for her patience and understanding while 
completing this degree, and to my parents, for their support and financial assistance 
when most needed. 
Ill 
ABSTRACT 
Reverse transcriptase (RT) performs several critical roles in the replicative cycle of the 
human immunodeficiency virus (HIV), and thus considerable effort has been directed 
towards this enzyme as a target for therapies treating the acquired immune deficiency 
syndrome (AIDS). A striking feature of RT is its considerable conformational flexibility 
(believed to be essential for several of its catalytic actions), which has complicated 
attempts at traditional structure based design of nonnucleoside RT inhibitors (NNRTIs). 
Furthermore, the widely differing conformations observed in the X-ray crystal 
structures of native and NNRTI complexed RT make accurate and objective comparison 
of relative conformation difficult, as no consensus on the "correcf alignment of 
structures exists. Effective rational inhibitor design and optimisation will require a 
comprehensive understanding of the modes of structural flexibility available to RT and 
their correlation with inhibitor structure. 
This study has developed several methods and computational tools to aid the objective 
comparison of protein conformation, and, through their application to RT, has 
addressed some of the earliest steps towards this goal. Difference distance matrices 
were used to study the relative geometry of apo and NNRTI bound RT crystal 
structures and characterise the regions of the enzyme that possess different degrees of 
conformational rigidity and flexibility. This technique has the advantage of not requiring 
superposition of the structures, so enabling an objective interpretation of the backbone 
movements induced by NNRTI binding to RT. It was observed that, while a significant 
portion of the enzyme was largely unaffected by complexation with the inhibitors, the 
thumb subdomain and small segments around the polymerase active site and inhibitor 
binding site underwent considerable conformational rearrangement. The determination 
of the structurally invariant regions of RT, by DDM analysis, was subsequently 
applied to the development of a protocol for the superposition of the RT crystal 
structures. This superposition protocol, based on the p51, RNase H and connection 
regions, was used to compare in detail the relative conformational change of small, 
selected regions of the enzyme, without the misalignment created by incorporation of 
the flexible RT subdomains, or the bias introduced by superposing only very small 
regions of the protein. It has been determined from these superposition studies that the 
conformational rearrangements around the NNRTI binding pocket are restricted 
primarily to side chain movement, with little adjustment of the backbone position. 
This observation was supported by the automated docking of multiple conformations of 
the NNRTI s into each of the binding pocket geometries determined from the crystal 
structures. These results suggest that, while the structure of the pocket in each NNRTI 
complex contains sufficient information to accurately reproduce the orientation of the 
ligand observed in the complex, only minor conformational adjustments of the other 
NNRTIs are required to allow them to fit into each pocket shape. This is consistent 
with there being no dramatic changes in pocket structure, for example by movement of 
the backbone, but some finer adjustment of shape, through repositioning of side chains. 
The steric and electronic complementarity of the docked inhibitors was considerable, 
showing good alignment of the 7t-systems and conservation of the "butterfly" shape in 
the docked conformations, and may lead to the development of a type of 
pharmacophore for the NNRTIs. 
Software to examine the changes in protein backbone dihedral angles was also developed, 
to allow an alternative method of examining the conformational changes occurring in the 
enzyme. Preliminary investigations using this method with RT are consistent with there 
being little change in secondary structure upon complexation with an inhibitor, with 
many changes being centred around changes in conformation of specific residues. The 
tools developed in this project will aid further detailed investigation into the 
conformational flexibility of RT. 
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CHAPTER ONE 
INTRODUCTION 
1.1 HIV and AIDS 
The acquired immune deficiency syndrome (AIDS) and its causative agent,^ the 
human immunodeficiency virus (HIV), are major public health problems. It has been 
estimated that almost 30 million people had been infected with the virus worldwide by 
the end of 1996, with AIDS killing 1.5'million people in that year alone. The 
HIV/AIDS pandemic has been countered by an unprecedented research effort into 
characterisation of the virus and development of effective therapies. While the 
widespread use of anti-HIV chemotherapy has delayed the onset of AIDS in infected 
persons, the long term survival of patients remains poor,^ and there is evidence that 
more virulent strains of HIV are emerging^ Thus, a pressing need for further 
development of potent and selective anti-HIV drugs remains. This study has 
investigated some aspects of the molecular flexibility of the reverse transcriptase (RT) 
enzyme, a well characterised and effective therapeutic target, that may be applicable to 
structure based design of antiviral agents. 
1.1.1 HIV Structure and Replicative Cycle 
Since the discovery of HIV '̂̂  an extensive understanding of the molecular, 
genetic, replicative and pathogenic features of the virus has been developed. The two 
known subtypes of the virus, HIV-1 and HIV-2, are retroviruses that belong to the 
lentivirus family and are genetically related to a range of other primate and mammalian 
immunodeficiency viruses. 
The extracellular HIV-1 virus particle, like other retroviruses, contains the 
RNA encoded genome, the three essential retroviral enzymes, the structural proteins and 
the envelope lipid membrane and glycoproteins.^ The virion, represented schematically 
in Figure 1, is a spherical particle approximately 110 nm in diameter, ^ consisting of the 
viral capsid and surrounding viral envelope. The conical capsid is composed of the p24 
major capsid protein and contains two molecules of the single stranded 9000 base RNA 
genome, each in a closely associated complex with the nucleocapsid proteins p7 and p9, 
and multiple copies of the retroviral protease, reverse transcriptase and integrase 
enzymes.^® The capsid is surrounded by the myristoylated pi 7 matrix protein and the 
virion envelope, containing a lipid bilayer membrane derived from the plasma membrane 
of the host cell and the viral glycoproteins gpl20 and gp41.^° The membrane 
glycoproteins form hetero-oligomers,^' with the gpl20 domain forming one of 
RNA 
Protsase 
Integras« 
Figure 1 Schematic Diagram of HIV Virion 
Reproducedfrom Barre-Sinoussi, 1996. 
approximately 72 "knobs" bound to the virion surface by the gp41 transmembrane 
subunits. ^̂  
The protruding gpl20 "knob" binds to cellular CD4 receptors, primarily found 
on immune system monocytes and helper T lymphocytes, allowing fusion of the host 
cell membrane and viral envelope, and the subsequent entry of the viral capsid into the 
cell. ^̂ ^̂  It has been proposed that virion binding to CD4^ cells also requires the 
presence of a co-receptor of the 7tm family. 
The capsid and RNA is then, at least partially, uncoated^ to allow 
transcription of the viral genome. Transcription of the viral RNA to pro viral DNA is 
facilitated by the viral enzyme reverse transcriptase (RT), which polymerises a double 
stranded DNA chain using the single stranded viral RNA genome as a template. 
The double stranded DNA genome is imported into the nucleus of the host cell 
in a protein complex containing the pi 7 matrix protein and the viral integrase enzyme. ^̂  
The integrase enzyme then cleaves the host DNA, and joins the viral DNA into the host 
cell DNA. Once this integration step occurs the cell, and the patient, become 
permanently infected, as the pro virus acts as a normal cellular gene and so all progeny 
cells will contain the viral genome. The integrated provirus may remain latent for 
many cell generations before expression of the virus begins. ^̂  Expression of the 
provirus is performed by the host cellular reproduction mechanism, but is regulated 
primarily by several HIV encoded accessory proteins. 
Assembly of mature virions occurs via aggregation of the polyprotein 
precursors and RNA at the plasma membrane of the host. Posttranslational addition of 
myristic acid to selected domains of the precursor proteins provides a hydrophobic 
region for interaction with the membrane, while association of the viral RNA with the 
p9 domain of the precursor protein directs the RNA to the site of assembly. ^ The 
precursor proteins are cleaved into individual viral proteins by the viral protease 
enzyme at a relatively late stage of virus assembly, creating the free integrase, RT and 
protease enzymes, and the capsid, nucleocapsid and matrix proteins. ^ The envelope 
glycoproteins gp41 and gpl20 are cleaved from their precursor and form oligomeric 
subunits prior to incorporation into the plasma membrane. ^ Upon formation of the p24 
protein shell around the viral capsid, the lipid membrane-envelope protein complex is 
incorporated into the budding virus particle, and new virions released from the infected 
cell. Figure 2 schematically illustrates the entire infection and replication cycle. 
HIV may also be spread by cell-cell, as opposed to virus-cell, contact. ^̂  The 
overproduction of the envelope glycoproteins results in the infected cell expressing the 
gpl20 and gp41 envelope proteins on the cell surface.^ Thus, when infected cells, 
expressing gpl20 and uninfected cells expressing CD4 make contact, they bind and 
fusion of cell membranes occurs, in a similar manner to virus-cell binding and fusion. 
The product of this is formation of large multinucleated cells, or syncytia, and 
represents a mechanism of viral infection that does not require the production of mature 
virions. ^̂  
The HIV replicative cycle is highly prolific, producing new virions and infected 
cells rapidly and continuously,^^ with over 10 billion new virions being produced per 
day. ̂ ^ The average lifespan of free plasma virions is 8 hours, with approximately two 
days passing between the time of cell infection to release of new virions. 
Fusion 
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Figure 2 HIV Replication Cycle 
Reproducedfrom Burrell & Li, 1992.^^ 
1.1.2 Disease Progression 
The cytotoxic effect of HIV infection is brought about via several biological 
mechanisms. Syncytium formation is a significant cause of cell death, particularly in 
the central nervous system. ̂ ^ Accumulation of toxic quantities of unintegrated viral 
DNA within the cell, secretion of cytotoxins and neurotoxins^ '̂̂ "^ by infected cells, HIV 
induced apoptosis, and the immune system response, have all been linked to 
cytotoxicity in HIV infected subjects. ^̂  
After infection, the body mounts a potent immune response that may control 
viral replication and symptoms of infection for over 10 years,^^ but eventually the virus 
evades the immune defences, severe immunosuppression ensues and development of 
AIDS occurs?^ Progression to AIDS is characterised by depletion of CD4^ T-cells,̂ "^ 
development of Kaposi's sarcoma, ^̂  neurologic disorders, ^̂  and lymphoadenopathy. ^̂  
The depressed immune system allows opportunistic infection with a variety of 
secondary pathogens, most commonly pneumonia, ñmgal, bacterial and latent viral 
infections, which, while relatively innocuous to an immunocompetent subject, are lethal 
to AIDS patients. ^ Progression of AIDS is rapid, with median survival between 12 and 
20 months, and less than 22% of patients surviving for longer than three years, after 
diagnosis of AIDS. ^ 
1.2 Therapeutic Strategies for HIV Infection 
While substantial progress has Been made in the development of vaccines 
suitable for immunisation against HIV infection,^^ significant limitations remain that 
appear to preclude their large scale clinical application in the foreseeable ñiture.̂ '̂̂ ® 
However, the complex replicative cycle of HIV offers many processes that have 
potential to be exploited for highly selective antiviral chemotherapy.^ 
Interfering with the gpl20-CD4 interaction can prevent the virus binding/fusion 
process and syncytium formation.^^ However, many inhibitors of the binding/fusion 
process showing potent in vitro activity, such as polyanionic compounds (e.g. low 
molecular weight dextran sulphate and heparin [typical inhibitory concentrations 
0.1-1 iLigml'^]) and protein derivatives (e.g. aconitylated albumins,^^ [0.02 |ig ml"']), 
suffer from poor oral bioavailability.^^ 
Several compounds that bind to the nucleocapsid protein and prevent the 
sequestering of the viral RNA by the capsid have been reported, while bicyclam 
derivatives have been proposed to bind to the viral capsid and inhibit the capsid 
uncoating and disassembly process, at concentrations as low as 1-10 ng ml'̂ "̂ ^ 
Other strategies have targeted the viral regulatory proteins Tat"̂ ^ and Rev,"̂ ^ 
glycosylation of the envelope glycoproteins,myristoylation of structural proteins, 
or use of antisense oligonucleotides ^̂  and DNA-binding agents"̂ ^ to bind to viral RNA 
and DNA. Several DNA binding agents have been reported to inhibit the viral integrase 
enzyme,which offers the potential to prevent the incorporation of the viral genome 
into cellular DNA, and thus permanent infection of cells."̂ ^ Most anti-HIV drug 
development effort, however, has been directed towards the viral protease and reverse 
transcriptase enzymes. 
Inhibition of HIV protease prevents the processing of viral polyproteins into 
the individual catalytic and structural proteins necessary for formation of mature, 
infectious virions. Initial protease inhibitors were peptidomimetics containing an 
isostere of similar geometry to the enzyme catalysed hydrolysis reaction transition 
state. However, the peptide based inhibitors suffer high rates of metabolism and poor 
oral bioavailability.^^ Several potent nonpeptide HIV protease inhibitors have been 
designed,̂ '̂̂ ^ taking advantage of the Ci symmetry of the protease enzyme, but were 
subsequently withdrawn from clinical trials due to poor bioavailability. ^̂  The protease 
inhibitors saquinavir ^̂  and indinavii^^ have progressed to market, but both suffer from 
poor bioavailability (approximately 4% for saquinavir) and require administration of 
massive doses (2.4 g/day in the case of indinavir) in order to suppress viral replication. 
1.2.1 Nucleoside Analogue Reverse Transcriptase Inhibitors 
Inhibitors of HIV reverse transcriptase can generally be classified into two 
categories: the nucleoside analogue inhibitors and the nonnucleoside inhibitors. The 
nucleoside analogues were among the first drugs discovered to have anti-HIV activity 
and constitute the majority of anti-HIV drugs currently available for clinical use. All 
nucleoside analogue inhibitors are derivatives of the natural 2',3'-dideoxynucleoside 
substrates of RT that lack the 3'-hydroxy group. Examples that have been approved or 
are in clinical trials include (Figure 3) azidothymidine (1) (AZT, zidovudine, Retrovir), 
2',3'-dideoxyinosine (2) (DDI, didanosine, Videx)and 2',3'-dideoxycytidine (3) (DDC, 
zalcitabine,Hivid).^^'^^ 
The nucleoside analogues act at the substrate binding site of RT, acting both as 
CO 
competitive inhibitors with the natural substrate, and as DNA chain terminators. It 
has been proposed that the 02, 04 ' and 05 ' oxygens of the thymidine analogues,^^ and 
the position of the 5'-phosphate determined by the torsion about the C4'-C5' bond,̂ ® 
are significant in the recognition of the nucleoside analogues by RT. When incorporated 
o 
HO-
NH 
J 
// 
HO N w 
o 
NH 
HO-
NHg 
vJ 
N3 
(1) AZT (2) DDI (3) DDC 
Figure 3 Nucleoside Analogue Reverse Transcriptase Inhibitors 
into the DNA strand being polymerised by RT, the absence of the 3'-OH group on the 
nucleoside analogue (but present on normal dideoxynucleosides) prevents the formation 
of a 5'-3' phosphodiester link with the next nucleoside, causing premature termination 
of the growing DNA chain. ^̂  
The first anti-HIV drug approved for clinical use, AZT, rapidly demonstrated 
^ 1 /iO 
its potential for attenuation of HIV infection and progression of AIDS, ' reducing 
mortality sixfold over nine months and improving the immune response. Similar 
promising clinical results were obtained with the nucleoside analogues didanosine and 
zalcitabine.^^'^'^^ The trials did not, however, indicate whether the nucleoside analogues 
were of any clinical benefit in the treatment of patients during the early stages of 
infection.^ '̂̂ ^ Furthermore, all nucleoside analogues suffer from significant dose limiting 
toxicity, including bone marrow suppression, anaemia and peripheral neuropathy. ^̂  
This toxicity arises from inhibition of cellular DNA polymerases, ^̂  despite having a 
greater affinity for reverse transcriptase.^ '̂̂ ^ 
The other significant disadvantage of nucleoside analogue inhibitors is the 
requirement to become phosphorylated to the 5'-triphosphate form in vivo by cellular 
kinases in order to function potently. The low kinase activity of monocytes and 
macrophages, as well as the differing affinity amongst the nucleoside analogues for 
38 
nucleoside kinases, can dramatically reduce their inhibitory activity in vivo. 
1.2.2 Nonnucleoside Reverse Transcriptase Inhibitors 
Like the nucleoside analogue RT inhibitors, the nonnucleoside RT inhibitors 
(NNRTIs) were mostly discovered through random screening programs for novel 
anti-HIV agents/^ This structurally diverse class of RT inhibitors bind 
noncompetitively with both the nucleoside analogue inhibitors and DNA/RNA 
templates, at an allosteric site on Unlike the nucleoside analogue RT inhibitors, 
the NNRTIs are highly specific for HIV-1 RT, having no inhibitory activity against 
HIV-2 RT and cellular polymerases, and thus are only cytotoxic at concentrations 
several orders of magnitude greater than their effective antiviral concentrations.^^ 
Furthermore, the NNRTIs do not require activation by cellular kinases, enabling them to 
exert their antiviral activity immediately upon uptake into the cell and to remain potent 
in cells that have suppressed kinase activity.̂ ^ 
The first normucleoside inhibitors reported were the HEPT^ '̂̂ ^ (4) and 
TIBO^ '̂̂ ^ (7) series (Figure 4). In cell culture assays with MT-4 cells, HEPT displayed 
50% inhibitory (IC50) and cytotoxic (CC50) concentrations of 7.0 |xM and 740 |xM, ^̂  
respectively, while the (+)-(S) TIBO lead (R78305) displayed IC50 = 70 [LM and 
CC50 = 674 jiM. ̂ ^ Analogue synthesis rapidly lead to significantly more potent and" 
selective inhibitors,̂ ® including the HEPT derivatives MKC-442'̂ '̂  (5) and 
TNK-651 ̂ ^ (6), and the TIBO derivatives 9-Cl-TIBO^^ (R82913, (8)) and S-Cl-TIBO^^ 
(R86183, (9)), with IC50 values of only a few nanomoles. 
To date, the only NNRTI in large scale clinical use is the dipyridodiazepinone 
nevirapine^\ (BI-RG-587, Figure 4, (10)), developed via a series of structure-activity 
studies from a tricyclic diazepinone derivative. Nevirapine, and its derivative 
1051U91 '̂̂  (11) possess IC50 values of 84 nM^^ and 0.4 ^M^^ respectively, have low 
cytotoxicity and good pharmacokinetic properties. ^̂  
'NH 
S' - N ^ O 
HO' 
(4) KEPT 
ICso = 7.0 iiM^^ 
(5) MKC-442 
IC30 = 8 nM 
81 
(7) TIBO 
IC30 = 70 fiM^^ 
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•CH, 
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IC50 = 4 nM 
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(10) Nevirapine 
IC50 = 84 nM 
83 
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(11) 1051U91 
Figure 4 Nonnucleoside Inhibitors of Reverse Transcriptase 
Other potent NNRTI classes include (Figure 5) the a-anilinophenylacetamide 
(a-APA) derivatives^^ (e.g. R89439, loviride, (12)), (phenylethyl)thioureathiazole 
(PETT) derivatives (e.g. LY297345, (13)), 2-pyridinones (e.g. L697,661, (14)), 
bis(heteroaryl)piperazine (BHAP) compounds ^̂  (e.g. U-87201E, (15)), 
alkenyldiarylmethane (ADAM) derivatives^^ (e.g. (16)), and TSAO nucleoside 
derivatives (e.g. (17)). 
Despite the apparent diversity of NNRTI structures that display potent RT 
inhibitory activity, there appears to be several common structural features of the 
compounds that are essential for the inhibitory mechanism. All NNRTIs have 
substantial hydrophobic character, contain- 7C-electron systems and have similar overall 
steric bulk.̂ ® Superposition of three dimensional models, generated from x-ray 
crystallography and computational techniques, of several different NNRTIs have shown 
a remarkable degree of conformational alignment between the compounds. 91,92,93 j^^q 
more rigid NNRTIs are constrained to, or in the case of the flexible inhibitors, can adopt, 
a "butterfly"-like conformation. Coupled with observations from various 
structure-activity investigations of many of the NNRTIs - most notably showing 
that loss of certain aromatic functional groups, a feature common to all the inhibitors, 
results in a substantial drop in potency - several pharmacophore models of the NNRTIs 
have been derived. 
The NNRTI pharmacophores and alignment data indicate that an important 
structural feature of the inhibitors is the arrangement of two regions with 7:-electron 
systems (aromatic rings or double bonds) in the "wings" of the butterfly-like 
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H,C 
(14) 2-Pyridmone 
IC50 = 19 nM^^'^^ 
HN, 
CH, 
(15) BHAP 
IC50 = < 1 
o 
H3C0 
C00CH3 COOCH3 
OCH, 
(16) ADAM 
IC50 = 7.1 fiM^ 
HN 
CH3 o ^ ^ ^ N - ^ 
CH3 \ 
\ 
o A 
CH3 
-Si — 
CH. 
(17) TSAO 
IC50 = 58 nM^^ 
Figure 5 Nonnucleoside Inhibitors of Reverse Transcriptase 
3 0 0 0 9 0 3 1 9 2 5 4 8 5 
conformation. The centre of the 7t-systems are positioned 4.5-5.0 A apart and lie within 
two planes that are at an angle of approximately 110° to each other. ^̂  The 
pharmacophores have been used successfully to discover (by database searching), design 
and optimise several novel NNRTIs, including isoindolinone ^ ^ 
dibenzodiazepinone ^̂  analogues. 
The significance of the common conformational and structural features of the 
NNRTIs lies in the specific protein-ligand interactions required for tight binding to 
reverse transcriptase, and is further discussed in section 1.3.2. 
1.2.3 Combination Therapy 
A significant deficiency in the use of either the nucleoside analogue RT 
inhibitors or NNRTIs as single agents for the treatment of HIV infection is the rapid 
development of resistance to these drugs by the virus.̂ '̂̂ ^® The combination of the high 
viral mutation rate and the selective pressure exerted by the drugs results in the 
emergence of HIV strains with diminished susceptibility to the antiviral agents. This 
may be overcome by either the use of high "knocking out" drug concentrations that 
totally suppress viral replication and therefore mutation development,̂ ®^ or the use of 
combinations of drugs that target distinct stages in the replicative cycle. ^̂  
If the drugs used in combination therapy have different mechanisms of action, 
the potential for the drugs to act synergistically exists, allowing lower doses of 
individual drugs to be administered with a corresponding reduction in side effects. ^̂  
With careful analysis of the resistance mutations that occur with different inhibitors, a 
combination of drugs that gives rise to resistance mutations that are mutually 
antagonistic may be selected. ^̂  
Examples of anti-HIV drug combinations that have shown synergy include 
AZT and castanospermine (a glycosylation inhibitor),'®^ AZT and nevirapine,̂ ®^ and 
AZT and DDI.̂ ®"̂ '̂ ®̂  Recently, the administration of a combination of two nucleoside 
analogues and a protease inhibitor have reduced the plasma levels of HIV virus in 
patients to undetectable levels. 
1.3 Reverse Transcriptase 
Reverse transcriptase has been an extensively studied and very productive 
target for the development of anti-HIV therapies. The essential role of RT in viral 
replication ^ and the absence of the enzyme in uninfected cells, make RT an attractive 
candidate for the design of potent and selective anti-HIV agents. Considerable 
progress has been made in the design of anti-HIV drugs that inhibit RT, with the 
majority of current clinically approved drugs acting at this enzyme. 
1.3.1 Reverse Transcriptase Structure and Function 
HIV reverse transcriptase is responsible for conversion of the viral RNA 
encoded genome into proviral double stranded DNA, requiring three enzymatic 
activities: ^̂  RNA-dependant DNA polymerase; DNA-dependent DNA polymerase; 
and ribonuclease H (RNase H). During viral replication, RT first transcribes the 
plus-strand RNA to a minus-strand DNA chain, while digesting the RNA template to 
expose the single strand DNA product. Finally, the newly synthesised minus-strand 
DNA is used as a template to synthesise a complementary plus-strand DNA chain. 
HIV RT exists as an unusually asymmetric heterodimer of homologous 66 kDa 
(p66) and 51 kDa subunits (the p51 subunit is derived by proteolytic cleavage of 440 
amino terminal residues of the p66 polypeptide). The p66 subunit is folded into 
polymerase and RNase H domains, with four subdomains of the polymerase region 
arranged in a form resembling a right hand (Figure 6). Thus, three of the polymerase 
subdomains have been named "fmgers", "palm" and "thumb", with the remaining 
"connection" subdomain linking these to the RNase H domain.^ ̂ ^ A list of the residues 
in each subdomain is given in Table 1. The side-by-side arrangement of these 
subdomains gives the p66 subunit an elongated and curved structure, measuring 
approximately 110 x 30 x 45 A, with an approximately 100 A long DNA/RNA binding 
cleft running between the polymerase and RNase H active sites (located in the palm and 
RNase H subdomains, respectively). ^̂ ^ 
The fmgers subdomain is composed of a four stranded mixed P-sheet 
supported by one long and two short helices,^^^ the palm and connection each consist of 
Subdomain Residues 
fmgers 1-88, 121-146 
palm 89-120, 147-242 
thumb 243-311 
connection 312-425 
RNase H 426-560 
Table 1 Reverse Transcriptase Subdomain Definitions 
Segments of the HIV-1 RT polypeptide chain composing each of the five RT 
subdomains as defined by Ren, et al ̂ ^^ 
five stranded ^-sheets flanked by two long a-helices on one side, ^̂ ^ and a four helix 
bundle forms the thumb. The RNase H domain consists of a five stranded mixed 
P-sheet, surrounded by a cluster of three a-helices on one face and a single helix on the 
other.^^' 
Several alternative, and in a few places conflicting, assignments of secondary 
Figure 6 Ribbon Diagram of Reverse Transcriptase Heterodimer 
Ribbon diagram of the backbone of the p66 andp51 submits of HIV-1 RT 
complexed with the NNRTI nevirapine, showing the heterodimeric structure. 
The fingers, palm, thumb and connection polymerase subdomains ere 
coloured blue, green, orange and red, respectively (p51 subdomains are 
coloured in lighter tones than the correspondingp66 subdomains) and the p66 
RNase H is coloured purple. The NNIBP and polymerase active site are 
coloured black and grey, respectively. Nevirapine is shown as a wireframe 
model Coordinates from PDB entry IVRT^^^ 
structure have been made to the protein sequence on the basis of crystal structure 
coordinate data. The nomenclature scheme adopted by Ren, et 
(reproduced in Appendix A 1.1) will be used for discussion of individual secondary 
structural elements in this report. While this decision was essentially arbitrary, this 
definition is based on structures of higher resolution and has been assigned to more RT 
structures than either of the other nomenclature systems. 
Despite having an identical sequence and similar secondary and tertiary 
structure to the polymerase domain of p66, the subdomain arrangement of the p51 
subunit is remarkably different to that of p66. The p51 subunit has no RNA/DNA 
binding cleft as the fingers have moved towards the palm and the connection subdomain 
is folded back into the region between the thumb and fingers, so that the connection 
makes contact with all three of the p51 subdomains, and the polymerase active site is 
buried. ^̂  The two subunits are positioned in a head-to-tail arrangement, with the major 
interactions between the connection subdomains, and minor interactions between the 
p51 fingers and p66 palm, and the p51 thumb and p66 RNase H. The p66/p51 dimer 
interface is hydrophobic in nature and results in a very strong association between the 
two subunits .Refolding of p51 and dimer formation results in burying approximately 
4560 A^ of hydrophobic surface area in a solvent inaccessible conformation.' ̂ ^ 
The X-ray crystal structure of a RT/DNA complex''^ shows the DNA 
template held into the binding cleft by substantial interactions with the p66 fingers, 
palm and thumb subdomains. The polymerase and RNase H active sites are separated 
by a distance corresponding to approximately 18 nucleotides,'and the tip of the p66 
thumb moves by approximately 30 Â to accommodate the DNA/RNA template. Once 
the RT-template complex is formed, chain elongation proceeds by binding of the 
appropriate nucleoside triphosphate substrate to the complex at the polymerase active 
site resulting in nucleophilic attack to form the phosphodiester linkage} RT performs 
this DNA polymerisation with very low fidelity^^^ with one in every 2000-7000 
nucleotides being misincorporated. 
1.3.2 Nonnucleoside Inhibitor Binding Pocket and Interactions 
with Nonnucleoside Inhibitors 
As the nonnucleoside reverse transcriptase inhibitors do not bind competitively 
with template/primer DNA or nucleoside triphosphates but can displace each other 
from RT c o m p l e x e s , i t was thought that they all act at a common site distinct from 
the binding location of the nucleoside analogue RT inhibitors. ^̂  Supporting this 
hypothesis was the observation that mutations that result in lower susceptibility of RT 
to any particular nonnucleoside inhibitor also confer resistance to many other NNRTIs, 
but not to the nucleoside analogues. ^̂ 3̂ 23,124 Biochemical and kinetic analyses^^^ 
provided further evidence for a common binding site. An azido photoaffmity labelled 
derivative of nevirapine, BI-RJ-70, that binds covalently to side chains at the active site 
when irradiated with UV light, has been used to locate the NNRTI binding site around 
the p66 residues TyrlSl and TyrlSS."^ '̂̂ '̂̂ ^^ The solution of the X-ray crystal 
structures of HIV-1 RT complexed with eight different NNRTIs (nevirapine, 
1051U91,^^^ HEPT,^^^ TNK-651,^^ MKC-442,^' 
and a-APA subsequently provided confirmation of the binding site location 
determined by the biochemical and mutagenesis analyses. 
All NNRTIs bind in a deep pocket within the p66 palm subdomain, at the 
interface between the p51 and p66 subunits, approximately 10 A from the polymerase 
active site.̂ ®'̂ ^^ An opening linking the nonnucleoside inhibitor binding pocket 
(NNIBP) to the bulk solvent is formed by a narrow hydrated channel near the p51/p66 
interface. The NNIBP does not exist in the disparately folded p51 subunit ^̂^ or in 
the structures of the apo e n z y m e a n d the complex with double stranded 
DNA. ^̂ ^ The NNIBP is the largest cavity in the enzyme, with volumes ranging 
between 620 to 720 A^ in complexes with different inhibitors. Figure 6 
(page 17) shows the position of the NNIBP within the RT molecule. 
The secondary structural elements forming the NNIBP (Figure 7) are the three 
central P-strands (P4-P8-P7) and the p7-p8 hairpin of a five stranded P-sheet in the p66 
palm on one side, and on the other side by the p9-pl0-pi 1 P-sheet and the p9-pi0 and 
plO-pi 1 hairpins of the palm near the base of the thumb. The coil prior to the P4 
strand loops around the "front" of the pocket, distal from the P7-P8 hairpin. The 
only region of the p51 subunit contributing to the NNIBP is the p5-p6 loop of the 
fingers subdomain. The rim to the solvent accessible entrance to the NNIBP is formed 
by p66 residues from the loop leadingto P4 (LeulOO, LyslOl, Lysl03), p7 (TyrlSl), 
the termini of P7 (Vall79) and p8 (Serl91) and the p51 p5-p6 loop (Glul38). 94,i28,i30 
The residues forming the internal surface of the NNIBP are predominantly 
hydrophobic, with many aromatic side chains (Tyrl81, Tyrl83, Tyrl88, Phe227, 
Trp229 and Tyr232). ^̂ ^ There is little electrostatic character in the vicinity of the 
bound NNRTI, with the only hydrophilic residues in the pocket located around the 
solvent accessible entrance, namely LyslOl and LyslOS of p66, and Glul38 of 
is conceivable that these flexible and hydrophilic side chains help guide the 
NNRTI into the binding pocket. 
Since both the NNIBP and the NNRTIs have substantial hydrophobic 
character, the interactions between the pocket and inhibitors are predominantly 
hydrophobic. The side chains forming the pocket close down on the inhibitor to make 
close contact with it, complementing the butterfly shape of the NNRTI. The 
pio pn 
Figure 7 Structure of the Nonnucleoside Inhibitor Binding Pocket 
Backbone (ribbons) and key side chains (wireframe) of the amino acid 
residues forming the NNIBP in the complex with the NNRTI nevirapine (ball 
and stick). The two P-sheets and associated loops are displayed in black and 
the P-strands labelled. The chain prior to p4 and the p51 p5-p6 loop are 
shaded in light and dark grey, respectively. The entrance to the pocket is 
located towards the bottom of the diagram. Coordinates from Brookhaven 
Protein Databank entry 1VRT ^^^ 
nonnucleoside inhibitor lies on the p4-p8-p7 sheet, with the P7-(38 hairpin (containing 
the polymerase catalytic residues Asp 185 and Asp 186) aligned along the long axis of the 
drug. One "wing" of the NNRTI forms significant interactions with Tyrl81, Tyrl88, 
Trp229 and possibly Pro95, while the other wing forms weaker hydrophobic 
associations with Vall06, Vall79, Phe227, Tyr318 and LeulOO lies 
between the two wings of the inhibitor, interacting with the concave face of the 
butterfly. ^̂  The close packing of the NNIBP around the nonnucleoside inhibitors is 
reflected in the large number of protein-ligand interactions reported with the inhibitors, 
e.g. 38 for nevirapine ^̂ ^ and 43 for a-APA. 
Specific interactions between the aromatic rings of the NNRTI and the side 
chains of aromatic amino acid residues in the binding pocket are a common feature of all 
the NNRTI complexes. The crystal structures show these side chains, particularly 
Tyrl81 and Tyrl88, oriented so that favourable aromatic-aromatic interactions can be 
made between the rings of the inhibitor and amino acids. Furthermore, 
substitution Tyrl81 and Tyrl88 with residues that lack aromaticity dramatically 
reduces NNRTI potency, while substitution with other aromatic residues (Phe or Trp) 
has little effect on binding affinity, ̂ ^̂  implying that the aromatic nature of these 
residues is significant to inhibitor binding. 
Aromatic-aromatic interactions between phenylalanine, tyrosine and 
tryptophan residues are an important contributing force to tertiary structure 
stabilisation in proteins. Although commonly referred to as K-n interactions, the 
favourable interaction between these side chains actually arises from attractive a-n 
electronic interactions. ̂ ^̂  The direct coulombic interaction between 7C-electron systems 
is repulsive. However, as the hydrogen atoms attached to aromatic carbons have a slight 
positive charge, electrostatic attraction between the hydrogen and the 7i-electron cloud is 
possible if the side chains are oriented in the correct geometry. There are two 
preferred geometries for these "ir-stacking" interactions: parallel displaced (aromatic 
rings in parallel planes, but with the centroids of the rings offset from one another so 
that the H is positioned over the 7i-electron system) and perpendicular (rings oriented at 
right angles so that the H can approach the K system). ^̂ ^ The edge-to-face 
perpendicular arrangement is the form most commonly observed in proteins, albeit with 
some tilting from the normal. 
Analysis of protein structures and theoretical calculations have 
shown that residues with favourable n-K interactions are separated by 4.5-7.0 Á, with 
an optimal distance of 5.5 A. The optimal distances determined computationally are 
slightly shorter and indicate that the parallel displaced geometry involves closer 
approaches than the edge-to-face arrangements. ^̂ ^ With ideal relative orientation, 
separation and surrounding environment, the K-K interaction energy can be up to 
-2 kcal mo^^ ^̂ ^ ^̂ ^ and therefore can make a considerable contribution to the binding 
, affinity of the aromatic NNRTIs to the NNIBP. 
The significance of Tc-stacking interactions to the binding of nonnucleoside 
inhibitors to RT are reflected in the crystallographic structures. Relative orientations of 
the NNRTI and aromatic side chains that place the aromatic rings in positions so that 
they can form both edge to edge and parallel displaced interactions are observed in the 
crystal complexes. The crystal complexes of nevirapine, TIBO and a-APA with 
RT shows the inhibitors oriented so as to make K-K interactions between both wings of 
the inhibitor and side chains of several aromatic residues. The 4-methylpyridine ring of 
nevirapine and the aniline ring of a-APA have typical 7t-stacking geometries with side 
chains of three aromatic residues, Tyrl81, Tyrl88 and Trp229 (parallel displaced, 
edge-to-face and edge-to-face, respectively), and the aromatic ring of TIBO is 
oriented edge-to-face with TyrSlS.^"^ The other aromatic wing of nevirapine and 
a-APA is less extensive in its n-n stacking potential, making only one such interaction 
with the protein: Tyr319 (edge-to-face) for nevirapine and TyrSlS (parallel displaced) 
for a-APA. 
Modelling studies of nonnucleoside inhibitors docked into the binding pocket 
have also reported the importance of K-n interactions in the drug-enzyme 
complexes. In addition to reproducing the original crystal orientation of several 
inhibitors, these studies calculated several orientations distinct from the crystal 
geometry of known NNRTIs, ^̂  or alternate binding modes of proposed binaphthyl 
inhibitors, using molecular mechanical methods. However, the relative geometry of 
aromatic groups and/or energy calculations, indicated that n-n interactions made 
significant contributions to the total binding energy in all the orientations determined. 
The hydrophobic nature of the NNIBP means that hydrogen bonds between 
the inhibitor and pocket are scarce, however most of the NNRTIs contain functional 
groups suitable for hydrogen bond formation. The amide group of a-APA forms 
H-bonds with main chain carbonyl groups of Tyrl88 and Vail89, the nitrogen of the 
imidazole ring of 8-Cl-TIBO and 9-Cl-TIBO makes one H-bond with the main chain 
carbonyl of LyslOl,^^'^^ and KEPT and the MKC-442 and TNK-651 derivatives make 
one H-bond between the LyslOl carbonyl and a nitrogen of the thymine ring. No 
hydrogen bonds between the inhibitor and protein residues are observed for the 
nevirapine and 1051U91 complexes. Several crystallographic waters can also be 
found forming hydrogen bonds with the inhibitors in several complexes (three with 
nevirapine, two for 9-Cl-TIBO, one for 1051U91 and a-APA). It is likely that 
these water molecules serve to shield charged groups on the inhibitor from the 
hydrophobic surface of the NNIBP. ^̂ ^ 
1.3.3. NNRTI Resistance Mutations 
The rapid and productive replication of HIV, ^̂  in conjunction with the high 
replication error rate of RT and the selective pressure exerted by antiviral drugs, 
contributes to the ready emergence of HIV strains in vivo with diminished susceptibility 
to the antiviral drugs.̂ ^^ Resistance develops via the mutation of codons in the viral 
genome, with the consequent point substitution of amino acids in the viral proteins 
having little effect on the activity of the enzyme but conferring resistance to the 
inhibitory mechanism of the drug. Development by HIV of resistance is a significant 
deficiency suffered by many classes of antiviral drugs, including protease inhibitors, 
nucleoside analogue RT inhibitors and NNRTIs. In clinical use, resistance develops 
to nucleoside analogue RT inhibitors over a period of six months and is particularly 
rapid with the NNRTIs. ̂ ^̂  
Resistance to RT inhibitors can be traced primarily to point mutations of 
amino acid residues in or around the inhibitor binding site. Table 2 lists the 
common amino acid substitutions that confer resistance to different inhibitors of both 
nonnucleoside and nucleoside analogue classes. For the NNRTIs, the point mutations 
are located at the NNIBP, with most altered residues having significant interactions with 
the NNRTI in the wild-type enzyme. While the TyrlSlCys mutation generates 
resistance to most classes of NNRTI, ^̂ ^ the other common mutations generally only 
affect a limited group of NNRTI classes. HIV-2 RT is resistant to the NNRTIs, 
apparently due to the Tyrl81->Ile and Tyrl88->Leu substitutions compared to HIV-1 
Most of the residues that undergo effective resistance mutations are oriented 
with their side chains directed towards the NNIBP, suggesting that resistance is 
mediated by changes in the interactions between side chains and the inhibitors. ̂ ^̂  
Furthermore, the relative surface area of the contacts between individual residues and the 
inhibitors correlate well with the loss in potency that occurs upon substitution of these 
amino acids. ^^ The susceptibility of resistant RT to NNRTIs may partly depend on 
the flexibility of the inhibitor, as the more flexible classes, such as a-APA and HEPT, 
generally suffer lesser reductions in potency than the more rigid compounds, such as 
nevirapine. ^^ A flexible Ugand may be more capable of changing its conformation to 
maximise interactions with other NNIBP regions to compensate for the loss in binding 
with the mutated side chain. 
Residue Mutation Change in Properties Inhibitors Affected 
41 Met^Leu AZT 
67 Asp—>Asn AZT 
69 Thr-^Asp DDC 
70 Lys—>Arg AZT 
74 Leu^Val DDI 
98 Ala^Gly size i , flexibility T Nevirapine, TIBO, Pyridinone 
100 Leu-^Ile solvent accessibility i Nevirapine, TIBO, Pyridinone, BHAP 
101 Lys^Glu + —> - charge Pyridinone 
103 Lys—>Asn size i , charge loss Nevirapine, TIBO, Pyridinone, BHAP 
106 Val^Ala size i Nevirapine, HEPT 
108 V a l i n e size T Nevirapine, Pyridinone 
138 (p5l) Glu^Lys - —> + charge TSAO 
179 Val->Asp size T, charge T, 
hydrophobicity i; 
TIBO, Pyridinone 
181 Tyr-^Cys size i, aromaticity i Nevirapine, HEPT, TIBO, Pyridinone, 
BHAP, a-APA 
184 Met^Val DDC, DDI, 3TC, FTC 
188 Tyr->His size i HEPT, TIBO, Pyridinone 
188 Tyr->Cys size i , aromaticity i Nevirapine, TIBO, Pyridinone 
215 Thr—>Tyr AZT 
215 Thr-^Cys DDC 
219 Lys-^Gln AZT 
228 Leu->Phe size T, aromaticity T BHAP 
233 Glu-^Val size i , charge i , 
hydrophobicity T 
BHAP 
236 Pro-^Leu size t , flexibility T BHAP 
238 Lys^Thr size i , charge i BHAP 
Table 2 Selected Reverse Transcriptase Resistance Mutations 
All amino acid residue numbers refer to the p66 subunit, unless specified. 
Data from Tantillo, etal, 1994, ^^.'^andDe Clercq, 1994. 
The decrease in susceptibility to most NNRTIs by mutation of the tyrosine 
residue at position 181, and to a lesser extent Tyrl88, further supports the importance 
to binding affinity of the 7c-stacking interactions between these aromatic amino acids and 
the aromatic groups present in all NNRTIs. Substitution of Tyrl81 or Tyrl88 with 
other aromatic residues (tryptophan and phenylalanine) resulted in minimal loss in 
activity, while substitution with non-aromatic amino acids induced significant 
resistance. ^̂ ^ Therefore, disrupting the 7c-stacking interactions decreases NNRTI 
activity. 
It has been shown that nevirapine binds to the Tyrl81Cys and wild-type 
NNIBPs with similar association rates^ but dissociates more readily from the 
Tyrl81Cys mutant. This suggests that the inhibitor remains capable of binding to the 
resistant NNIBP, but the loss of the specific 7c-stacking interaction between the NNRTI 
and Tyrl81 results in only weak association and the inhibitor is easily ejected from the 
resistant mutant. Confirmation of NNRTIs binding to the resistant NNIBP is given 
by the recently solved X-ray structure of a TIBO compound, which relies less 
extensively on interactions with Tyrl81, in a complex with Tyr 181 Cys RT. ^̂ ^ The 
thiol side chain of Cysl88 in the Tyrl81Cys RT-8-C1-TIB0 complex showed 
significant flexibility compared to the corresponding tyrosine side chain in the complex 
of the same inhibitor with wild-type RT, which is held in a relatively rigid conformation 
by the 7r-stacking interaction with the inhibitor. ^̂ ^ 
1.3.4 Conformational Flexibility of Reverse Transcriptase and 
the Mechanism of Inhibition by NNRTIs 
A distinctive characteristic of the reverse transcriptase heterodimer is its great 
conformational flexibiUty. Crystallographic data show that significant subdomain 
and tertiary structural movements in RT can be induced by factors such as crystal 
packing and NNRTI or DNA binding, 2̂1,132,133 ^ ^ fluorescence experiments suggest 
that conformational changes occur during the polymerisation process. The 
conformational flexibility of RT is further evidenced by the large variety of different 
space groups ̂ ^̂  and cell dimensions^ ̂ ^ in which of crystals the enzyme can be grown, 
most of which are internally disordered and possess poor X-ray diffraction 
properties. ^̂ ^ Important structural changes are mostly restricted to the NNIBP, 
polymerase active site, and fingers and thumb subdomains, and have implications for the 
binding of nonnucleoside inhibitors to RT as well as the polymerisation and NNRTI 
inhibitionmechanisms. 
RT may undergo up to three different conformational changes during a single 
polymerisation cycle in order to facilitate the DNA binding, chemical catalysis and 
translocation steps. ^̂ ^ Structural ^̂ ^ and fluorescence^^^ information indicates that RT 
changes conformation upon binding to the DNA primer, with movement restricted 
primarily to the thumb subdomain. Subsequent to binding of a deoxynucleoside 
triphosphate substrate, a change in the positions of several side chains in the region is 
thought to slide the substrate into a position suitable for chemical incorporation into the 
DNA strand. conformational change involves movement of the DNA 
strand to position the new 3'-0H terminus at the active site, via a 'ratchet'-type 
motion. ^̂ ^ The flexibility of the thumb ^̂ ^ and an internal swivel motion of the palm 
and fingers ^̂ ^ are believed to facilitate this repositioning of the DNA primer. 
Complex formation between NNRTIs and RT is associated with dramatic 
changes in the orientation of side chains and the relative position of the backbone of the 
region containing the NNIBP. The flexibility of the binding pocket is such that it does 
not actually exist in a solvent accessible form m the apo enzyme, only forming upon 
complexation with an inhibitor, 132,133 ^ ^ ^p^ structure and the RT/DNA complex 
the side chains of Tyrl81, Tyrl88, Phe227 and Trp229 are well packed and point 
towards the hydrophobic core and thus occupy the location of the NNIBP in the 
inhibitor bound structures. ^̂ ^ The opening to the NNIBP is absent in the inhibitor free 
structures, however a depression in the solvent accessible surface exists in the equivalent 
location, surrounded by the p66 residues LeulOO, LyslOl, LyslOS, Vall79, TyrlSl, 
TyrlSS and Glul38 (p51). Even in the complexes with NNRTIs, the entrance is 
too narrow to allow an inhibitor to pass through if the structure remained rigid. ̂ ^ A 
solvent inaccessible cavity of 360 A^ volume near tyrosines 181, 183 and 188 and 
Trp229 has been reported in the apo structure by Esnouf, et al,^^^ however a 
corresponding void was not found in the other uninhibited structures. (a serious 
concern ^̂ ^ about the validity of the conformation of the apo structure determined by 
Esnouf, et al exists, in which the method of crystal production may have locked the 
enzyme into a conformation similar to that of the KEPT complex, see page 34). When 
an inhibitor binds to RT, amino acids Tyrl81, Tyrl83 and Tyrl88 fill this cavity and 
the larger NNIBP opens up further along the P4-P8-P7 sheet. ^̂ ^ The expansion of the 
NNIBP is facilitated by a rigid body shift of up to 2 A by the P4-P8-P7 p-sheet, an 
approximately 30° twisting of the p9-plO-(3ll P-sheet, displacement of up to 2.9 A of 
the piO-pl 1 hairpin and 2 A by the backbone leading to p4, and rotation of about 120° 
of the side chains of Tyrl81 and Tyrl88. Thus, many degrees of conformational 
flexibility are available to the NNIBP, enabling it to accommodate the structurally 
diverse NNRTIs. 
The geometry of the pocket varies to optimise interactions with each different 
NNRTL The side chains of the NNIBP amino acids orient themselves to maximise the 
ligand-protein contacts with each individual inhibitor, ahering the volume of the cavity 
in the range from 620 up to 720 A^ in complexes with different inhibitors. 81.93,i09,i3i 
After superposition based on the binding site, the five inhibitors nevirapine, 1051U91, 
a-APA, KEPT and 9-Cl-TIBO occupy a total volume of 440 A^ of which 100 A^ is 
common to all (and represents the two wings of the NNRTI). Movement of the 
310-pll hairpin, containing the residue Pro236, over a broad range of positions (up to 
5.3 A movement of C^ of Pro236) accounts for most of the difference in NNIBP 
volumes. ^̂  The movement of the plO-pi 1 hairpin allows the pocket shape to change to 
best fit the different sized inhibitors. Other, smaller, deviations in backbone position 
with the different NNRTIs are concentrated in the p4-p8-p7 and p9-pi0-pil 
P-sheets. The most significant differences in side chain movements in the NNIBP 
involve the aromatic residues: tyrosines 181, 183, 188, 318 and 319, phenylalanine 227, 
and tryptophan 229; as well as the non aromatic residues Pro95, Leu234 and Glul38 
(p51). ^̂  For example, the HEPT complex, unlike the tighter binding NNRTIs, does not 
alter the conformation of Tyrl81 from that of the apo enzyme. ^̂  The number of 
specific close protein-inhibitor contacts also varies amongst the different inhibitors: 
from eight for nevirapine and HEPT down to three with a-APA. ^̂ ^ The implication of 
the NNIBP flexibility for structure based drug design is to limit reliable predictions of 
the binding mode and energy of docked inhibitors to only those modelled in a cavity 
constructed from the coordinates of the corresponding crystal complex. ^̂  
The change in the three dimensional structure of the NNIBP induced by 
inhibitor binding is also associated with short and long range conformational changes in 
other regions of the enzyme, which offer possible explanations of the inhibitory 
mechanism of the NNRTIs. Three (potentially complementary) mechanisms have been 
proposed, implicating conformational changes in the polymerase active site, thumb 
subdomain and the 'primer grip' (p9-(310 hairpin of the palm). 
The close proximity of the NNIBP to the polymerase active site immediately 
suggests that conformational changes in the inhibitor binding pocket will have an effect 
on the geometry of the active site. The shift of the P4-P8-P7 P-sheet and p7-p8 
hairpin, which contains the polymerase active site catalytic aspartic acid residues 110, 
185 and 186, coupled with reorientation of the side chains of tyrosines 181 and 188, 
places the p7-p8 hairpin in a conformation remarkably similar to that of the inactive p51 
polymerase active site. ^̂^ The Tyrl81 and Tyrl88 side chains are rotated away from 
the NNIBP towards the polymerase active site in the NNRTI complexes. The 
p51-like conformation of the p66 polymerase active site observed in the inhibited 
enzymes may either reposition the catalytic aspartic acid residues into a catalytically 
inactive conformation, or moderate the mobility of the polymerase active site. ^̂ ^ For 
efficient catalysis, conformational flexibility of the polymerase active site may be 
required so that favourable interactions with the continually changing template-primer 
can be maintained and different deoxynucleoside triphosphate substrates may be 
distinguished. The observation that complex formation between RT and NNRTIs 
does not affect nucleotide binding but inhibits the chemical reaction step of the 
polymerisation process is consistent with this mechanism. ^̂  
The second possible inhibition mechanism proposes that NNRTI binding 
restricts the conformational flexibility of the thumb subdomain. In this model the 
NNIBP acts as a 'hinge' between the fingers and thumb subdomains. Mobility of the 
thumb, which makes extensive contacts with the DNA primer-template, ^̂ ^ may be 
required for strand transfer and displacement. Binding of nevirapine in the pocket 
results in repositioning of the thumb into a conformation very similar to that observed in 
the RT/DNA complex. This displacement is achieved by the rotation and shift 
towards the thumb of the small p9-pi0-pll P-sheet at the base of the thumb in the 
palm, and a 1T hinge-like rotation around Pro243 and Val317. ^̂ ^ Combined, these two 
rotations break the contact between the thumb and fingers and open up the binding cleft. 
Despite the similarity in the orientation of the thumb in both the nevirapine and DNA 
complexes, the mechanism of the thumb movement induced by nevirapine differs from 
that of the DNA complex. In the DNA complex, the hinge movement around Pro243 
and Val317 is more pronounced (29° compared with 17° with nevirapine), but the 
rotation at the base of the thumb of the p9-pl0-pil sheet is absent. ^̂ ^ It has been 
proposed that the occupation of the NNIBP by an inhibitor, in the hinge region, 
prevents movement of the thumb and therefore interferes with polymerisation and 
translocation. 
This large scale displacement of the thumb is not observed in the P2{1\2\ 
crystallographic space group structures determined by Ren and coworkers 
Comparison of the various P2]2{lx NNRTI complexes with the apo crystal structure of 
the same space group show little or no rearrangement of the orientation of the thumb 
after inhibitor binding. Ren and coworkers have used the similar conformation of the 
thumb in the apo and NNRTI complexed crystals to argue that movement of the thumb 
is not integral to the inhibition mechanism. Kinetic experiments have shown that neither 
DNA binding a f f i n i t y o r conformational flexibility^^ is reduced by NNRTI 
binding. With this kinetic information and no consensus between the orientation of the 
thumb in the different inhibited structures, it has been suggested that the dominant 
inhibition mechanism is via the alteration of the precise geometry of the polymerase 
active site catalytic aspartic acid residues, rather than any effect on the thumb 
conformation. 
However, the method by which XhQ P2{1{1\ space group crystal was prepared 
severely influenced the conformation of the thumb in this structure: the inhibitor free 
crystals were obtained from P2i2\2\ HEPT complex crystals by soaking out the 
NNRTI. ^̂^ However, the rigidity of the protein when in the crystalline state, due to the 
intermolecular packing forces and arrangements, may have prevented the thumb 
adopting a different conformation in the newly formed apo crystal. An examination of 
the molecular packing of the protein in the P2\2\2\ crystal form^^^ indicated that the 
p66 thumb is interlocked between the p66 thumb and RNase H domain of an adjacent 
protein molecule in the crystal lattice, thus preventing the thumb folding into the DNA 
binding cleft. Therefore, the thumb adopts an extended conformation rather than being 
folded into the palm, as occurs in the C2 apo crystal structure. This open orientation of 
the thumb in the P2{l\2i space group apo RT structure almost certainly does not 
represent the natural conformation of the thumb in the native enzyme, particularly when 
the different conformations of the thumb in other crystal space group apo structures are 
considered. The effect of the apo crystal production method on the conformation of 
other regions of the enzyme is unknown, but it is feasible that the geometry of other 
regions of the enzyme in this structure may also be biased towards that of the HEPT 
complex geometry, as is the thumb subdomain. 
This anomalous apo crystal structure throws into doubt the observations of 
conformational change of NNRTI complexes made by comparison with the inhibitor free 
state of the enzyme, in the P2x2{li space group. Unfortunately, a large proportion of 
the available literature on conformational changes occurring in have-
been made with reference to this crystal structure, and must be treated with caution. 
NNRTI induced distortion of the ß9-ßl0 hairpin, designated the primer grip, 
offers a third possible mechanism of inhibiting reverse transcriptase enzymic 
activity. The ß9-ßl0 hairpin forms part of the NNIBP, containing the aromatic 
residue Trp229 which has 7c-stacking or hydrophobic interactions with many NNRTIs, 
and is connected to the ß9-ßl0-ßl 1 ß-sheet that undergoes significant movement during 
the formation of the NNIBP. The primer grip is also involved in binding between the 
DNA binding cleft of RT and the DNA primer. ^̂ ^ Interactions between the primer grip 
and the 5'-phosphate of the terminal primer nucleotide retains the 3'-hydroxy 1 group of 
the latter in the correct position for nucleophilic attack on the incoming deoxynucleoside 
triphosphate substrates.^® Distortion of the precise geometry of the p9-pi0 hairpin by 
a bound NNRTI may impair the ability of the primer grip to place the primer in the 
correct position relative to the polymerase active site and thus inhibit 
polymerisation. Mutation of Trp229 and other residues of the primer grip 
reduces polymerase activity, ^̂ ^ providing some support for this hypothesis. These 
three proposed inhibitory mechanisms are not necessarily mutually exclusive, and may 
act cooperatively to prevent DNA polymerisation by reverse transcriptase. 
1.3.5 Caveats of Determination of Conformational Change in 
Reverse Transcriptase 
Most of the detailed structural information available in the literature on the 
different conformational changes occurring in RT has been determined by comparison of 
the three dimensional atomic coordinates of the enzyme determined by X-ray 
crystallography. Although the examination of conformational differences between two 
structures by direct superposition of atomic coordinates can provide detailed and 
precise information on changes in geometry, a concern arises when applied to a molecule 
exhibiting such dramatic and spatially dispersed flexibility as reverse transcriptase. 
Superposing the entire protein backbone can average out systematic conformational 
changes, with the effect of smoothing out and obscuring localised changes in protein 
geometry. Furthermore, a bias towards maximising the quality of the superposition of 
larger domains, that may have different conformations in the two structures, can 
introduce a shift in the relative orientation of other smaller regions that otherwise have 
more similar conformations. The problems associated with superposition of flexible 
proteins are discussed in Chapter Four. 
Some of the observed conformational changes reported so far have been based 
on superposition of the entire protein backbone (for an example, see reference 129) and 
therefore may have introduced some deviation from the optimal alignment of some 
important regions of the protein. Other studies have examined changes in pocket 
geometry by superposition of only the residues within and around the NNIBP, ^̂  in an 
attempt to minimise this effect. The reasoning behind the selection of regions of the 
protein to be used during the superposition have not always been made clear, and are 
not uniform amongst the different authors. The question of which regions of the protein 
would give the most objective and informative alignment when used as the basis for 
superposition, so that individual structural motions can be identified and interpreted 
with confidence as to their validity, has not yet been answered, and was the object of a 
large portion of this project. 
1.4 Drug Design in Flexible Binding Sites 
Structure based drug design relies on the notion that ligand molecules interact 
with their protein targets in a highly specific manner.^ The foundations for structure 
based design were laid a century ago by the seminal work of Fischer and Ehrlich, using a 
"lock and key" analogy to embody drug-receptor interaction at the cellular level 
At the atomic level, binding of the drug to the receptor is mediated by a combination of 
hydrophobic, electrostatic and hydrogen bonding interactions, as well as changes in the 
solvation state of the ligand and binding site.̂ ^ '̂'̂ "^ In the lock and key model, the 
relative spatial arrangement of atoms and functional groups in the drug and binding site 
determines the ability of the drug to fit into the receptor, i.e. binding affinity and 
specificity is a function of the three dimensional complementarity of molecular shape 
and electronic properties between the ligand and binding site. ^̂ ^ The assumption made 
in the lock and key model is that both the ligand and protein target have a rigid structure 
that does not differ between the complexed and dissociated states. This model is the 
fundamental premise of structure based approaches to drug design, and has been 
employed successfully in the rational development of a number of promising enzyme 
inhibitors.î '̂̂ ^«'̂ ^ '̂̂ ^« 
The lock and key model of rigid ligand-receptor interaction, while still serving 
structure based drug design strategies well,̂ ^^ has become mcreasingly compromised by 
the observation of large conformational changes in enzyme structure that occur upon 
ligand binding.^ Numerous examples of "induced-fit" conformational changes have 
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been reported, ranging from surface loop flips in the streptavidin-biotin complex, to 
large-scale domain motions due to sugar binding with yeast hexokinase'^'^ and 
periplasmic maltodextrin binding proteins, ̂ ^̂  AMP and ATP complexation by adenylate 
kinases,^^^ and the closing of the HIV-1 protease "flaps" around peptidomimetic 
i n h i b i t o r s . T h e s e induced fit effects can result in dramatic alterations in protein 
geometry, with residue movements of as much as 32 A and domain rotations of up to 
92° in the case of ATP binding to adenylate kinase. ^̂ ^ 
It is reasonable to expect that alterations in both ligand and protein geometry 
may occur upon binding, as it is the stability of the ligand-receptor system as a whole. 
rather than the stable conformations of the separate components, that determines the 
binding affinity of a drug. ^̂ ^ In the complex, the degrees of freedom available to the 
receptor structure are interlinked with the conformational, rotational and translational 
degrees of freedom available to the inhibitor. ^̂ ^ Thus, the conformation of the drug and 
binding site in the complex may differ substantially from the conformation of the free 
ligand and the unbound enzyme. Ideally, therefore, attempts at structure based drug 
design should utilise the geometry of the binding site when complexed with an inhibitor, 
rather than the unbound structure. Induced fit effects will frustrate attempts to design 
drugs on the basis of the apo binding site, or even the conformation when complexed 
with other, structurally different, inhibitors. 
Molecular docking, a computational tool for structure based drug design, is the 
process of positioning a ligand within the protein binding site and predicting the relative 
orientation of the ligand within the receptor (binding mode) and the binding energy of 
the ligand-receptor complex. Examples of docking packages that treat the problem 
of conformational flexibility in the association process are l i m i t e d . ^ I n order to 
determine the bioactive conformation and binding mode, a docking algorithm should, 
ideally, consider all degrees of freedom available to both the ligand and protein 
(translational, rotational and conformational), ^̂ ^ as well as all interactions involved in 
the association (hydrogen bonding, steric, electrostatic and hydrophobic). ^̂^ It is, 
however, impractical to consider so many degrees of freedom because of the enormous 
number of conformations that would need to be generated (primarily due to the many 
internal torsional degrees of freedom of ligand and receptor). It is for this reason that 
most docking algorithms treat only the orientational degrees of freedom between the 
two components of the complex (three rotational and three translational), and consider 
both the ligand and protein to be rigid bodies. While the use of rigid models is a serious 
oversimplification of the association process, the inclusion of molecular flexibility 
requires the incorporation of either systematic searching methods or molecular 
mechanics and dynamics into the docking algorithm, which is often too expensive 
computationally. ^̂ ^ 
Several docking approaches have been developed that treat ligand flexibility to 
some extent. Ligand flexibility may be incorporated in a relatively simple manner by via 
docking of multiple conformations of the ligand into the site.̂ ^̂ '̂ "̂̂  Exploration of the 
ligand conformation while bound to the protein, using systematic searching 
algorithms,̂ ^^ simulated a n n e a l i n g ' M o n t e Carlo techniques'^^ or genetic 
algorithms,'^^ in conjunction with appropriate energy evaluation, offer better sampling 
of conformational space, however can be computationally demanding. 
The treatment of binding site flexibility in docking is limited to incorporation of 
amino acid side chain flexibility,'^® very restricted amino acid movements during 
docking,'^' or molecular mechanical optimisation of the entire protein-ligand complex.'̂ ^ 
In the first approach, the protein backbone is held rigid while the orientation of the side 
chains is systematically varied amongst a set of favourable conformations determined 
from analysis of high resolution protein structures. The rigidity of the backbone, 
however, will not provide very good modelling of geometry changes in cases of 
significant induced fit effects. The approach of Mizutani, et al is to select a small set 
of optimal ligand orientations obtained by docking into the rigid binding site, and then 
minimise the entire complex using a molecular mechanics application. Due to the narrow 
convergencerangeof the molecular mechanics optimisation, the change in the protein 
geometry is relatively minor, ^̂ ^ and is unlikely to reproduce the large conformational 
changes observed in reverse transcriptase. Geometry optimisation of a very large 
protein such as RT is also likely to be a computationally demanding process. 
Furthermore, the screening algorithm employed by Mizutani, et al. to reduce the number 
of complexes to be minimised selects conformations based on the number of hydrogen 
bonding interactions between ligandand protein. This dependence on hydrogen 
bonds discriminates against predominantly hydrophobic protein-ligand interactions, ̂ ^̂  
and so would be unlikely to select the non-polar NNRTIs for further optimisation when 
docked into the hydrophobic NNIBP. 
Kroeger Smith and coworkers ^̂  have shown how the flexibility of the NNIBP 
complicates docking of NNRTIs to reverse transcriptase. In this study, nevirapine, 
a-APA and 8-Cl-TIBO complexes were minimised using molecular mechanics, allowing 
full flexibility in amino acids 10 A from the inhibitor and side chain flexibility in those " 
up to 20 A away, as well as incorporating solvent molecules. Despite allowing this 
degree of flexibility during geometry optimisation, reliable inhibitor docking was only 
obtained when each inhibitor was modelled in the NNIBP constructed from the original 
coordinates in its own crystal structure complex. ^̂  When the inhibitor was docked into 
the binding pocket from a different NNRTI complex, predictions of relative binding 
energy failed to correlate with experimental measurements of potency, and on several 
occasions the calculated orientation of the ligand within the binding pocket differed 
substantially from that observed in the crystal structures. ^̂  
Similar problems were encountered with another study that attempted to 
determine the bioactive conformation and orientation of 9-Cl-TIBO by docking into the 
NNIBP from the crystal complex with nevirapine. ^̂  In the modelled structure (PDB 
entry IRVQ) the geometry was incorrect, suggesting protein-ligand interactions that 
were not observed in the actual crystal structure of the 9-Cl-TIBO/RT complex. Other 
attempts at predicting the bioactive conformation of TIBO by comparison with 
nevirapine, have also failed to predict the conformation of the NNRTI observed in the 
complex withRT.^^'^2'^^^ 
The conformational flexibility of HIV-1 reverse transcriptase, particularly in 
the region of the nonnucleoside inhibitor binding pocket, complicates attempts at 
structure based design of nonnucleoside RT inhibitors. ^̂ '̂ 3,94,109 variety of NNIBP 
conformations observed with different NNRTIs prevents the effective use of the pocket 
geometry for rational design of inhibitors that are not closely related in structure to that 
in the original complex. Thus, no single RT crystal structure will be suitable for generic 
modelling of NNRTI-NNIBP interactions and structure based drug design. 
The implications of receptor flexibility for structure based drug design are 
increasingly becoming appreciated. ^̂ ^ Although most successful structure based design 
examples to date have used relatively rigid binding sites, the inherent plasticity of 
many proteins often makes treatment of binding site flexibility mandatory for effective 
drug design. However, no suitable computational technique currently exists that can 
adequately model extensive receptor flexibility during docking of potential ligands. 
1.5 Research Objectives 
To facilitate rational structure based design and optimisation of novel 
nonnucleoside RT inhibitors, a detailed and comprehensive understanding of the 
conformational flexibility available to RT will first need to be developed. An 
appreciation of the correlation between conformational changes within the inhibitor 
binding pocket and those involved in the putative NNRTI inhibition mechanisms, the 
polymerase active site, primer grip and thumb movements, will aid the development of 
potent RT inhibitors. Furthermore, the ability to design better inhibitors with 
optimised binding affinity and resilience to resistance mutations will benefit greatly from 
knowledge of the flexibility of the NNIBP, and the capability to associate amino acid 
movements with specific structural and chemical features of the NNRTIs. This project 
addresses some of the earliest steps towards this goal through the development of 
several techniques and computational tools to aid the comparison of protein structure 
and their application to the multitude of high resolution HIV-1 RT X-ray crystal 
structures currently available. 
To facilitate the comparison of different crystal structures by superposition, 
while avoiding the pitfalls of this technique already highlighted, a rational superposition 
strategy is needed that will allow comparison of protein conformations without 
introducing artefacts due to the alignment method. The first step towards development 
of this superposition protocol involves identification of the conformationally invariant 
regions of RT that may form the basis for superposition. By construction of difference 
distance matrices (DDMs) of a range NNRTI complexed and apo RT crystal structures, 
an objective assessment of the rigid body regions of RT can be made. With this 
knowledge the structures could then be superposed on the basis of these rigid regions 
and the relative alignment of the more flexible areas could be examined. It was intended 
that the structures aligned in this manner would give a more representative description 
of the conformational changes induced by NNRTI binding, without obscuring subtle 
alterations in geometry or misrepresenting the "true" nature of other protein 
movements, and could subsequently be used for detailed and objective characterisation 
of RT flexibility. 
The DDMs were also to be used directly for the characterisation of protein 
flexibility, as they are capable of detecting and quantifying protein backbone movement 
without the need for superposition, circumventing the known problems of this method. 
By studying the DDMs of each NNRTI complex compared to the inhibitor free 
structure, precise location of the segments of RT that move upon inhibitor binding may 
be determined, without concern that the observed change may have been adulterated in 
some manner by the standard superposition procedure. 
Other methods of protein structure comparison were to be investigated, 
including development of software to enable the calculation of the difference between 
the polypeptide backbone dihedral angles ([) and \|/ of two protein conformations. This 
technique will allow the movement of the backbone to be studied in a complementary 
manner to the DDM and superposition methods. The (t)/\|/ angle difference calculations 
will be able to identify modes of conformational change that are not detected by the 
DDM programs, in addition to providing an alternative representation of conformational 
change that does not require prior superposition of structures. 
To probe the relationship between NNRTI structure and conformation with 
the NNIBP geometry, a molecular docking study of nine inhibitors, and seven pocket 
geometries was initiated. By docking of multiple conformations of each inhibitor into 
each pocket, it is hoped that some insight into the range of potential interactions 
available between the inhibitors and binding site may be gained. 
By comparing the conformation of RT in fifteen different available crystal 
structures, this project aims to study the conformational flexibility of RT in a more 
comprehensive manner than previous studies. Aspects of the modes of conformational 
change induced by inhibitor binding were investigated by studying complexes of RT 
with nine different NNRTIs, encompassing both a diverse range of inhibitor structures 
as well as closely related analogues of one another. The availability of several 
RT-NNRTI complex and apo structures in two different crystal space groups will allow 
the effects of inhibitor structure and crystal packing on the conformational change to the 
enzyme to be distinguished. 
It is intended that the application of the protein structure comparison tools 
developed during this project will assist in the future understanding of the 
interrelationships between the various modes of HIV-1 RT flexibility, by providing 
detailed and objective information of relative conformational changes between various 
inhibitor-free and NNRTI bound enzyme crystal structures. 
CHAPTER TWO 
DOCKING 
2.1 Introduction 
The high resolution structures of HIV-1 reverse transcriptase in the apo 
form, and complexed with double-stranded DNA and nine different 
nonnucleoside i n h i b i t o r s , ^^^^ ^̂ ^̂ ^̂  determined by X-ray 
crystallography. The solution of the three dimensional structure of RT and RT 
complexes has enabled the determination of the overall protein fold, the structure of the 
NNIBP, and the interactions between RT and DNA and the NNRTIs. Taken together, 
the 16 available crystal structures have also provided a great deal of insight into the 
conformational flexibility of RT, including the structural changes that are induced by 
binding of NNRTIs. 
The crystal structures have shown that although portions of the inhibitor 
binding pocket possess similar geometry in each of the NNRTI complexes, several 
regions undergo significant conformational changes when bound to different inhibitors. 
The volume of the pocket can differ by up to 100 Á̂  between the different 
complexes. 8i>93,i3i,i09 Despite this variability in NNIBP structure, the crystal structures 
show that the inhibitors, in their bound conformation, achieve a relatively good degree of 
steric overlap with one another (the compounds nevirapine, 1051U91, a-APA, HEPT 
A1 
and 9-Cl-TIBO occupy a common volume of 100 A^ out of a total of 440 A^). The 
changes in NNIBP conformation serve to optimise, and "customise", the protein-ligand 
interactions with each inhibitor. ^̂  Thus, in each RT-NNRTI complex, the NNIBP 
exists in a geometry that can be considered to be, in one way or another, specific to that 
particular inhibitor. The consequence of this customisation of pocket geometry is to 
render ineffective the use of any "consensus" NNIBP structure for accurate modelling of 
protein-ligand binding for anything but the most closely related NNRTI analogues. 
2.1.1 Docking Strategy 
Docking studies involving nonnucleoside inhibitors and HIV reverse 
transcriptase have been performed previously, and have shown that the differing 
pocket geometries can affect the validity of the relative ligand binding energies calculated 
when docking other NNRTIs into the cavity. ^̂  Most importantly, it has been shown 
that the optimal binding energy is most often obtained only when the correct NNIBP 
structure for each particular inhibitor is used as the starting conformation. ̂ ^ Although 
these previous docking experiments allowed limited flexibility of the NNIBP amino 
acids and optimisation of the ligand conformation within the pocket, they have studied 
only a limited range of NNRTIs. The complexity of the conformational searching and 
minimisation schemes used, and the use of manual initial fitting of the inhibitors into the 
pockets, precludes the use of this approach (although desirable) for docking of any more 
than a few chosen compounds. 
To investigate the effect on the NNIBP conformational changes on inhibitor 
binding it was attempted to dock the various inhibitors into the different pocket 
geometries. As the previous studies have examined only a Hmited range of 
NNRTI-NNIBP combinations, a more comprehensive investigation is required. The 
approach employed in this study was to generate a series of low energy conformations 
of many different inhibitors prior to docking into a larger range of different pocket 
geometries, using an automated molecular docking program. Although this method does 
not explicitly treat NNIBP flexibility, or account for the effect of protein-ligand 
interactions on the conformation of the inhibitor, it enables the binding potential for a 
large number of inhibitors and conformations to be determined relatively rapidly. It was 
intended, by analysis of the resulting relative docked ligand-protein geometries in each 
pocket, to detect any common inhibitor conformational or orientational features that 
may give some insight into the NNIBP-NNRTI binding interactions. The application of 
this technique to seven different inhibitor induced NNIBP conformations, spanning four 
classes of NNRTI, will allow greater sampling of the range of interactions available than 
the prior investigations, as well as aiding the determination of both the commonalities 
and distinctions between the binding modes of the different NNRTIs. Furthermore, the 
ability to search a large number of ligand conformation-orientation combinations in the 
different pocket geometries, allows the NNIBP cavity to be probed for potential 
inhibitor-protein interactions that may not be observed in the crystal complexes. While 
any new interactions found may not represent real interactions between RT and the 
existing NNRTIs, due to the difference between the calculated low energy conformations 
and the true bound geometry of the inhibitors, they may suggest possible avenues for 
modification of existing and new compounds in order to improve the inhibitor-RT 
binding affinity. 
Docking was performed on the seven high resolution crystal structures 
determined by Ren, et al, complexed with the NNRTIs nevirapine,10511)91,^^^ 
HEPT,^^^ MKC-442,«^ TNK-ÓSl/^ Cl-a-APA^^^ and 9-Cl-TIBO.'^ These structures 
were selected because of their comparatively high resolution (2.2-3.0 A) and uniform 
crystal space group (the reservations expressed about observations made from the 
P2i2i2i structures, section 1.3.4, page 34), are not relevant to the docking studies, as the 
apo structure is not required). Use of structures within the same crystal packing 
prevents any structural changes introduced by different crystal lattice forces, rather than 
the binding of different inhibitors, complicating interpretation of the results. Inhibitors 
were, however, selected from the entire set of available crystal structures (as their 
conformations were to be altered anyway), and include 8-Cl-TIBO and Br-a-APA, in 
addition to those listed above. 
2.1.2 Docking Method 
The program DOCK 3.5 (Department of Pharmaceutical Chemistry, University 
of California, San Francisco) was used in all docking experiments. DOCK explores 
many different relative alignments of ligand and receptor molecules, in order to 
determine geometrically^^ and energetically^®^ feasible ligand binding modes. Ligand 
structures, obtained from X-ray crystallography or molecular modelling studies, may be 
docked individually ^̂ ^ or by searching of a database of small molecule three dimensional 
coordinates.̂ ®^ The receptor structure, generally determined by X-ray crystallography, 
is represented by a set of overlapping spheres that fill the binding site. These spheres 
are calculated to fit the solvent accessible surface of the binding site, ' which 
delineates the continuous convex and concave protein area that a water molecule can 
make contact with, without the narrow (and misleading) channels between atoms that 
are produced by the normal van der Waals surface. 
Each ligand is then oriented within the binding site by systematically pairing 
individual sphere centres and ligand atoms. A second atom-sphere pair is then set by 
finding another sphere centre which has a similar distance from the previously matched 
sphere to the distance between the original atom and another ligand atom. This process 
is repeated for further atoms and spheres until four pairs have been assigned, which is 
sufficient to describe a rigid orientation. ^̂ ^ The entire ligand is subsequently rotated and 
translated to minimise the rms deviation between the matched atom and sphere centre 
coordinates. This matching algorithm provides a thorough, although not necessarily 
complete, sampling of orientational space, while avoiding a combinatorial explosion in 
the number of orientations to be tested with increasing numbers of spheres and 
atoms. 
The matched ligand orientations are then evaluated for their steric and/or 
energetic fit to the protein binding site (as those atoms not used in the matching step 
may make unacceptable contacts with the protein) and scored according to their van der 
Waals contact or interaction energy with the receptor. Scoring algorithms use a 
pre-calculated grid of the contribution to the receptor-ligand interaction made by the 
protein atoms, to speed the scoring process. DOCK also provides several additional 
features to increase the proportion of acceptable calculated ligand orientations, including 
ensuring that certain selected atoms and spheres are always matched (for example, to 
ensure known hydrogen bonds are c o n s e r v e d ) a n d optimisation of the ligand 
orientation using a molecular mechanics forcefield.^®^ 
The most significant caveat of the DOCK algorithm is the rigid body 
approximation. Both ligand and receptor have fixed internal geometries during all stages 
of the docking, scoring and optimisation process. That is, all conformational (bond 
length, bond angle and torsion) degrees of freedom in the ligand and receptor are 
constrained, with only the orientational (translation and rotation) degrees of freedom 
optimised. Limited treatment of ligand flexibility is achieved in this study via searching 
of a database of low energy conformations of each inhibitor. 
The energy function used for fofcefield scoring in DOCK is based upon the 
A M B E R m o l e c u l a r mechanical forcefield, and thus includes no explicit 
representation of hydrogen bonds, hydrophobicity or k-k interactions. 200'209 Although 
the absence of explicit treatment of k-k interactions could possibly diminish the 
contribution made to NNRTI binding by these forces, its has been shown that the 
electrostatic nature of K-K interactions enables reasonable representation by the atomic 
point charges used in molecular mechanics force fields. Coupled with the 
reproduction of aromatic-aromatic interactions in other NNRTI-RT docking 
studies, using the CFF91 molecular mechanics forcefield (Biosym/MSI), these 
observations provide some confidence in the ability of the DOCK molecular mechanics 
potential to treat the 7i-stacking interactions equitably. 
2.2 Validation of the Docking Method 
To ensure that the ligand orientations and positions obtained from the docking 
studies were likely to represent valid and reasonable potential binding modes of the 
inhibitors, the D O Œ program, docking parameters and sphere selections had to first be 
validated for each crystal structure used. Each NNRTI, in the conformation found in the 
crystal structure of the RT-NNRTI complex, was docked into its corresponding binding 
pocket, to determine the ability of DOCK to reproduce the orientation and position of 
the inhibitor observed in the crystal structure. 
2.2.1 Contact Scoring 
Initial contact scoring calculations showed that the choice of surface spheres 
provided a good representation of the NNIBP in six of the seven crystal structures. 
This was not surprising as, except for possibly those spheres located around the 
entrance, the enclosed nature of the pocket made the distinction between spheres that 
were either in (and therefore retained) or out of (and so deleted) the NNIBP, relatively 
clear. Table 3 shows that, on the basis of shape complementarity only, DOCK 
determined the optimal orientation of the docked inhibitors to be close to that of the 
original orientation found in the crystal. The low rms deviations (all below 1 Â, for all 
non hydrogen atoms) between the docked and crystal ligand coordinates indicate very 
good alignment of the experimental and calculated positions, especially considering the 
resolution limit of the crystal structures (2.2-3.0 Â). Visual inspection of the docked 
coordinates relative to the crystal structure NNRTI coordinates showed that in all cases 
the top three scoring results, and usually more, had orientations very similar to the 
Inhibitor PDB 
File 
Contact Forcefield 
RMS Orientations RMS Orientations 
Nevirapine IVRT 0.331 318 0.480 554 
1051U91 IRTH 0.915 676 0.756 581 
KEPT IRTI 0.946 45 0.895 42 
MKC-442 IRTI 0.679 3 0.613 13 
TNK-651 1RT2 0.495 3 0.417 4 
9-Cl-TIBO IREV - 0 - 0 
Cl-a-APA IVRU 0.980 70 0.786 53 
Table 3 Docking of NNRTI Crystal Conformations 
Highest scoring orientations from docking of seven NNRTIs into their 
NNIBPs in the conformation found in their respective crystal complexes, 
using contact (section 2.2.1) and forcefield (section 2.2.2) scoring. Table 
shows rms deviation of highest scoring orientation from that reported in the 
crystal structures, and the total number of ligand orientations found by 
DOCK for each scoring scheme. DOCK could find no favourable 
orientations of 9-Cl-TIBO in either scoring mode. 
crystal structures (Figure 8). The discrepancies in the relative positions were due to 
minor translation and rotation of the docked NNRTIs. 
The exception was 9-Cl-TIBO, for which no orientations were docked into the 
binding pocket. This could possibly be due to particularly close association between 
the inhibitor and protein in the crystal structure, thus producing a large number of steric 
clashes and preventing any favourable calculated interactions. A contact scored docking 
run in which the size of the inhibitor was reduced, by removing all hydrogens from the 
ligand, returned 4394 favourable docked orientations, however the highest scoring 
orientation had a rms deviation of almost 2 Â from the crystal structure. 
CONTACT SCORING FORCE FIELD SCORING 
Figure 8 Superposition of Docked and Crystal Structure NNRTIs 
Orientation of the crystal structure conformation (thick lines, black) of six 
NNRTIs relative to several of the best contact and forcefield scoring 
orientations (thin lines) docked into the respective NNIBP structures. Docked 
orientations are coloured blue, red and yellow, from best to third best scores, 
respectively, 9-Cl-TIBO was not included due to DOCK not being able to 
find any favourable orientations in the pocket. 
The ability of DOCK to reproduce the ligand orientation observed in the 
crystal structure by evaluating only the van der Waals interaction is interesting, as this 
scoring scheme cannot have any bias towards maximising the important 7i-stacking 
interactions between the NNRTI and aromatic residues, or the few observed hydrogen 
bonds. The contact scoring scheme relies solely on the complementarity between the 
three dimensional shape of both ligand and receptor. All orientations of MKC-442 and 
TNK-651, 7-9 of the 10 highest contact scoring orientations of nevirapine, HEPT and 
a-APA, and 4 of 10 for 1051U91 were in the "correct" orientation (along with more 
correct orientations in the remaining, lower scoring, ranges of the data sets). The high 
proportion of correct contact scored orientations calculated in each pocket indicates that 
the conformation of the NNIBP alone, contains enough information to accurately 
reproduce the crystal structure binding mode of the inhibitor, without requiring further . 
7i-stacking and electrostatic complementarity to distinguish them from other binding 
modes. This implies that the three dimensional shapes of each pocket are highly 
mutually complementary with that of their respective NNRTIs. This result does not 
detract from the significance of n-K interactions between the NNIBP and NNRTI, 
however, as they would make a considerable contribution to the formation of the 
complementary ligand and protein conformations in the complex. 
2.2.2 Forcefield Scoring 
Similar promising results were obtained when using a forcefield scoring scheme 
for measuring protein-ligand interaction energies. The rms deviations between the 
docked and crystal coordinates in Table 3 show relatively minor, considering the 
resolution of the crystal structures used, discrepancies between the docked and original 
ligand positions. Visual comparison again indicated very good relative orientation with 
the crystal structure, with only small rotations and translations (Figure 8). As occurred 
using contact scoring, 9-Cl-TIBO could not be docked into its original binding pocket, 
although the ligand with no hydrogens could adopt 4322 orientations, of which none of 
the ten highest scoring results resembled the crystal orientation. 
2.2.3 Forcefield Scoring with Rigid Body Minimisation 
The good correlation between the docked and crystal positions and orientations 
obtained using contact and forcefield scoring was not repeated when attempts were 
made to optimise the ligand positions using rigid body minimisation. Rigid body 
minimisation involves refinement of each ligand orientation prior to scoring by 
optimising non-bonded interactions between the ligand and receptor (without altering 
bond lengths, angles or torsions), using a grid based minimiser. The intended 
objective of applying minimisation is to give more representative forcefield scores and to 
retrieve orientations that may otherwise be rejected due to short range steric clashes 
with the binding pocket. However, the orientations of the crystal complex 
conformation of nevirapine when minimised using DOCK, in its own NNIBP geometry, 
were very poor relative to the crystal coordinates. The resulting top ten "optimised" 
forcefield scored orientations had rms deviations from 3.61 to 10.24 Â relative to 
nevirapine in the crystal structure. All ten orientations were rotated and translated so 
significantly from the original location that any atom-to-atom correspondence between 
the docked and crystal orientations was lost. Even a selection of ten orientations with 
worse forcefield scores, but with the lowest rms deviations from the original crystal 
coordinates, were translated by up to 2 A from the correct position. Furthermore, 
overlaying the optimised orientations with the solvent accessible and van der Waals 
surfaces of the NNIBP showed severe steric clashes between the inhibitor and protein in 
many cases. 
The cause of this disastrous "refinement" of ligand orientation is not known, 
but may be due to an error in the minimisation algorithm or parameters, although rigid 
body optimisation has previously been used successfully.^®^ The DOCK3.5 
package ^̂ ^ includes several utility programs for rigid body optimisation of the standard 
non-minimised orientations that employ different minimisation algorithms (simplex and 
quasi-Newton) and methods of energy calculation (grid-based and continuum), that may 
produce improved orientation refinement. These methods were not tested however, as 
good reproduction of the crystal binding mode was obtained without minimisation using 
contact and forcefield scoring schemes only, making further refinement of ligand 
orientation of little value. For the same reasons, minimisation was not pursued with the 
other RT-NNRTI complexes. 
2.2.4 Crystallographic Waters 
There are four structural waters located in the NNIBP of the nevirapine crystal 
structure, three around the entrance and one within the pocket. ^̂ ^ These water 
molecules were not included in the docking experiments described to this point. To test 
the dependence upon crystallographic waters of the accuracy of the docked ligand 
orientations, nevirapine was docked into the binding pocket containing the single water 
molecule located within the pocket. Despite the minimal change in the number of 
surface spheres needed to represent the water bound pocket (55 compared to 58), a 21% 
decrease in the number of calculated favourable orientations was obtained when contact 
scoring docking of nevirapme was performed. The ten best scoring results were all in 
identical relative positions to those calculated in the absence of water, however. As 
none of the structural waters are conserved amongst all the RT-NNRTI crystal 
complexes, and their presence or absence appeared to have little effect on the higher 
scoring orientations, as well as one goal of the subsequent docking experiments being to 
investigate the full orientational space available to the docked NNRTIs, crystallographic 
waters were not included in any of the other docking experiments. 
2.2.5 Ligand Flexibility and Number of Docked Orientations 
It is interesting to note the apparent correlation between inhibitor flexibility 
and the number of docked orientations that were calculated (Table 3). The more rigid 
NNRTIs, nevirapine and 1051U91, can fit into the binding site with several hundred 
favourable orientations (of which many of the lower scoring results do not resemble the 
crystal orientation), while the flexible NNRTIs, such as HEPT and analogues, can adopt 
comparatively few favourable geometries. As the docking experiments described here 
did not alter the conformation of the inhibitors from that observed when complexedto 
RT, the results suggest the association between NNRTI and NNIBP may be closer with 
the more flexible molecules. One possible explanation accounting for this is that the 
combined conformational freedom in both the binding pocket and inhibitor may allow 
both to adopt a more mutually complementary geometry, leaving minimal "free space" 
in the cavity to allow the ligand to adopt other orientations during docking. The rigid 
NNRTIs must rely almost entirely upon conformational change of the NNIBP to tailor 
the protein-ligand interactions, and so may not be able to achieve a completely 
complementary interface. The resulting voids between protein and ligand would 
effectively increase the pocket volume relative to the inhibitor, making possible the 
docking of different orientations in the static structures. 
Calculation of the proportion of each NNIBP geometry filled by its NNRTI, 
from the reported pocket and inhibitor volumes, provides some support for this: 
while the flexible KEPT derivatives MKC-442 and TNK-651 occupy 42 and 48% of the 
NNIBP, respectively, nevirapine and 1051U91 fill only 35 and 36%. This could also 
support the proposed cause of the inability oi DOCK to fit 9-Cl-TIBO back in to its 
receptor site. The flexibility of 9-Cl-TIBO may allow the NNIBP to form an interface 
with particularly close contact with the ligand, producing steric interactions during 
docking that were above the acceptable limits of the program parameters, and preventing 
the crystal orientation being detected. Reducing the size of the inhibitor relative to the 
pocket, by removing the ligand hydrogens, allowed the smaller molecule to adopt many 
orientations within the cavity. 
2.3 Docking of Multiple Ligand Conformations 
2.3.1 Ligand Conformations 
To increase the extent to which each binding pocket was probed by the docking 
study, multiple alternative low energy conformations of the inhibitors were generated 
using a simple molecular dynamics and minimisation protocol (section 6.2.3). A unique 
set of conformations was then collected from the minimised structures, by selecting a set 
of conformations that differed by 0.3 Â rms, or more, from each other, and discarding 
duplicates or very similar conformations (i.e. rms < 0.3 A). The range of energies of the 
selected conformations corresponded exactly with the range of the entire set of 
dynamics conformations in each case. The use of the 0.3 A rms cutoff allowed selection 
of structures with fairly subtle differences in conformation, while at the same time 
preventing the docking process becoming cluttered with many copies of near identical 
ligand structures. 
The number of unique conformations generated for each ligand varied 
enormously (Table 4), and gives some perception of the flexibility of the different 
classes of NNRTI: the HEPT series compounds were able to adopt a large number of 
distinct conformations, as were the TIBO and a-APA analogues to a lesser extent, while 
nevirapine and 1051U91 were restricted to only two and six conformations. 
Inhibitor Compound Conformations Energy Range (kcal) 
Nevirapine (10) 2 142.2-142.2 
1051U91^ (11) 6 61.7-74.0 
HEPT (4) 29 3.6-9.5 
MKC-442 (5) 20 3.7-10.3 
TNK-651 (6) 38 9.1-14.2 
8-Cl-TIBO (9) 20 24.0-29.4 
9-Cl-TIBO (8) 22 22.6-28.1 
Cl-a-APA (12) 7 6.1-13.8 
Br-a-APA (12)î 12 7.7-15.2 
Table 4 Unique Conformations of NNRTIs 
Number of conformations of each NNRTI differing by at least 0.3 Â rms after 
molecular dynamics and minimisation, and range of minimised energies of 
the selected conformations. ^ Nitro substituent replaced by carboxylate, see 
section 6.2.3. ^ Dibrominated analogue of Cl-a-APA. 
respectively. The resulting total of 156 dynamics ligand conformations and the nine 
original crystal structure conformations were assembled into a database file in 
preparation for automated docking. 
2.3.2 Number of Conformations Docked into Each Pocket 
The intention of the docking studies was to attempt to dock many discrete 
conformations of different NNRTIs into each binding pocket, and to gain some 
appreciation of the structural, conformational and chemical characteristics required by an 
inhibitor to bind to each NNIBP structure. It was expected that the specific geometry 
of each pocket for a particular NNRTI would provide some filtering of the large set of 
calculated structures to a relatively small and characteristic set of compounds and 
conformations, that would allow the interpretation of the ligand and NNIBP 
conformational features that gave rise to the binding mode of each docked compound. 
When contact scoring was employed, DOCK was much more prolific in its 
ability to dock the low energy inhibitor conformations into the pockets than anticipated. 
Table 5 lists the number of inhibitor conformations that could fit into each pocket in at 
least one favourable orientation, showing that in contact scoring mode between 66 and 
99% of the database was successfully docked into all NNIBP structures. (In database 
searching mode, as used here, DOCK returns only the best orientation found for each 
compound, or conformation, in contrast to the mode used in previous sections - when 
only one inhibitor conformation was being docked - in which many orientations of the 
one ligand conformation are returned - without this restriction the number of potential 
NNIBP PDB Contact Forcefield 
Nevirapine IVRT 142 69 
1051U91 IRTH 164 99 
KEPT IRTI 109 58 
MKC-442 IRTl 112 48 
TNK-651 1RT2 112 44 
9-Cl-TIBO IREV 160 101 
Cl-a-APA IVRU 161 127 
Table 5 Docking of Inhibitor Conformation Database 
Number of NNRTI conformations docked into each NNIBP, from a total of 
165 conformations of nine different inhibitors. 
permutations of different conformations and orientations may well have been 
incomprehensible. ) 
The lack of specificity of each NNIBP structure for the range of inhibitor 
conformations (in the case of the 1051U91 pocket, all but one ligand conformation was 
successfully docked using contact scoring) was unexpected, and made the intended 
objective of determining characteristic inhibitor geometries for each NNIBP geometry 
difficult. The large number of successfully docked conformations made the detailed 
analysis of the results prohibitively time consuming, as no automated method of 
analysing the resulting ligand-protein interactions existed. Due to the need to convert 
the ligand structures between several file formats during conformation generation and 
database construction, the names originally used to identify each set of coordinates were 
absent in the final database file, preventing the docked structures being easily correlated 
to the original molecular dynamics conformations. Identification and analysis of each 
docked conformation required direct visual comparison with the calculated structures, 
one inhibitor at a time. As a total of 960 structures were docked into the seven binding 
sites, this was not considered practical. 
While use of a database with a coarser selection of inhibitor conformations 
(differing by 0.5 or 1.0 A rms, for example) would have reduced the number of 
conformations requiring analysis, it would also result in a reduction in the extent to 
which the conformational/orientational space of the NNRTI-NNIBP interaction was 
searched. Arbitrarily eliminating potential ligand-protein binding modes in this fashion 
could potentially reduce the utility of this method of analysis of the binding site 
conformation, and so was not pursued. 
Application of forcefield scoring to the database search proved to be much 
more promising, reducing the number of docked conformations significantly (although 
still not to levels suitable for individual manual analysis of the entire data set - a total of 
546 structures with a negative interaction energy were determined). The forcefield 
scoring mode (without rigid body minimisation) has been shown to be capable of 
determining reasonable ligand binding modes (section 2.2.2), and may be better able to 
incorporate K-K interactions into the scoring process, increasing the relevance of the 
forcefield scored results over the contact scored data. Furthermore, the observation of 
some relatively high ranked contact scored orientations of the database structures that 
were positioned partly outside the pocket or within the pocket entrance, implied that 
particular caution would be required during analysis of the contact scored results. 
Although bmding modes in which the inhibitor is partially exposed to solvent have been 
observed in docking experiments with larger compounds, ^̂^ and may be necessary if the 
larger RT inhibitors, such as the biaryl compounds and michellamines,are to act at the 
NNIBP, it is unlikely that it would be a favourable binding mode of a much smaller 
compound that is known to be capable of being completely sequestered by the protein. 
Similar binding modes were not observed in any of the high ranked forcefield scored 
conformations. 
The more manageable size of the forcefield scored data set, its consideration of 
electronic factors during scoring, and the absence of binding geometries that were not 
intuitive (i.e. ligands partially outside the pocket) enabled the interpretation of these 
resuhs with much greater confidence with respect to their validity, so only the forcefield 
scored results were further analysed to any extent. 
2.3.3 Steric Complementarity of Inhibitor Conformations 
Inspection of the ten to twenty highest scoring inhibitor conformations, and 
their relative orientations, after docking and forcefield scoring of the database, showed 
only limited specificity for the inhibitor from which the NNIBP structure was derived. 
Conformations of nevirapine and 1051U91 dominated the highest scoring structures of 
most of the seven binding pocket geometries, despite the protein structure being derived 
from a different NNRTI complex. In several cases, the highest scoring conformation did 
not even belong to the original ligand in the complex from which the structure was 
derived. This suggests that, despite the difference in pocket shape, only relatively 
minor adjustments of each ligand conformation are required to allow the NNRTIs to fit 
into other pockets. 
Superposition of the docked conformations over the crystal structure 
orientation of the original inhibitor of each pocket showed very good alignment of major 
structural features. Despite the structural diversity of the NNRTIs, the aromatic rings 
of most of the high scoring docked conformations were aligned with one another and 
with the crystal structure orientation, as were many of the various other functional 
groups in the inhibitors. The overlaying of the aromatic regions of the high scoring 
inhibitor conformations suggests that a significant contribution to their relative scores 
was made by the electrostatic component of 7i-stacking interactions between the 
inhibitors and NNIBP. Those conformations that had large rotations relative to the 
majority of the other docked conformations still retained a good degree of overall steric 
overlap, occupying the same volume even if the correspondence between functional 
groups was not conserved. 
Figure 9 shows the high degree of steric similarity and overlap of the 
conformations docked into a NNIBP structure of each of the four classes of NNRTI 
examined. Each component of Figure 9 shows the crystal structure conformation of the 
inhibitor from which the pocket structure was derived, and five different NNRTIs in 
their highest scoring conformation and relative orientation, from two different view 
points. A significant feature of the superposed structures is the alignment of the 
butterfly-like curvature of each NNRTI, as shown in the left hand column of Figure 9, 
amongst the various types of inhibitor structure. The 9-Cl-TIBO NNIBP possessed the 
least degree of comi)lementarity in the overlayed docked structures, and the original 
inhibitor itself was not amongst the first five different inhibitors docked into the pocket. 
Nevirapine 
MKC-442 
CI-a-APA 
9-CI-TIBO 
Figure 9 Shape Complementarity of Docked NNRTIs 
Relative orientation of the highest scoring conformation of each of the five 
highest ranked structures (grey, thin lines) docked into the NNIBPs of 
nevirapine, MKC-442, Cl-a-APA and 9-Cl-TIBO (crystal structure 
conformation drawn in thick, black lines). The two different perspectives of 
each set show the high degree of steric complementarity between the different 
inhibitors, particularly the conservation of the curvature of the two wings of 
the "butterfly Note that the structures shown are not necessarily the five 
highest scoring conformations overall, but the highest scoring conformation 
of each of the five inhibitors shown. 
It should be noted that the conformations shown in Figure 9 are not necessarily 
the five highest scoring structures overall, but the highest scoring conformation of each 
of the first five different NNRTIs to be successfully docked. Lower ranked 
conformations of NNRTIs that had already been docked are not shown - all are amongst 
the twenty highest scoring structures overall, however. 
The docking study of Kroeger Smith, et al,^^ found that a reliable correlation 
between the calculated binding energy and experimental inhibitory potency could not be 
made when an inhibitor was docked into a NNIBP geometry not derived from its own 
crystal complex. The five docked ligands shown in Figure 9, drawn in grey, belong to at 
least three of the four different classes of NNRTI in each case, suggesting that with 
reasonable adjustments of conformation, most NNRTIs are capable of fitting into the 
different NNIBP geometries. The ability of DOCK to fit low energy conformations of 
different NNRTIs into the one pocket geometry, often with better binding energies than 
conformations of the original ligand, implies that the NNIBP shape may not have as 
great an influence on docking calculations as previously suggested. ^̂  
The previous study allowed optimisation of both the binding site amino acid 
and inhibitor conformations in situ, ideally giving a more realistic representation of the 
protein-ligand interaction. This differs from the current study, in which the ligand 
conformation is optimised in vacuo and the binding site geometry held rigid. The 
absence of any treatment of binding induced conformational changes in either the ligand 
or protein may prevent the resolution of any minor steric clashes or optimisation of 
protein-ligand interactions (for example, slight adjustment of aromatic side chains to 
improve k-k interactions), that could otherwise favour the "correct" inhibitor structure. 
This is the most likely cause of the differences between the conformations selected by 
DOCK and those of the more computationally intensive molecular mechanics 
approaches employed previously. As the DOCK orientations are determined on 
the basis of steric factors, and then ranked according to their energetic interaction with 
the binding site, this method does not offer the same level of "fine tuning" of the ligand 
orientation as does full molecular mechanical treatment or even rigid body minimisation 
(which was unavailable, see section 2.2.3). Even though DOCK orients ligands on the 
basis of steric factors only, these results show that the pocket geometry is sufficiently 
similar in the different complexes to allow other NNRTIs to fit favourably into the 
cavity. Although the NNIBP has been reported to change conformation and volume 
with different NNRTIs, the steric and chemical complementarity illustrated in Figure 9 
suggests that a considerable amount of structural similarity remains, particularly the 
features that favour the butterfly shape and aromatic character of the inhibitors. 
2.4 Summary 
The initial docking experiments, using the corresponding NNRTI and NNIBP 
crystal structures, indicated that the geometry of each specific NNIBP structure 
contained sufficient steric information to enable DOCK to accurately reproduce the 
correct crystal binding mode. This is concordant with the notion that the NNIBP 
adopts a conformation that optimises interactions with each specific inhibitor. The 
subsequent conformational database search has shown, however, that relaxation of the 
NNRTI crystal complex conformation allows most inhibitors to fit into each different 
pocket, without alteration of the NNIBP conformation. In several cases, the most 
favourably docked inhibitors are not those from which the structure of the pocket was 
obtained. This contradicts findings from earlier docking investigations ^̂  in suggesting 
that the geometry of the RT binding pocket may not be as influential to docking 
experiments as previously thought. Furthermore, the range of NNRTIs docked in each 
case, along with the good alignment of their structural features, implies that the 
conformation of the NNIBP in each different complex is conserved sufficiently to 
influence particular uniform ligand binding modes. 
To test the validity of these observations, further modelling experiments are 
required. The rigid representation of both components, and the steric (rather than 
energetic) basis to the determination of the ligand orientation performed by DOCK may 
prevent optimal docking and relative interaction energy evaluation of many inhibitor 
conformations. By allowing some molecular mechanical conformational refinement of 
both the NNIBP and NNRTI in situ, using the conformation and orientation of the high 
scoring DOCK results as a starting point, the effect of the ligand conformation and 
orientation on the energy of the complexed system may be determined, giving a better 
impression of whether the current docked complexes represent reasonable binding 
modes. 
The NNRTI conformations and orientations selected by the docking process 
with each pocket exhibit an impressive degree of similarity in the arrangement of their 
steric and electronic features, namely the curvature of the inhibitor wings and 
approximate alignment of aromatic regions. Overlaying different inhibitors in this way 
(based on their docked orientation) can provide information about the important 
structural features contributing to the association to the enzyme, analogous to that 
obtained by construction of a pharmacophore from the ligand structures alone. The 
interesting aspect of this approach is that the observed close alignment of NNRTI 
structure is not a direct consequence of the similarity in the structure of the ligands 
themselves, as would be the case with a standard pharmacophore, but is determined by 
the structure of the pocket that they have been docked into. Application of this 
approach to other inhibitors, and a more thorough analysis of the superposed 
conformations, are potential avenues for further development of this method. 
CHAPTER THREE 
DIFFERENCE DISTANCE 
MATRICES 
3.1 Introduction 
As discussed in the introduction, the flexibility of reverse transcriptase has 
important implications for the polymerase activity of the enzyme and the inhibition 
mechanism by nonnucleoside reverse transcriptase inhibitors. A thorough understanding 
of this conformational flexibility will offer great benefits to structure based design and 
optimisation of these inhibitors. Thus, there is a need to characterise the structural 
movements in the various RT domains that are induced by binding of a NNRTI, with 
reference to the enzyme in its inhibitor free, and therefore active, state. 
A cursory visual inspection of the superposed protein backbones of the native 
RT and NNRTI bound enzyme X-ray crystal structures reveals that the gross features 
of the secondary, tertiary and quaternary structure are largely unaffected by inhibitor 
binding (for example. Figure 10). Superposition based on the entire protein backbone 
tends to average systematic changes in conformation, smoothing out and obscuring 
localised adjustments in the polypeptide conformation. 
Figure 10 Superposed Backbones of RT and RT/Nevirapine Complex 
Ribbon diagram of superposed backbones of native RT (dark blue) and RT 
complexed with nevirapine (light blue), showing the similarity of secondary 
and general tertiary structural features. Superposition based on 7606 heavy 
atoms common to both crystal structures, rms 2.59. Coordinates from PDB 
entries IRTJ''' (RT) and 1VRT'""^ (RTI nevirapine). 
For similar reasons, quantitative representation of the degree of coincidence 
between two molecules by calculation of the root-mean-square (rms) deviation of the 
corresponding atomic coordinates of two three dimensional structures fails to describe 
the distribution of conformational differences within the proteins.̂ ^®^^^ For example, 
while a small, but nonzero, rms value for two superposed structures indicates that 
conformational discrepancies exist, it does not indicate whether these differences are 
uniformly dispersed throughout the protein, are confined to movements in highly 
flexible motifs (e.g. loops and turns), are due to secondary structural changes 
(e.g. disruption of a-helices or p-sheets), or minor alterations in tertiary structure 
(e.g. relative movement of two helices). 
To overcome the shortcomings of large scale superposition of flexible proteins, 
a superposition strategy based on the structurally rigid areas of RT was used, and is 
discussed in Chapter Four. To be effective, the "rigid body" superposition protocol 
first requires a detailed characterisation of the conformationally flexible and invariant 
regions of the enzyme, to guide the selection of the segments of RT on which the 
superposition is to be based. Although rough superposition and visual inspection of the 
geometry of the different RT-NNRTI complexes may be able to identify the larger rigid 
regions, a detailed characterisation by this method is not practical. A far more effective 
method for objectively identifying and locating widely distributed conformational 
variations between two three dimensional structures involves comparison of the 
conformations without actual superposition of the structures being performed. Distance 
matrices (DMs) represent three dimensional structure using internal, rather than' 
Cartesian, coordinates.^^^ The elimination of the Cartesian reference frame results in a 
representation of structure that is independent of rotation and translation, and so is 
amenable to structural comparison without superposition. The use of difference 
distance matrices (DDMs), calculated by simple subtraction of the DMs of two 
homologous structures, enables rapid identification of regions of conformational 
similarity and dissimilarity.^^^ 
DDMs have been used previously to compare the structure of 
immunoglobulins?^"^ to monitor conformational changes during molecular dynamics^ 
and temperature changes to myoglobin,^ ̂ ^ and to assign secondary structure to 
crystallographic coordinate data?^^ Jäger, et al have used DDMs to identify regions 
of conformational flexibility in HIV-1 RT crystal structures. In this study the relative 
domain movements between RT complexes containing either DNA or nevirapine, in two 
different crystallographic space groups, were analysed using a combination of 
comparison methods, including DDM calculation. The study revealed, via identification 
of related domain movements amongst the different complexes and crystal forms, a 
specific twisting motion between the polymerase active site and the rest of the RT 
molecule. ^̂^ 
The study by Jäger and coworkers ^̂^ used a relatively small set of crystal and 
inhibitor data (four crystal structures, three of which were complexed with nevirapine) 
and did not attempt to correlate the RT subdomain movements with binding to the 
NNRTI. This was not possible due to the possible contribution of crystal packing 
forces to the conformational changes observed, as comparison of structures in different 
crystal forms were made. Our approach has substantially expanded on this by making 
use of 14 of the currently available high resolution crystal structures of RT in native and 
NNRTI bound forms with nine different inhibitors and in two crystallographic space 
groups. The crystal structures of the native enzyme have been compared using DDMs 
with those of RT complexes with the NNRTIs nevirapine, 1051U91, 8-Cl-TIBO, 
9-Cl-TIBO, MKC-442, TNK-551, KEPT, Cl-a-APA and Br-a-APA to identify ligand 
induced-conformational changes. The information extracted from DDMs can either be 
used for direct interpretation of conformational changes induced by binding of NNRTIs 
to RT, or for the selection of suitable rigid regions to use for the basis of superposition 
studies, for more detailed analysis (Chapter Four). 
To minimise the effect of different crystal packing forces on the fold of the 
structures being compared, RT-NNRTI complexes have only been compared with an 
apo-enzyme structure of the same crystallographic space group. This allows structural 
changes induced by the NNRTI to be isolated from those due to inter-protein domain 
interactions in different crystal packing arrangements. Furthermore, the availability of 
several apo and inhibitor bound RT structures in multiple crystal space groups has 
enabled greater discrimination between ligand and crystal packing induced 
conformational changes in the X-ray structures. 
3.2 Calculation and Interpretation of Difference 
Distance Matrices 
A normal distance matrix is constructed by calculating the distances r^ between 
the a n d a m i n o acids, i.e. every combination of two residues in a single protein. The 
coordinates of the backbone atoms are used to represent the position of an amino 
acid. These distances are stored in an « x « square matrix with the residue numbers i and 
j along the axes, where n is the number of residues in the protein. The internally 
referenced DM contains all the structural information required to regenerate the relative 
Cartesian coordinates of the molecule, with the exception of chirality.^^^ Pairs of 
residues that are close to each other in the three dimensional structure will have small 
values of while those that are distant, even if they are close together in the 
polypeptide sequence, will have larger r^ values. The pattern of r^ values in the DM 
represents the three dimensional structure of the protein, with secondary structure 
located along the diagonal and higher order tertiary and quaternary structure in the 
off-diagonal regions. ^̂ ^ 
A difference distance matrix comparing two protein conformations A and B is 
constructed by first calculating separate DMs containing the distances and r̂ ® from 
conformations A and B, respectively. Subtraction of one DM from the other, by 
calculating the difference Ar^ between elements r^^ and r / that have corresponding 
values of / and j , yields the DDM comparing the conformations of A and B. This is 
constructed more directly by calculating: 
for all combinations of i and j ^iJ 'J 
and storing in a square matrix with i and j along the axes. 
If the two conformations A and B are identical, even if not superposed, the 
corresponding distances and will be identical and so the difference Ar,y equal to 
zero. However, if a residue x is in a different position in one structure it will have 
different distances to every other residue j in the protein and the differences in the 
DDM will be nonzero for every value where i = x. Thus, regions of dissimilarity 
between the two structures will appear as clusters of nonzero difference values in the 
DDM, with the value of Ar,y indicating the magnitude of conformational change. 
A computer program was written to facilitate the construction and 
interpretation of the DDMs. This program, developed in C++ to run in the Microsoft 
Windows environment on a PC, is described in section 6.3. Briefly, the program reads 
the atomic coordinates of the C„ atoms from PDB format files, calculates the Ar,y values, 
and displays them in a graphical format. 
The DDM is represented graphically by plotting the matrix as a three 
dimensional graph, with residue number (/ and j) along the x and y axes and Ar^ on the z 
axis. This is most conveniently achieved by partitioning the Ar,y values into discrete 
distance ranges and plotting as a series of coloured contours on the graph, as shown in 
Figure 11. As the distance nj -r, / = r j i - r / the plots are symmetrical across the 
diagonal, so only half the DDM plot need be calculated. 
The DDM plots in this section are contoured at 2.5 A intervals: 
white 0 - 2.5 A; yellow 2.5 - 5.0 A; green 5.0 - 7.5 A; and red > 7.5 A. The residue 
sequence number is indicated along the axes, with the p66 subunit at the top and left 
sides and p51 at the bottom and right sides of the y and x axes, respectively. Gridlines 
are positioned every 50 residues. Using this contouring scheme, corresponding regions 
of the two structures that have similar conformations appear as white areas in the 
DDMs (i.e. Ar,y nearly zero). Residues that have undergone conformational change can 
be identified by vertical or horizontal coloured bands (i.e. Ar^ nonzero), with red 
indicating larger relative movements. 
The crystal coordinate data used for DDM calculation was incomplete in many 
short segments of the polypeptide, due to the poor electron density in some highly 
disordered regions. The consequence of this is that small 'gaps' appear in the plots 
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Figure 11 DDM of Native RT and RT-Nevirapine Complex 
C^-Q difference distance matrix of RT in native form and complexed with the 
NNRTI nevirapine (10) in space group crystal structures (PDB 
entries IRTJ^^^ and IVRT/^^ respectively). Inter-residue distances 
calculated using coordinates of C^ atoms y calculated for both p66 and p51 
subunits (residue numbers are indicated on both axes). The plot is contoured 
in 2.5Á intervals: white 0 - 2.5 Á; yellow 2.5 - 5.0 A; 
green 5.0 - 7.5 A; and red > 7.5 A. Polypeptide segments that did not 
appear in both crystal structures, and so were not calculated, are indicated by 
black rectangles on the axes. 
where calculation of Ar^ is not possible due to missing data. Although several 
approaches exist to overcome minor sequence inhomogeneities, insertions and 
deletions, the problem here is one of missing data, so these regions have not 
been calculated in the DDMs. Regions with missing data appear as vertical and 
horizontal white bands of varying widths in the DDM plots, with rectangular markers 
on the axes distinguishing them from regions of near zero 
3.3 Characterisation of Rigid and Flexible Regions of 
HIV-1 Reverse Transcriptase by Difference 
Distance Matrix Analysis 
The DDM approach has been used to characterise inhibitor dependent domain 
movements in RT and to identify regions of structural rigidity that may be suitable as 
the basis for further superposition studies. It is shown that conformational changes of 
the RT heterodimer are restricted to selected regions of the enzyme, and the scale of the 
movement differs amongst the different classes of NNRTIs. 
3.3.1 RT Complexes with Nevirapine and Derivatives versus 
Apo-RT Difference Distance Matrices 
The DDM of the crystal structures of the native RT heterodimer ^̂^ and its 
complex with the NNRTI nevirapine ^̂ ^ (10), both in the P2x2{lx crystal space group, is 
shown in Figure 11. Inspection of this diagram immediately indicates that while the 
majority of the nevirapine complex possesses a similar conformation to that of the apo 
enzyme, there are several distinct regions that have undergone significant rearrangement 
in the inhibitor complex. 
Reading from the x-axis, the yellow and green vertical bands covering segments 
of the polypeptide chain corresponding to the fingers (p66 residues 1-88 and 121-146) 
and thumb (p66 residues 243-311) subdomains indicate that these structural features 
have altered their distance to the remainder of the protein when compared to that of the 
native protein. The greatest relative movement (> 7.5 A) is between the fingers and 
thumb subdomains. In contrast, the large uncoloured areas corresponding to the p51 
subunit, connection subdomain (p66 residues 312-425) and RNaseH domain (p66 
residues 426-560) represent distance differences of less than 2.5 A between the two 
crystal structures, indicating that these regions behave as relatively rigid bodies. The 
thin (only a few residues wide) streaks that appear in the DDMs can usually be 
attributed to changes in the conformation of flexible loop and coil regions of the two 
proteins under examination. 
Although difficult to see with the scale of the DDM plots, a thin white band 
(only 5-10 residues wide) runs along the diagonal of Figure 11. As the points plotted 
near the diagonal are calculated from the coordinates of atoms close together in the 
polypeptide sequence, they represent changes in secondary structure of the proteins. 
The thin white diagonal band in Figure 11 shows no appreciable differences in the 
relative internal distance between the residues forming individual secondary structural 
features, indicating that little internal rearrangement of the a-helical and P-sheet motifs 
exists in these two structures. Also, the white areas at the top left area of the DDM 
(p66 residues 1-240 on both x and y axes) and a region fiirther along the diagonal 
representing p66 residues 240-310 (on both x and y axes), suggest that little 
rearrangement of the internal tertiary structure of the fingers, palm, and thumb 
subdomains is induced by inhibitor binding. A thin horizontal band in the palm region, 
the vicinity of the p66 amino acids 227-229, indicates that movement of 2.5-7.5 A 
relative to these subdomains does occur for a few residues, although the overall 
geometry is similar in both structures. This band represents the p9 strand, which forms 
part of the NNIBP, and has been shown to move in order to expand the volume of the 
pocket to fit the different NNRTIs. ^̂  
The palm subdomain (p66 residues 89-120 and 147-242), which is dispersed 
amongst the fingers and between the fingers and thumb subdomains in the polypeptide 
sequence, also shows reasonable conformational rigidity relative to the remainder of the 
protein. Slight movements (2.5-5.0 A) jn the regions positioned at approximately 
residues 100-110 (relative to the thumb) and 180-190 are evident. These segments of 
the sequence contain residues of both the polymerase active site and the NNIBP. 
Figure 11 shows that while the thumb has moved relative to most of both the 
p66 and p51 subunits, the fingers domain has confined the change in distance primarily 
to the p66 subunit. This situation could possibly arise by rotational movement of the 
fingers relative to the p51 subunit, thus largely maintaining a constant distance (at least 
within the 2.5 A threshold) between the two regions. It should be noted that the DDM 
contains no directional information of the residue movements, just the scalar change in 
relative distance. Furthermore, as the distances are calculated as absolute values, the 
DDMs used here do not indicate whether the residues are moving closer together or 
further apart relative to each other. 
Figure 11 is constructed from the P2i2i2i space group crystal structures of the 
apo and nevirapine complexed enzymes. The suspect conformation of the apo enzyme 
in this space group, due to the method of crystal production, has been discussed in 
section 1.3.4. The arrangement of RT molecules in the P2i2i2i crystal prevents the 
thumb subdomain from folding into the DNA binding cleft and thus adopts a 
conformation similar to that of the NNRTI complexed enzyme. Despite this. Figure 11 
suggests that significant differences in the conformation of the thumb (in excess of 
7.5 A) exist between the apo and nevirapine complexed crystal structures. The effect 
that this has on the geometry of other regions of the apo P2i2i2i structure is unknown. 
An examination of the DDM calculated from the corresponding C2 crystal structures 
(which do not suffer from this crystal packing effect) show a much more dramatic 
rearrangement of the thumb and fingers subdomains, however (see below). Although 
concerns about the validity of the conformational changes measured against the P2i2i2i 
apo structure must be considered, the "cleaner" appearance of the DDM of Figure 11 
make it more amenable to the introductory description of DDM interpretation. 
Comparison of the apo ^̂ ^ and nevirapine complexed forms of RT in the 
crystal space space group C2, is shown in Figure 12. The DDM indicates significantly 
larger movement of the p66 thumb and fingers subdomains, as well as greater 
rearrangements in the p51 subunit in this crystal form. Many of the smaller structural 
differences (2.5-5.0 A) may be partly accounted for by the lower resolution of these 
crystal forms compared to those of the P2i2i2i structures (3.2 A versus 2.3 A and 
2.9 A versus 2.2 A for the apo and nevirapine bound forms, respectively). The greater 
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Figure 12 DDM of Native RT and RT-Nevirapine Complex in C2 Form 
C^-C^ difference distance matrix of RT in native form and complexed with the 
NNRTI nevirapine (10) in C2 space group crystal structures (PDB entries 
IHMV^^^ and respectively). Contour levels and missing 
polypeptide segments are as described in the caption to Figure 11. 
uncertainty of the precise atomic coordinates in the C2 crystals may result in the 
calculated relative distance differences falling above the 2.5 A threshold that would 
obscure any minor conformational changes occurring in the P2i2i2i structures. If the 
effects of the lower resolution are taken into account, it can be seen that, in general, the 
conformational changes are similar to those identified with the P2i2i2i structures 
(Figure 11), i.e. the rearrangements are restricted primarily to the fingers and thumb 
subdomains of p66. 
The much greater magnitude of the p66 thumb movement (the majority of 
changes in excess of 7.5 A) in Figure 12 cannot reasonably be ascribed solely to the 
lower resolution of the atomic coordinates, but represents a true relative 
conformational change in this domain in the P2{l{lx and C2 crystal forms. In the 
nevirapine complex belonging to the C2 space group the thumb is rotated 34° from its 
position in the apo enzyme, so that the DNA binding cleft formed by the fingers and 
thumb is in an open conformation. ^̂ ^ In the apo protein, the thumb folds into the cleft 
and lies over the polymerase active site. ^̂ ^ In the P2i2i2i structures the rotation of the 
thumb in the nevirapine complex relative to the apo enzyme is substantially less (only 
12°), a result of the "open" conformation of the thumb in the apo structure. 
Yet another different conformation of the p66 thumb is observed in the P2i2i2i 
complex of RT with the nevirapine analogue 1051U91 The DDM in Figure 13 
shows virtually no conformational rearrangement of the fingers and thumbs in the 
1051U91 complex when compared to the apo structure. This indicates that the 
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Figure 13 DDM of Native RT and RT-1051U91 Complex 
difference distance matrix of RT in native form and complexed with the 
nevirapineanalogue!051U91 (11) in P2,2,2, space group crystal structures 
(PDB entries IRTJ^^^ and IRTH/^^ respectively). Contour levels and 
missing polypeptide segments areas described in the caption to Figure IL 
conformation of the thumb in the 1051U91 complex is almost identical to that of the 
P2{l{li apo enzyme. Although the thumb must still be in a relatively "open" 
conformation (on account of the apo thumb orientation), the effect of 1051U91 the 
thumb position is minimal compared to its close analogue nevirapine (Figure 11). In 
fact, the only noteworthy conformational changes are confined to three short segments 
of the protein: the ß4, ß7 or ß8, and ß9 strands of p66. ß4, ß7 and ßS contain the 
catalytic aspartic acid residues of the polymerase active site (Asp 110, Asp 185 and 
Aspl86), and ß7 and ß8 contain the important NNIBP aromatic residues TyrlSl, 
Tyrl83 and Tyrl88. No other changes that can confidently be discriminated from 
artefacts of the model resolution are observed in either the p66 or p51 subunits. Thus, 
the only significant conformational changes induced by binding of 1051U91 are localised 
around the polymerase active site and the NNIBP. 
While the absence of movement of the thumb and fingers subdomains in this 
complex could possibly be correlated with the lower potency of 1051U91 compared to 
nevirapine (IC50 = 0.4 )IM and 0.08 |LIM ^^ respectively), lack of conformational 
change of these domains is also seen in other very potent inhibitors in the P2\2\2\ 
crystal form (see below). Even accounting for the anomalous position of the thumb in 
the apo P2i2i2i crystal structure, different NNRTIs produce differing magnitudes of 
conformational change in the P2i2i2i structures. Although the DDMs of the P2{2{2i 
crystals do not show the true magnitude of the thumb movements, conformational 
changes in other important regions, particularly the NNIBP, are detected. The effect of 
the method of P2\2\2\ apo enzyme crystal creation upon the conformation of other 
regions of the protein is currently not known, but it appears from inspection of the 
P2i2i2i DDMs that the geometry of some regions of the apo crystal (such as the 
NNIBP) is not restricted to that of the NNRTI bound state. 
3.3.2 RT Complexes with HEPTand Derivatives versus Apo-RT 
Difference Distance Matrices 
The DDMs for the complexes with the HEPT series compounds HEFT (4), 
MKC-442 (5) and TNK-651 (6) versus apo RT were calculated using crystal structures 
of the P2i2i2i space group (Appendix A2.1, Figure 14 and Appendix A2.2, 
respectively). As was the case for the DDM calculated with the nevirapine analogue 
1051U91, the DDMs calculated for the HEFT series compounds identified no dramatic 
conformational changes in RT when going from the apo to the inhibitor bound state. 
The p51 subunit, p66 connection and RNase H domains displayed effectively no 
differences in geometry, and the rearrangement of the p66 thumb and fingers subdomains 
seen in the nevirapine complex was also absent. This is not surprising as the P2i2i2i 
apo crystal structure was derived from a crystal of the HEFT complex (see section 
1.3.4, page 34), so a similar conformation to the apo enzyme would be expected 
amongst these complexes. 
The DDMs of HEFT (Appendix A2.1) and TNK-651 (Appendix A2.2) 
complexes indicated some minor 2.5-5.0 A protein backbone movements corresponding 
to the loop joining the p2 and p3 strands in the p66 fingers (residues 65-68 on DDM), 
(34 (106-111 on DDM), and the region between helix a6 and strand (39 (215-220). The 
TNK-651 complex also showed some changes around the segment 
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Figure 14 DDM of Native RT and RT-MKC-442 Complex 
C^-C^ difference distance matrix of RT in native form andcomplexed with the 
HEPT analogue MKC-442 (5) in space group crystal structures 
(PDB entries IRTJ^^^ and IRTl,^^ respectively). Contour levels and 
missing polypeptide segments areas described in the caption to Figure 11. 
joining the (35 and p6 strands. Movement of 2.5-5.0 A in the P? strand of the HEPT 
complex was also observed. These regions are all located in the fingers ((32, (33, (35 and 
P6) and palm (P4, p7, P9 and a6) subdomains. MKC-442 (Figure 14) binding induced 
changes common to most, but not all, of the movements observed in the HEPT and 
TNK-651 complexes: p4, the segment between P5 and P6, p7 and the region between 
a6 and P9. The strands P4, p7 and P9 are associated with the NNIBP. Upon solving 
the crystal structures, Hopkins, et al, ^^ concluded that the inhibition mechanism of the 
HEPT analogues was due to movement of the P4, p7 and pS strands containing the 
polymerase active site catalytic residues, as no movement of the thumb was observed. 
This observation is, however, a consequence of the method used to prepare the apo 
crystals (see section 1.3.4). 
Contouring of the HEPT series DDMs using shorter intervals may have 
revealed some conformational changes that have been obscured by the 2.5 A lower 
contour limit, however, with the resolution of the crystal structures used ranging from 
2.3 to 3.0 A, it would be difficult to interpret changes in atom positions indicated by 
the DDMs with any confidence. 
3.3.3 RT Complexes with TIBO Derivatives versus Apo-RT 
Difference Distance Matrices 
The structure of RT in complex with the NNRTI 9-Cl-TIBO (8) has been 
determined in both the and C2 ^̂ ^ crystal space groups and that of 
8-Cl-TIBO (9) in the C2 space group. Furthermore, the structure of 8-Cl-TIBO 
complexed with a Tyrl81->Cys mutant RT has been solved in the C2 crystal form. ^̂ ^ 
Comparison of the 9-Cl-TIBO/RT ^̂ ^ complex with the apo protein ^̂ ^ in the 
C2 space group (Figure 15) shows a pronounced rearrangement of tertiary structure, 
primarily involving movements of the fingers and thumb. In addition, some 
repositioning of both the RNase H domain and the p51 fingers subdomain is evident in 
the CI DDM, which is not observed in the corresponding P2i2i2i DDM 
(Appendix A2.3) Even accounting for the slightly lower resolution of the C2 crystal 
structures compared to the P2i2i2i coordinates (2.7 A versus 2.3 A and 3.0 A versus 
2.6 A, for the apo and complexed structures, respectively), this rearrangement is 
considered to be significant. 
In the p51 subunit, the chain joining the a2 helix and P4 strand has a different 
conformation relative to the entire protein, while the apparently more subtle movements 
of the amino terminal chain and the loops joining the (31 and P2 strands, and the a3 and 
a4 helices of the fingers are only evident when compared to other moving residues 
(namely the thumb and RNase H), due to the minimum threshold of 2.5 A. In the 
RNase H domain changes in geometry are localised around the (318 and (319 strands and 
the a l 5 helix. This concerted movement of the p51 fingers with the p66 subdomains 
probably accounts for the striated appearance of the p66 fingers and thumb regions on 
the DDM. 
All these regions in p51 and RNase H are in relatively solvent accessible outer 
extremities of the protein and/or form long flexible chains with little secondary structure, 
and so the observed conformational changes could possibly be artefacts of inter-protein 
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Figure 15 DDM of Native RT and RT-9-C1-TIBO Complex 
C^-Q difference distance matrix of RT in native form and complexed with 
9-Cl-TIBO (8) in CI space group crystal structures (PDB entries IDLO^^^ 
and ITVR/^^ respectively). Contour levels and missing polypeptide 
segments areas described in the caption to Figure 11. 
packing in either of the crystal structures (the P-sheets of the RNase H domain, at least, 
function as an intermolecular interaction surface during crystal formation). ^̂ ^ The 
secondary structural elements that have moved in RNase H do not contain any of the 
catalytic residues of this domain (Asp443, Glu478, Asp498 and Asp549), ^̂^ so the 
observed conformational changes are unlikely to affect RNase H activity. 
In the P2{1\2\ space group, the change in geometry of RT when bound to 
9-Cl-TIBO is very similar to that observed for nevirapine with the same crystal packing 
(see Appendix A2.3 for DDM). Significant movement (2.5-5.0 A) of the fingers and 
thumb occurs, with the greatest relative movement (> 7.5 A) between the fingers and 
thumb themselves. Movements of 2.5-5.0 A in the |34 and (37 strands are also clearly 
evident, while the p51 subunit, RNase H domain and connection subdomain remain 
relatively rigid. 
The DDM calculated for 8-Cl-TIBO (9) complexed with RT̂ ^® 
(Appendix A2.4) is very similar to the 9-Cl-TIBO DDM. Interestingly, 8-Cl-TIBO 
complexed with the NNRTI resistant mutant Tyr lSl^Cys RT^^^ also adopts a very 
similar conformation to the other TIBO complexes, according to the DDM (Figure 16). 
The Tyrl81-^Cys mutant RT retains some binding affinity for 8-Cl-TIBO and so has 
reasonable susceptibility to 8-Cl-TIBO compared to most of the other NNRTIs. 
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Figure 16 DDM of Wild Type RT and TyrlSl^Cys RT-8-Cl-TroO Complex 
C^-C^ difference distance matrix of wild type RT in native form and 
Tyrl81-^Cys mutant RT complexed with 8-Cl-TIBO (9) in C2 space group 
crystal structures (PDB entries IDLO^^^ and lUWB/^^ respectively). 
Contour levels and missing polypeptide segments are as described in the 
caption to Figure 11. 
3.3.4 RT Complexes with a-APA versus Apo-RT Difference 
Distance Matrices 
The DDMs of the complexes of Cl-a-APA (12) (P2,2i2i space group) and 
the dibrominated analogue (Br-a-APA) (C2 space group) show very similar 
conformational changes to those observed for nevirapine in the corresponding crystal 
forms (Appendix A2.5, A2.6). The thumb subdomain moves by more than 7.5 A in the 
C2 form and the fingers by 2.5-7.5 A in both crystal forms. The secondary structural 
elements P4-a3 (105-117), (35-p6 (133-141), and (37-(38 (179-191) and the loop joining 
P2 and p3 (residues 65-70) have all undergone rearrangement in the P2i2\2i crystal. In 
the C2 DDM of the Br-a-APA complex many of these precise movements are either 
absent or obscured by missing coordinate data for the loop regions in the crystal 
structures. How^ever, movement of the link between a6 and (39 (212-226), and the p9 
strand (227-229), is evident. Rearrangements in the RNase H domain and p51 subunit 
are similar to those observed previously. 
Thus, the a-APA DDMs suggest movement of the backbone in the regions 
located around the polymerase active site (P4, P7 and (38), the NNIBP (p7 and p8) and 
flexible loops in the fingers subdomain, as well as the rigid body movement of the 
thumb. Ding, era/. reported conformational changes in the P7-P8 and P9-P10-P11 
regions by superposition with the apo and DNA complexed forms of RT. The 
Br-a-APA complex DDM also shows some rearrangement of P-strands in the RNase H 
domain, as is observed in many of the other C2 DDMs. 
3.4 Summary 
Comparison of the DDMs of P2i2i2i space group complexes and the 
corresponding C2 DDM with the same inhibitor shows that the most dramatic 
structural difference between the two crystal forms is the position of the p66 thumb 
subdomain. This difference is principally due to the different conformations of the 
thumb in the apo crystal structures (see section 1.3.4, page 34). In the NNRTI 
complexes of RT in both the P 2 { l i 2 , ^ ^ ^ 129,127,128,94,130 ^^^^^^ ^^^^^ ^^^ 
thumb is in an 'open' position, similar to its orientation in the RT-DNA-Fab 
complex. However, the orientation of the thumb in the apo RT crystal structures 
differs between the two crystal forms: in the C2 form the thumb is folded into the DNA 
binding cleft so that it lies over the polymerase active site and comes into contact with 
the fingers, while the P2x2{li form retains the thumb in a relatively 'open' 
conformation. ^̂^ Thus, the DDMs calculated using P2{li2x structures indicate a 
relatively minor thumb movement compared to the C2 structures. 
The DDMs derived from the P2i2i2i structures do, however, suggest that 
different inhibitors may induce different conformations of the thumb. The DDMs of 
the 1051U91 and HEPT series complexes show an almost identical conformation to the 
thumb of the apo structure (and therefore are in relatively "open" orientations, see 
section 1.3.4). The nevirapine, 9-Cl-TIBO and a-APA complexes, however, show 
movements of over 7.5 A of the thumb relative to the fingers, compared to the apo 
structure. The direction of this movement cannot be determined from the DDMs, and 
could indicate either closing or opening of the DNA binding cleft, although the later 
would be more intuitive, considering the open conformation observed in the other 
crystal space groups. 
Conformation of the thumb aside, most DDMs, in both crystal forms, detected 
movements of the backbone in regions near the polymerase active site and NNIBP for 
each of the different classes of mhibitor. The most frequent conformational changes 
involved the (34, (37 and (39 strands, of which (34 and (37 contain polymerase active site 
catalytic residues, P7 and P9 form part of the NNIBP and contain the aromatic residues 
TyrlSl and 183. Movement of the aspartic acid residues of the polymerase active site 
into a conformation in which they can no longer maintain catalytically active interactions 
with the DNA and incoming nucleotides has been suggested as a possible mechanism of 
inhibition for the NNRTIs. 
The DDMs also indicate that major structural alterations to RT are confined to 
only selected areas of the protein. Many areas of RT behave in a fairly rigid body 
manner and do not change their orientation relative to each other upon binding of an 
NNRTI. Even the subdomains that do move, to a large extent, maintain their internal 
geometry. Common to all NNRTI complexes, and both crystal space groups, is the 
general conformational inflexibility of the region covering the p51 subunit, RNase H 
domain and connection and palm subdomains. Large subdomain movements are 
restricted to the p66 fingers and palm, however, most of these regions maintain 
approximately the same internal structure during movement. Identification of these rigid 
regions by DDM analysis subsequently contributed to the development of the rigid 
body superposition protocol (Chapter Four). 
It should be remembered that, as the DDMs are calculated using the C„ atoms, 
only information on movement of the backbone is provided by the DDMs. They give 
no insight into the relative position of the side chains between the two structures. 
Examination of side chain movements, which are of particular interest to the NNIBP and 
polymerase active site geometry, requires superposition of the two structures. 
One line of investigation currently being followed is the construction of DDMs 
comparing the complex conformation to different NNRTI complexes, rather than to the 
apo conformation. This will enable direct determination of the differences in enzyme 
conformation induced by each NNRTI. Further developments of the DDM method 
centre primarily around modifications of the software to increase the amount of 
information that may be obtained, including use of narrower contour intervals and a 
larger overall range of contours to detect information obscured by the current contouring 
scheme. 
CHAPTER FOUR 
SUPERPOSITION OF H I V - 1 
REVERSE TRANSCRIPTASE 
CRYSTAL STRUCTURES 
4.1 Introduction 
To make the most efficacious and rational use of structural information to 
optimise the activity of nonnucleoside RT inhibitors, a detailed understanding of the 
conformational flexibility of RT will be required. To achieve this goal, the 
characterisation of conformational changes occurring in the protein must extend past the 
broad identification of large subdomain and secondary structural element movements, 
down to an in depth analysis of the relative conformation of important amino acid side 
chains and short segments of polypeptide backbone. Comparison of the conformation 
of residues around the NNIBP in different NNRTI complexes and apo structures could, 
for example, identify how the pocket changes shape to optimise the interaction with the 
ligand. Ideally, this would culminate in the correlation of inhibitor structure with the 
protein conformational changes that confer loss of enzyme activity. 
This depth of knowledge requires far more information than can be obtained 
by difference distance matrix comparison of selected RT-NNRTI complexes. 
Comparison of protein structures by distance difference matrix analysis provides a rapid 
and objective method of identifying systematic relative movements of subdomains and 
local secondary structural elements. However, the DDMs obscure any information on 
the direction and mode of movement (i.e. translation, rotation) of the protein backbone. 
Additionally, rotation of a portion of the backbone along its axis will not be detected by 
a DDM as this involves little or no change in the three dimensional coordinates of the 
individual C„ atoms. Changes in the position of the amino acid side chains, whether due 
to rotation of the backbone or along the C„-Cp axis, or conformational changes in other 
regions of the side chain, are also not represented by DDMs. 
Consequently, the DDMs of apo and inhibited RT cannot be used to determine 
whether the structural changes around the- NNIBP induced by NNRTI binding involve 
the backbone closing down upon or moving away from the inhibitor, twisting of the 
backbone to move side chains closer to or further from the inhibitor, or conformational 
change within the side chains themselves. 
Comparison at this level of detail is possible by superposition of the two 
structures, but, as indicated in Chapter One, care must be taken to ensure that the 
superposition process does not introduce misleading alignments of residues or conceal 
localised and more subtle protein movements. The spatial separation and differences in 
magnitude of the modes of flexibility available to RT make this a particular concern 
when interpreting superposed structures of the enzyme. The DDMs have shown that 
the flexibility of RT is distributed amongst several regions of the protein, and involves 
movement of large subdomains as rigid bodies as well as short individual segments of the 
polypeptide. Most superposition algorithms give equal weighting to all regions of the 
structure when trying to minimise the rms difference between the two sets of 
coordinates.^^^ Thus, each pair of atoms that deviate from the ideal coincident position 
will cause some (insignificant) rotation and/or translation of the remainder of the 
structure. The consequence of this is that if larger subdomains containing many atoms 
have moved, superposition will attempt to fit them in a best "average" position and 
induce a rotation and/or translation from the ideal superposition in the other regions, 
that can no longer be considered to be insignificant. The uniform weighting scheme 
means that there is a bias towards maximising the fit between larger flexible regions, such 
as the fingers and thumb, at the expense of perturbing the superposition of regions with 
more coincident structures, such as the connection subdomain. Furthermore, the 
resulting juxtaposition of smaller flexible regions, containing fewer residues, such as the 
NNIBP and polymerase active site, may not be representative of an ideal fit, due to their 
lesser contribution to the superposed coordinate sets. The consequence of these biases 
is to make the interpretation of changes in the relative position of the residues in these 
regions difficult. 
Previous analyses of binding site conformational change have used 
superposition of the entire protein backbone (for example reference 129) and therefore 
take no account of the effect of more distant conformational changes upon the alignment 
of the regions under examination. Other studies have examined changes in pocket 
geometry by superposition of only the residues within and around the NNIBP. ^̂  This 
strategy, however, has the potential to hide information describing movement of this 
region relative to the remainder of the protein. 
The obvious solution to this problem is to base the superposition upon only 
those regions that have very similar conformations in both structures. Superposition of 
these regions will achieve a very good rms fit, while the movement of the variable 
regions, which have not been used in the superposition calculation, will be more readily 
identified and quantified. Some analyses have based the superposition upon residues 
that are distributed throughout the structure and/or show some degree of similarity in 
conformation in different complexes, hQ^gygj-^ several of these cases, the 
justification for the selection of these regions has not been extensively described. Our 
approach employed the data gained from the DDM studies to identify those regions 
that are sufficiently conformationally invariant to be suitable for superposition. 
Objective identification of the regions of RT that behave as rigid bodies, and so may be 
used as the basis of superposition, was the original motivation of performing the DDM 
analysis. 
4.2 Selection of RT Subdomains for Superposition 
The DDM comparison of apo and inhibitor bound RT, with various NNRTIs 
and in both crystal forms, showed that all the subdomains (including the fingers and 
thumb) have, overall, a relatively rigid internal structure. However, the fingers and 
thumb subdomains move significantly relative to the rest of the enzyme and the palm 
subdomain contains several short segments around the polymerase active site and 
NNIBP that change conformation when complexed with a NNRTI. The remaining 
regions of RT, the p51 subunit, RNase H domain and connection subdomain, all showed 
a reasonable degree of conformational rigidity, both internally and externally. 
Superposition of the backbones of the apo and NNRTI complexed RT 
structures confirmed this. For example, in the P2{li2\ space group, the p51, RNase H 
and connection backbones of the nevirapine complex ^̂ ^ superpose on the corresponding 
apo backbones with a rms fit of 1.29 A, while the entire backbones fit to 2.15 A rms, 
and those of the fingers, palm and thumb fit to just 2.84 A rms. In the CI space 
group 2̂7,128,132 ^^^ corresponding rms fits are 2.89, 5.54 and 7.94 A, respectively (note 
the closer relative alignment of the P2i2i2i structures, due to the unusual conformation 
of the thumb in the apo structure - section 1.3.4, page 34). Similar figures, showing a 
large decrease in rms fit when the fingers and thumb subdomains were included in the 
superposition, were obtained with all the other NNRTI complexed-apo RT 
comparisons. Full details of the superposition of various combinations of domains are 
given in Appendix 3. 
Based on the DDM interpretation and the preliminary superposition data, it 
was decided that the p51 subunit, the RNase H domain and connection subdomain, 
would provide the best "rigid region" for further superposition studies. In the following 
description, "direct superposition" refers to superposition of only those residues 
described, while "rigid body superposition" refers to the alignment of the residues 
described after superposition of the rigid p51, RNase H and connection region. 
4.3 Gross NNRTI Induced Structural Changes 
Direct superposition of individual subdomains of the NNRTI complexed 
crystal structures with the corresponding apo structures, indicates relatively little 
internal conformational change in these regions upon inhibitor binding (Table 6). For 
Inhibitor Space 
Group 
p66+p51 Thumb Palm Fingers Connection RNase H 
Nevirapine ^̂ 212121 2.15 0.66 1.51 1.22 1.18 1.04 
Nevirapine C2 5.54 1.69 2.07 1.68 2.25 0.98 
1051U91 ^^2,2,21 0.98 0.48 1.19 0.84 0.55 0.42 
KEPT P2{1{1, 0.94 0.46 1.36 0.87 0.57 0.45 
MKC-442 P2{1{1, 0.82 0.50 1.23 0.88 0.53 0.29 
TNK-651 P2x2{lx 0.94 0.46 1.12 1.00 0.56 0.56 
9-Cl-TIBO P2{2{2, 2.12 0.61 1.52 1.16 1.22 1.10 
9-Cl-TIBO C2 5.39 1.33 2.15 1.44 1.44 0.96 
8-Cl-TIBO C2 5.09 1.46 2.06 0.90 1.35 0.81 
8-Cl-TIBO^ C2 5.34 1.27 2.15 1.39 1.43 0.91 
Cl-a-APA P2{2{2I 2.27 0.68 1.51 1.35 1.18 1.07 
Br-a-APA C2 4.90 1.41 2.03 0.92 1.35 0.68 
Table 6 Superposition of Individual RT Subdomains 
RMS deviation in positions of backbone (-N-C^-CO-) atoms after 
superposition of the specified subdomain backbones of the NNRTI complex 
and apo RT crystal structures, of the same crystal space group. All values 
are in A. f TyrlSl -^ys RT mutant. 
example, the backbones of the thumb superpose with a rms fit of between 0.46 and 
0.68 A in the P2{l{li structures, and 1.27 to 1.69 A in the C2 structures. In the fingers 
subdomain, the corresponding ranges are 0.84-1.35 A and 0.90-1.68 A, respectively. 
The higher rms values of the C2 structures can most likely be partly attributed to the 
lower resolution of these structures. 
Superposition of the rigid body regions of RT (i.e. p51, RNase H and 
connection regions) shows the movement of the fingers and thumb subdomains relative 
to the main body of the enzyme. The atoms of the p51, RNase H and connection of 
each combination of appropriate complexed and apo structures were superposed, and 
the resulting rms deviation of the relative positions of the backbone atoms in the fingers 
and thumb calculated (Table 7). The rms fit of the apo and complexed fingers and 
thumb subdomains is much poorer when this strategy is used, indicating the degree of 
conformational change caused by NNRTI binding. The thumb of the C2 NNRTI 
complexes have rms deviations as high as 15.30 A from the apo enzyme thumb. In the 
P2i2i2i space group, the complex and apo thumbs have better rms fits, but are still 
worse than those obtained by superposing the entire backbone of the two enzyme 
structures, particularly with nevirapine, 9-Cl-TIBO and a-APA. This is due to the 
Inhibitor Space .Rigid Fingers Thumb 
Group Region 
Nevirapine P2i2,2i 1.29 4.39 3.45 
Nevirapine C2 2.89 8.27 15.30 
1051U91 P2i2i2i 0.63 1.35 0.73 
KEPT P2{1{1, 0.62 1.38 0.91 
MKC-442 P2{1{1, 0.58 1.07 0.75 
TNK-651 P2i2i2i 0.74 1.30 1.12 
9-Cl-TIBO 1.38 4.50 3.27 
9-Cl-TIBO C2 2.28 8.47 14.37 
8-Cl-TIBO C2 2.06 6.99 14.65 
8-Cl-TIBO^ C2 2.30 7.86 14.67 
Cl-a-APA P2x2{2i 1.47 4.50 3.35 
Br-a-APA C2 2.00 5.54 15.03 
Table 7 Fingers and Thumb Movement After RT Rigid Region Superposition 
RMS deviation of backbone (-N-C^-CO-) of fingers and thumb after 
superposition of the C^ atoms of the p51 subunit, RNase H domain and 
connection subdomain (rms shown). All values are in A. f TyrlSl -^Cys RT 
mutant. 
thumb of the apo structure adopting a conformation similar to that of the 
NNRTI bound structures, rather than folding into the DNA binding cleft, as discussed in 
section 1.3.4. 
Figure 17 shows the change in the thumb conformation in the apo and 
nevirapine bound C2 structures, after superposition of the previously defined rigid 
region. The large movement of the thumb between "open" (nevirapine bound) and 
"closed" (apo) conformations can be clearly seen. Movement of the fingers subdomain 
is also evident. Superposition of the fingers, palm and thumb subdomain backbones 
apo enzyme ne^rapine complex 
Figure 17 Thumb and Fingers Movement in Nevirapine Complex 
Ribbon diagram of the backbone of the p66 fingers, palm and thumb 
subdomains of apo ^^^ (light blue) and nevirapine bound^^^-^^^ (dark blue) RT, 
after superposition of the C^ atoms of the rigidp51, RNase H and connection 
regions, showing relative movement of the thumb and fingers subdomains. 
Coordinates from PDB entries IHMV (apo) and 3HVT (nevirapine). 
yields a rms value of 7.94 A, however, the rms deviation of the thumb and fingers in the 
displayed positions are 15.30 and 8.27 A, respectively. This difference in rms values 
highlights the effectiveness of superposing rigid regions of two RT structures in order to 
determine conformational changes more objectively (the rigid body superposition of the 
corresponding P2i2{li structures yield much lower rms values for the fmgers and 
thumb, a consequence of the incorrect thumb conformation caused by the method of apo 
crystal production, see section 1.3.4, page 34). 
Inclusion of the amino acid side chains of the fmgers and thumbs subdomains in 
the calculation of the rms deviation between apo and complexed conformations results in 
only a relatively minor increase in the value of the rms fit. In the CI apo/nevirapine 
complex structures, the rms fit of all non hydrogen atoms of the thumb and fmgers are 
15.46 and 8.66 A, respectively, compared to 15.30 and 8.27 A, respectively, for the 
backbone only. Similar relative increases were obtained for all apo/NNRTI complexes 
compared. As inclusion of the side chains in the rms calculation has no appreciable 
effect on the value of the rms fit, the conformational change in the fingers and thumb 
subdomains upon complexation with an inhibitor must be due primarily to movement of 
the polypeptide backbone, with little reorientation in side chain positions occurring. 
Furthermore, the good rms fit obtained when these regions were superposed directly 
indicates that the movement of the thumb and fmgers occurs as an essentially rigid body 
motion. 
4.4 Conformational Changes in the Nonnucleoside 
Inhibitor Binding Pocket and Polymerase Active Site. 
As shown with the thumb subdomain, direct superposition of the NNIBP and 
polymerase active site can give a misleading impression of the conformational change 
occurring in these regions upon NNRTI binding. Superposition of the backbone of these 
regions yield rms fits of 0.55-1.15 A and 0.26-0.80 A for the NNIBP and polymerase 
active sites, respectively, for all sets of structures (Table 8), suggesting little 
conformational change. By superposing the two structures on the basis of the 
p51/RNase H/connection domains of RT, the movement of the residues of the NNIBP 
and polymerase active site relative to the rigid region of the protein can be examined. 
4.4.1 Nonnucleoside Inhibitor Binding Pocket 
Table 8 shows that the change in backbone position between the apo and 
NNRTI complexed NNIBPs varies significantly amongst the different NNRTIs, when 
compared by superposition of the rigid body area of RT. Most notably, while the rms 
deviation between the positions of the apo and complexed NNIBPs of most of the 
complexes increased to over 2-3 A (in both C2 and P2i2i2i structures), indicating 
significant relocation of the backbone, the NNIBP backbone of HEPT increased only 
marginally to less than 0.9 A . This minimal change in conformation is most likely a 
product of the conformation of the apo structure, which was derived from the HEPT 
complex crystal (section 1.3.4). Figure 18 illustrates the close alignment of the 
P4-p8-(37 and (39-plO-pil sheets of the apo and TNK-651 bound NNIBPs, based upon 
the superposition of the C„ atoms of the p51, RNase H and connection domains. The 
Inhibitor Space NNIBP NNIBP PAS PAS 
Group Direct Rigid Direct Rigid 
Nevirapine 0.90 2.34 0.51 3.01 
Nevirapine C2 1.05 3.36 0.64 4.16 
1051U91 0.97 1.80 0.26 3.075 
KEPT 0.55 0.89 0.38 2.24 
MKC-442 0.73 1.23 0.25 2.51 
TNK-651 P2{2{lx 0.76 1.02 0.33 2.305 
9-Cl-TIBO P2aai 1.05 2.26 0.35 3.48 
9-Cl-TIBO C2 0.85 3.48 0.80 4.27 
8-Cl-TIBO CI 0.78 3.21 0.66 4.34 
8-Cl-TIBO^ CI 0.87 3.54 0.78 4.27 
Cl-a-APA P2x2{l, 1.15 2.68 0.44 3.40 
Br-a-APA CI 0.90 3.14 0.66 3.88 
Table 8 Superposition of NNIBP and Polymerase Active Site 
RMS deviations of backbone (-N-C^-CO-) atoms of NNIBP and polymerase 
active site (PAS) after direct superposition andp51+RNase H+connection 
superposition, f Tyr 181->Cys RT mutant. 
rms deviation between the positions of the backbone of the important NNIBP residues 
LeulOO, LyslOl, Lysl03, Vall79, TyrlSl, Tyrl88, and p51 Glul38, in both structures 
in this alignment is 1.02 A, only marginally greater than the minimum possible value of 
0.76 A obtained by direct superposition. 
The complexes of the other NNRTIs show relatively good alignment of the 
NNIBP residue backbones by direct superposition (0.78-1.15 A rms), but greater 
misahgnment when the rigid body region of RT is superposed (1.80-3.54 A rms). While 
this misalignment may be interpreted as a conformational change around the NNIBP 
region, the similarity in geometry shown by direct superposition suggests that this 
misalignment may be an artefact of the superposition based on other regions of the 
Tyrl 83 
Tyr183 
apo 
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Figure 18 Supeiposition of Apo and TNK-651 Complex NNIBP Region 
Alignment of backbone (ribbon) and side chains (wire frame) of the NNIBP 
region of apo RT (light blue) and the TNK-65I/RT complex (dark blue), after 
superposition of the Q atoms of the p51 subunit, RNase H domain and 
connectionsubdomain (rms 0.74 A). 
protein. The use of the rigid p51, RNase H and connection domains to align the 
NNIBP, which is not contained within any of these regions, may introduce some minor 
relative rotation and/or translation between the two structures in the regions not used in 
the superposition. Thus, some care must be taken in interpreting the poorer rms fit of the 
NNIBP residues when the rigid body superposition strategy has been employed, although 
"fine tuning" of the rigid region definition (the current use of entire subdomains is 
relatively coarse grained) may alleviate this effect somewhat by removing isolated sections 
of misaligned protein from the superposed region. 
Inhibitor Space 
Group 
NNIBP PAS 
Backbone + Side Chains Backbone + Side Chains 
Nevirapine 0.90 2.95 0.51 1.38 
Nevirapine C2 1.05 3.23 0.64 1.41 
1051U91 0.97 3.01 0.26 1.57 
KEPT ^̂ 212121 0.55 2.35 0.38 1.35 
MKC-442 P2i2,2I 0.73 2.95 0.25 1.08 
TNK-651 P2{l{li 0.76 2.96 0.33 0.87 
9-Cl-TIBO P2{1{1, 1.05 2.98 0.35 1.61 
9-Cl-TIBO C2 0.85 2.81 0.80 1.56 
8-Cl-TIBO CI 0.78 2.95 0.66 1.78 
8-Cl-TIBO^ CI 0.87 2.42 0.78 1.45 
Cl-a-APA 1.15 2.98 0.44 1.10 
Br-a-APA CI 0.90 3.02 0.66 1.26 
Table 9 Side Chain Movement in NNIBP and Polymerase Active Site 
RMS fit after superposition of NNIBP and polymerase active site (PAS) using 
either backbone (-N-C^-CO-) atoms only or including side chain heavy 
atoms. ^ Tyr 181 ̂ Cys RT mutant. 
While superposition of the NNIBP backbone suggests relatively minor 
movement of the binding pocket residues upon ligand binding, inclusion of the amino 
acid side chains in the superposition shows much greater conformational change in this 
region. Table 9 shows that when all non hydrogen atoms of each residue are included in 
the superposition calculation, the quality of the rms fit decreases by almost 2 Â or more 
over that calculated on the backbone alone. As the rms fit of the NNIBP backbone itself 
is fairly good, these values indicate that much of the conformational change in the 
binding pocket is due to reorientation of the amino acid side chains. This is evident from 
visual inspection of the superposed geometries, such as in Figure 18. Large scale 
flipping of the orientation of the aromatic side chains of the residues TyrlSl and 
I l l 
Tyrl88 can be observed in the TNK-651 complex, along with rotation of the Tyrl83 
and Trp229 side chains. The differences in the positions of the Phe227 and Tyr232 side 
chains shown appear to be due to movement of the backbone, rather than from side 
chain reorientation. It can also be seen in Figure 18 that the reorientation of the aromatic 
side chains, particularly those of Tyrl81, Tyrl88 and Trp229, serves to improve 
Ti-stacking interactions with the aromatic regions of the inhibitor, and that TNK-651 
occupies the positions of tyrosines 181 and 188 in the apo structure. 
4.4.2 Polymerase Active Site 
Direct superposition of the five residues forming the polymerase active site 
(AspllO, Tyrl83, Metl84, Aspl85 and Aspl86) shows very little change in backbone 
conformation between the apo and NNRTI bound enzymes (Table 8). The movement 
of the polymerase active site backbone is, however, much greater relative to the rigid RT 
region. The rms deviation between the backbone atom positions increases by more than 
2 A in almost every case when direct and p51/RNase H/connection based superposition 
is employed. Significant change in active site geometry is observed even in the HEPT 
analogue complexes, which showed minimal change in geometry of the nearby NNIBP 
backbone, in the inhibitor/RT complexes. 
Figure 19 shows the active site conformational change of the TNK-651 
complexed enzyme, based upon superposition of the p51, RNase H and connection 
domains. The C„ atoms of the polymerase active site of the NNRTI complex have been 
translated by 1.9-3.0 A from their positions in the apo structure (2.30 A rms). As the 
backbone of the nearby NNIBP was aligned very well by using the same superposition 
strategy (Figure 18), and the entire palm region shows comparatively little change in 
geometry against the apo structure (rms fit after direct superposition of backbone 
1.12 A ) , reasonable confidence can be held in this being a genuine conformational change 
rather than an artefact of the superposition method. 
Inclusion of the side chain non hydrogen atoms in the calculation of rms 
deviation reduces the fit by approximately 0.5-1.5 A rms (Table 9), suggesting that 
some side chain reorientation occurs in the complex, although not as pronounced as that 
of the NNIBP. Figure 19 shows that, in the case of the TNK-651 complex, side chain 
movements are restricted primarily to the rotation of Tyrl83 and Asp 186. 
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Figure 19 Superposition of Apo and TNK-651 Complex Polymerase Active 
Site Residues 
Alignment of backbone (thick lines) and side chains (wire frame) of the 
polymerase active site residues AspllO, Tyrl83, Metl84, Aspl85 and 
Aspl86 of apo RT (grey) and the TNK-651/RT complex (black), after 
superposition of the atoms of the p51 subunit, RNase H domain and 
connection subdomain (rms 0.74A). The numbers indicate the distance 
between corresponding atoms of the complexed and apo enzymes. 
4.5 Summary 
Superposition of the backbone and side chains of several regions of RT suggest 
that conformational changes of the NNIBP are restricted to side chain reorientation. The 
backbone of the NNIBP and polymerase active site do not undergo significant changes in 
conformation, although they can move relative to the rigid region defmed by the p51 
subunit, RNase H domain and connection subdomain. In fact, this appears to be the 
only type of movement available to the polymerase active site residues that makes any 
noteworthy contribution to the conformational change. Most subdomains of RT, 
including the thumb, behave individually as rigid bodies, despite their large relative 
movement to the rest of the enzyme. 
The comparison of RT conformation using rigid body superposition is still in 
its preliminary stages, with several avenues of investigation remaining to be explored. 
While the calculation of rms deviations of the relative alignment of important 
subdomains and regions, after both direct and rigid body superposition, was 
comprehensive, covering all available RT-NNRTI complexes available, a more exhaustive 
and detailed visual comparison is required. The rms calculations confirm the usefulness 
of the rigid body superposition strategy in characterising conformational changes 
objectively, however further visual examination of the aligned structures is required to 
extract all available information on side chain and backbone flexibility. 
Rigid body superposition of different RT-NNRTI complexes, rather than the 
apo-complex superposition strategy described here also offers to provide much useful 
information, particularly concerning NNIBP movements common to all inhibitor 
complexes and those unique to each inhibitor. By pursuing this line of investigation, it 
may be possible to identify NNRTI induced structural changes that are essential for 
inhibitory activity and those that are not related to the inhibition mechanism, but may 
contribute towards binding affinity. 
While the usefulness of the rigid body superposition method has been 
demonstrated, there is room for refinement of the technique. The current selection of 
rigid regions is relatively coarse, using entire subdomains, and significant improvements 
may be achieved by closer examination of the DDM data and selection for superposition 
of shorter segments of polypeptide that have even greater conformational rigidity than 
the large sections currently being used. 
CHAPTER FIVE 
OTHER METHODS OF PROTEIN 
STRUCTURE COMPARISON 
5.1 Introduction 
In addition to the graphical difference distance matrix and superposition 
approaches to comparison of reverse transcriptase structure, two further techniques 
were investigated to enable more detailed, and complementary, inspection of 
conformational change. The first involved an extension of the DDM method to allow 
quantitative analysis of the changes in relative distance between residues in selected 
regions, rather than the more qualitative analysis discussed in Chapter Three. The 
second technique identifies changes in the conformation of the protein backbone by 
calculating differences in the corresponding and \|/ dihedral angles in the two structures. 
These methods were developed to allow the inspection of small regions of interest in 
greater detail, providing information complementary to that obtained from the DDM 
and superposition experiments. In particular, both techniques were directed towards the 
study of the backbone conformational change in the NNIBP and polymerase active site 
regions, with the aim of detecting more subtle features that were not readily identified 
by either the graphical DDM or superposition methods. Software was developed to 
facilitate both these approaches, however, due to time restrictions, neither method has 
been applied to RT in depth in the current project. Thus, the following discussion 
concentrates primarily upon the description of each method and the associated software 
that was developed, as well as the results of the preliminary investigation, and the 
conformational information that may potentially be gained from ñiture studies. 
5.2 Quantitative Difference Distance Matrix 
Calculations 
A disadvantage of the DDMs used in Chapter Three is the difficulty in 
examining fine conformational changes in the protein structure. The small scale of the 
plots, necessary to display the approximately 1000 residues of the entire polypeptide 
chain, makes accurate identification and analysis of movements involving only a few 
residues an arduous and uncertain task. Furthermore, the relatively coarse contouring 
scheme used, selected to simplify identification of rigid and flexible regions, can obscure 
much information about more subtle residue movements. 
To allow comparison of RT structure in greater depth, a second version of the 
DDM program (DDM), calculating precise distance difference data over a user defined 
selection of amino acid residues, was written. This version of the DDM program 
produces tables of distance difference values in an ASCII format suitable for display and 
interpretation by a third party three dimensional graphing software package. User 
specified parameters allow smaller, specific regions of the protein to be selected for 
examination. The use of third party software for graphical display and analysis of the 
calculated distance differences enables a more flexible, and potentially more informative. 
approach to representation of the DDM data. The DDM software is described in 
section 6.3. 
An example of one type of useful representation is shown in Figure 20. This 
diagram shows the movement of residues 180-240 of the palm relative to the thumb 
subdomain, by comparison of the C2 crystal forms of the apo^^^ and nevirapine 
bound ^̂ ^̂ ^̂  enzyme, as a three dimensional contoured surface. This form of DDM 
o n I 1 ftn 
Figure 20 3D Surface Representation of DDM Data 
Three dimensional contoured plot of the p66 palm residues 180-240 V5 the 
p66 thumb subdomain, from comparison of the apo^^^ and nevirapine 
bound^^^'^^^ C2 crystal structures, PDB entries IDLO and 3HVT, 
respectively. Calculateddistance differences have been rounded to the nearest 
0,5 Á. 
representation facilitates close inspection of the residue movements in regions of 
particular interest. Figure 20 shows movements in the region corresponding to the 
P9-P10-(311 sheet of the NNIBP (residues 225-240, appearing as a series of peaks and 
depressions running parallel to the x-axis, towards the back of the graph), the coil 
between a7 and a8 (residues 267-277, appearing as a ridge running parallel to the 
>^-axis), and the a6 helix (a valley and several peaks parallel to the x-axis, at residues 
200-210 on the graph). Care must be taken when interpreting the DDM data in this 
form, as the truncation of the sets of amino acid pairs being analysed may obscure 
information on the real nature of the residue movements, i.e. whether the distance 
changes are relative to the entire protein or just selected domains. It is therefore 
recommended that analyses of truncated DDMs are performed in close association with 
the DDMs calculated for the entire protein. 
Some relatively simple future modifications to this software will provide for 
the calculation of DDM data for all atoms in the backbone and the side chains, rather 
than just the C„ atoms. Including the side chains in the calculations will make possible 
the examination of side chain conformational changes by the DDM method, however, 
the complexity, and therefore difficulty of analysis, of the resulting 3D plots will 
increase significantly with the extra atoms. The absence of information on side chain 
conformation is a deficiency of the current DDM software, and implementation of this 
enhancement will further assist in the detailed analysis of the NNIBP region. 
5.3 (t)/\|/ Dihedral Angle Comparison 
The conformation of the polypeptide backbone of a protein can be specified 
completely by the set of dihedral angles and \|/ for each residue in the chaiii^® (the 
planarity of the peptide unit due to the partial double bond character of the amide group 
restricts the value of the third dihedral angle co to approximately 180° in all amino acids 
with trans configuration, and so can be reasonably excluded from the 
representation). It therefore follows that a change in the three dimensional 
conformation of a protein may be represented by differences in the corresponding (j) and 
\\f angles of the two structures. As is the case with the distance matrix representation of 
conformation, the use of an internally referenced coordinate system (i.e. dihedral angles) 
eliminates the need for superposition of the structures prior to comparison. 
A program (PhiPsi) was developed that reads the atomic coordinates of the 
protein in standard PDB file format and calculates both the (]) and V|/ angles for each 
amino acid along the polypeptide chain, and records the value in the temperature factor 
field of two separate output PDB files (one each for (|) and \|/ angles). The calculation of 
the dihedral angles is described in section 6.5.1. A second program {comparePDB) was 
written that calculates the difference in the recorded dihedral angles of two input files 
and produces two PDB format output files containing only those residues common to 
both input structures, with the difference in dihedral angles recorded in the temperature 
factor field. The changes in the and \\f angles could then be easily visualised by 
displaying the protein on a molecular graphics system and colouring the backbone 
according to the "temperature factor" of the constituent atoms, for example, as in 
Figure 21. 
As secondary structural elements have characteristic ranges of and \|/, 
residues within a-helices and p-sheets will have unchanged dihedral angles, even if they 
have moved relative to one another, provided that the secondary structure is conserved. 
For two secondary structural elements located close together in the protein sequence, 
relative movement will be described by changes in the (j) and \f/ angles of the residues 
connecting them. This has the advantage of describing rigid body movements of 
structure by changes at localised 'hinge' points, separating the movement of residues 
connected to flexible segments from those at the centre of the movement. 
Using this scheme, amino acids that have different backbone conformations in 
the two structures can be readily identified by visual inspection and precise values of 
the dihedral angle difference indicated by displaying the value of temperature factor. 
Figure 21 shows that many of the residues with greatest change in \\f angle between the 
apo and nevirapine complexed structures are located at or near the turns between 
(3-strands or at residues that undergo significant side chain movement. Of particular 
interest are the angle changes observed at residues Tyrl83 (which has Tc-stacking 
interactions with the NNRTIs and forms part of the polymerase active site), Trp229 
(located within the primer grip and has 7i-stacking interactions with many NNRTIs), 
and Pro236 (forms part of the Pro236 hairpin, which moves to close the pocket around 
the NNRTI). Conversely, the pale colouring of the residues forming the body of the 
p-strands indicates that the conformation of the backbone is unchanged in these 
segments and therefore that the secondary structure in the NNIBP has been conserved. 
While the DDM data has shown that these regions move upon ligand binding, the 
angle comparison indicates that this occurs with little change in the secondary structure of 
the segments concerned (i.e. a rigid body movement). 
While the representation of larger flexible backbone motions as conformational 
change at localised hinge points has obvious advantages, a few caveats of the (|)/i|) angle 
comparison method should be kept in mind. The residues targeted by this technique are 
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Figure 21 xp Angle Differences of Apo and Nevirapine Bound RT 
Differences between the backbone dihedral angle i^) of the apo and 
nevirapine complexed crystal structures (PDB entries IRTJ and 
1VRT, respectively) in the region of the NNIBP. Differences in degrees of 
angles are mapped onto the backbone and side chains of the nevirapine 
complex structure according to the spectrum indicated (note that values have 
been divided by afactor of 10 in order to accommodate the available colouring 
schemes of Insightll). 
often the loop regions that connect a-helices and P-strands of p-sheets. These segments 
are often highly flexible and therefore poorly modelled, and are often not modelled at all, 
in X-ray crystal s t r u c t u r e s . T h u s , the accuracy of the backbone dihedral angles 
calculated from the atomic coordinates of these residues may be limited, potentially 
making the calculated differences unreliable. It is unfortunate that the (t)/\|/ difference 
calculations often make use of the residues of the poorest resolution to determine the 
conformational change. On the other hand, the residues that are well defined due to the 
rigidity imposed by their secondary structure, and are identified by (t)/\|/ comparison to 
be undergoing no internal conformational change, can be confidently interpreted as being 
rigid (internally at least) due to the quality of the data. One ftirther caution to consider 
is that large movements created by the cumulative effect of many small variations in (j) 
and \|/ in a series of consecutive residues, such as the bending of an a-helix, may not be 
readily identified using this method^^^ (although it will be readily detected using DDM 
analysis). Keeping these caveats in mind, <t)/\j/ angle calculations are capable of providing 
useftil information on the relative orientation of the protein backbone in two structures, 
particularly if applied in conjunction with other structure comparison methods. 
A detailed comparison of RT conformations by analysis of (t)/v|/ angles has not 
yet been performed, and is an avenue of ftirther investigation. A preliminary analysis of 
the apo and nevirapine bound RT structures did not readily identify any major global 
conformational changes, although application of the technique to the NNIBP region of 
NNRTI complexed RT has further described the mode of conformational change around 
the pocket (little loss of secondary structure and localisation of the changes in backbone 
"twist" to a few residues only). The value of this method will most likely lie in its use, 
in conjunction with DDMs and superposition, as a complementary technique for the 
detailed analysis of selected regions of the structure, particularly for characterisation of 
the flexibility of the NNIBP. 
One advantage of this form of representation over the DDMs is that 
differences will detect conformational changes involving rotation of the backbone along 
its axis. This mode of movement cannot be detected by DDM analysis because it 
involves only minor translational changes in the coordinates of the C„ atoms. A possible 
further enhancement of this method would be modification of the software to calculate 
the side chain torsion angles so that- changes in side chain orientation may be 
identified. This approach would have particular application to the analysis of the 
geometry of the NNRTI binding pocket, as conformational changes in the NNIBP 
appear to be restricted primarily to side chain movements (section 4.4.1). 
CHAPTER SIX 
EXPERIMENTAL 
6.1 X-RayCrystalStructureAtomicCoordinates 
Atomic coordinates for all three dimensional protein models were obtained 
from the Brookhaven Protein Data Bank.̂ ^ '̂̂ ^^ A total of 16 sets of high resolution 
crystal structures of HIV-1 RT in NNRTI complexes, apo form or bound to DNA 
primers were downloaded. Table 10 lists tiie crystal structures used and some statistics 
relevant to the accuracy of the coordinates. 
6.2 Docking 
Docking studies were performed using DOCK version 3.5 (Department of 
Pharmaceutical Chemistry, University of California, San Francisco). The 
FORTRAN 77 source code supplied was compiled and used without modification, as 
were all utility and script programs (except for utility program autoMS, see below). 
6.2.1 Crystal Structure Preparation and Sphere Generation 
Atomic coordinate data were obtained from the Brookhaven Protein Data Bank 
(Section 6.1). Ligands and all crystallographic waters were removed from the files and 
hydrogens added to the protein. As some DOCK utility programs cannot work with the 
very large reverse transcriptase coordinate sets, a reduced subset of the structure was 
PDB 
Code 
Inhibitor Resolution i?-Factor Space 
Group 
Notes References 
IREV 9-Cl-TIBO 2.6 A 0.224 P2ai2, 93 
IRTI MKC-442 2.55 A 0.197 P2x2{lx 81 
1RT2 TNK-651 2.55 A 0.207 P2x2{lx 81 
IRTH 1051U91 2.2 A 0.214 P2i2i2, 109 
IRTI KEPT 3.0 A 0.236 P2i2i2, 109 
IRTJ none 2.3 A 0.219 ^̂ 212121 109,131 
IVRT nevirapine 2.2 A 0.186 P2ai2, 109 
IVRU Cl-a-APA 2.4 A 0.187 P2,2i2i 109 
IDLO none 2.7 A 0.249 C2 133 
ITVR 9-Cl-TIBO 3.0 A 0.259 C2 129 
lUWB 8-Cl-TIBO 3.2 A 0.274 C2 Y181C mutant 129 
IHMV none 3.2 A 0.254 C2 132 
IHNI Br-a-APA 2.8 A 0.255 C2 130 
IHNV 8-Cl-TIBO 3.0 A 0.249 C2 129,94 
3HVT nevirapine 2.9 A C2 127,128 
IHMI none 3.0 A P3212 DNA & Fab 116,196,197 
Table 10 Details of RT X-Ray Crystal Structures 
used for processing by selecting only those residues lying within 25 A of the Ĉ^̂  atom of 
p66 Tyrl88. The NNRTI binding region was defined by selecting a further subset of 
residues within 10 A of the location of the inhibitor in the crystal structure. The solvent 
accessible surface of this 10 A subset was generated at a density of 3 surface points per 
A^ using the MS program with a 1.4 A probe. Surface generation required 
detection and correction of an error in the DOCK utility program autoMS used to 
prepare files for surfacing by MS. 
Spheres with radii between 1.4 and 4.0 A filling potential binding pockets on 
the solvent accessible surface were generated using the DOCK utility sphgen, grouped 
into clusters of overlapping spheres and manually edited to remove those that did not 
fall inside or around the entrance to the NNIBP. Spheres were selected by visual 
inspection, using Insightll version 95.0 (MSI, San Diego, USA), of their position 
relative to the solvent accessible surface of the NNIBP. As the set of surface points 
describing the sphere generated by the DOCK utility program showsphere were 
incompatible with the Insightll ÍÚQ format for surfaces, a short script for the UNIX text 
editing utility awk was written to convert the file formats {D0CKsurf2Insight, 
Appendix A4.1.1). Generally, of the 150-240 spheres generated for each crystal 
structure, approximately 60-70 were sufficient to describe the NNIBP. 
6.2.2 Contact and Forcefield Scoring Grid Preparation 
Contact and forcefield scoring grids for docking were generated at a density of 3 
grid points per A for the region enclosing the spheres with an extra margin of 3 A. 
Contact grids were calculated by distmap with receptor hydrogen atoms removed, close 
contact limits for polar and nonpolar atoms of 2.3 and 2.8 A, respectively, and a cutoff 
distance of 4.5 A. Forcefield scoring grids, generated by the DOCK utility chemgrid, 
were calculated using AMBER parameters and the receptor structure with 
hydrogen atoms added, a distance dependent dielectric function of 4.5r, polar and carbon 
atom close contact limits of 2.3 and 2.8 A, respectively, and a nonbonded interaction 
cutoffof lOA. 
6.2.3 Ligand Preparation 
Inhibitors were docked in both the conformation found in the crystal complex 
and conformations generated by molecular dynamics simulation. After extraction of 
ligand atom coordinates from the RT/inhibitor complex structure PDB files, hydrogen 
atoms were added, bond orders corrected and CFF91 forcefield potentials set using 
InsightIL This was straightforward for all NNRTIs except 1051U91, in which the 
ligand structure in the PDB file IRTH was different to that reported in the literature: ^̂ ^ 
the PDB structure lacked a nitrogen from one pyridine ring and was corrected. Of more 
significance was the inability oi Insightll Xo find parameters for the nitro substituent on 
this pyridine ring in either the CFF91 or CVFF forcefield. The only alternative was to 
replace the nitro group with similar substituents that could be modelled in the CFF91 
forcefield. A carboxylate group was selected as a suitable replacement. 
Inhibitor conformations were generated using the CFF91 forcefield and 
Discover version 2.9.7 (MSI, San Diego, USA) module of InsightIL The molecular 
dynamics and minimisation protocol involved initialisation of dynamics at 900 K for 
100 fs, followed by 50 consecutive dynamics runs at 900 K for 1 ps each. The 50 
generated conformations were then minimised for 100 iterations using steepest descents 
and then with conjugate gradients until the maximum derivative was less than 
0.0001 kcalA'^ Cluster graph analysis (in Insightll) of each set of dynamics 
conformations revealed many duplicate or very similar conformations (rms values within 
0.3 A of each other), which were subsequently discarded from the data set. Of the 50 
minimised conformations generated by the dynamics run for each inhibitor, between 2 
(nevirapine) and 38 (TNK-651) 'unique' conformations were selected (averageof 17 for 
9 inhibitors). The resulting 156 conformations were combined with the original crystal 
conformation of the 9 different structures into a DOCK 3.5 format database file using 
the DOCK utilities pdb2syb and mol2db. 
6.2.4 Ligand Docking and Database Searching 
Ligand docking was performed using both forcefield (AMBER parameters) and 
contact (van der Waals only) scoring options. The chemical matching, degeneracy 
checking, critical sphere clustering and ligand mirroring options of DOCK 3.5 were not 
used. The default DOCK 3.5 parameters were used for all options that have not 
otherwise been specified Optimisation of the forcefield scores by rigid body 
minimisation of the ligand orientation was not used as during initial trial runs the 
'optimised' coordinates of the docked ligand were found to have extremely bad van der 
Waals contacts with the protein in many cases. The cause of this problem was not 
identified. 
The output from each dock run was sorted according to contact or forcefield 
score, as appropriate, and a set of the best 5-20 conformations/orientations extracted 
using the DOCK utilities sortDOCKout and splitmol. Visual inspection of relative 
orientations required superposition of the crystal structure and docked inhibitor 
coordinates using InsightIL The UNIX script listRMS (Appendix A4.1.2) was used for 
the rapid extraction of contact, forcefield and rms scores from DOCK output files. 
6.3 Distance Difference Matrices 
6.3.1 Software Development 
A search of the literature and computational chemistry internet sites failed to 
find any suitable computer applications meeting our requirements for DDM calculations 
and graphical representation. It was therefore decided to design and implement a 
computer program that could read three dimensional atomic coordinates, calculate 
interatomic distances and construct the DDMs. Two versions of the program were 
written: one with a graphical output that can be displayed either on screen or printed to 
a colour printer; and another with numeric output, in ASCII format, that can be written 
to a file and analysed using a separate third party graphing program. To reduce the 
amount of data created, and aid analysis, the numeric output version also had the 
capability to calculate difference values for a specified range of residues only by 
including residue numbers as command line arguments. 
The graphical DDM program, winDDM, was developed in C++, using the 
Microsoft Foundation Class Library version 2.0 and Microsoft Visual C++ version 1.0 
(Microsoft, Redmond, USA), and run on a 486 PC under Windows 3.1. The ASCII 
output version, DDM, was written in ANSI C and run on a Silicon Graphics R5000 
Indy workstation. ORIGIN 4.1 (Microcal, Northampton, USA) was used for graphical 
representation of the output from DDM. Both programs read the entire set of C„ 
coordinates from two PDB format files into memory and then calculate the distances 
and r / , for all pairs of atoms i a n d i n each structure A and B, and the difference Ar^ 
between the corresponding pairs of distances of A and B, i.e.: 
Ar.. = Ir^ - r ^ for all combinations of / < j 
where r^ is the distance between the coordinates ( x y a n d {xj^yj^j) of the f^ and f ^ 
residues of a structure, respectively, given by: 
As each value of Ar^ is calculated, it is either written to disk, in the case of DDM, or to 
the screen as a dot coloured according to the value, in the case of winDDM. Axes, labels 
and gridlines marking every residue are also plotted by winDDM, while DDM 
records the current residue number at the beginning each line and column of output. 
When matching residues do not appear in both input structures winDDM does not plot 
any points and marks the location of the gap with a rectangle on each axis. DDM marks 
these instances by recording very large numbers in the data fields. As the length of the 
A chain (p66) varied between different crystal structures, special attention to the point 
where the PDB file data changed from the A chain to the B chain was also required to 
ensure that the residues used for calculation of the B chain were synchronised. 
Calculation of DDM values has been further described in section 3.2, and the algorithm 
for the program is given in Appendix A4.2. 
6.3.2 Protein Data Bank File Preparation 
Both DDM programs read the atomic coordinate data in standard Brookhaven 
Protein Data Bank coordinate entry file format.̂ ^® However, to simplify the task of 
parsing the PDB format files the DDM programs recognise files containing only a 
reduced subset of the record formats. The programs assume that the input files contain 
only "ATOM" records describing the coordinates of the atoms, thus requiring PDB 
files to first be fihered to produce valid DDM input records. A short UNIX script was 
written for preparing DDM input files from PDB format files {getCa, Appendix 
A4.1.3). This progam filters PDB files and removes any record that does not contain 
both the "ATOM" and "CA" strings in the record name and atom name fields, 
respectively. 
6.4 Superposition 
6.4.1 Generation of Common PDB Files 
Superposition of structures were performed using subsets of the original atomic 
coordinates that contained only those atoms that were common to both structures being 
compared. These subsets were created using the program comparePDB (see Appendix 
A4.4 for algorithm) which was developed in ANSI C and run on a Silicon Graphics 
R5000 Indy workstation. The program comparePDB reads two PDB format files 
(containing only ATOM records, prepared using the awk script get ATOM, Appendix 
A4.1.4) and writes out versions of the original files that contain only those residues that 
appear in both input files (the coordinate data remains unchanged, however). Depending 
on options easily set at compilation time, comparePDB can be configured to match 
residues on the basis of only the residue sequence number and chain identifier specified 
in the PDB files, or to check that matching residue names appear as well. Options for 
the output format allow writing of either all atoms or only the backbone atoms of 
matching residues (regardless of whether corresponding atoms appear in both 
structures), or only those atoms that are common to both matched residues. Files used 
for superposition of structures were generated by matching residues using sequence 
number and chain identifier only and writing only the atoms that were common to both 
input structures. This combination of settings creates files that contain both the 
backbone and side chains of identical residues, and the backbone of residues that are not 
of the same type in both structures. These settings were chosen so that residues that 
were modelled as alanines due to poor electron density of the side chain in the X-ray 
structure may still be used for backbone and C„ rms calculations. 
An additional feature of comparePDB enables the calculation of the difference 
between the values in the corresponding PDB temperature factor fields of each matching 
residue. The difference is recorded in the same field of both of the output PDB files, 
after scaling by an appropriate factor to ensure values conform to the temperature factor 
field specification. This facility was used for the comparison of (j) and \\f angles 
calculated by the program PhiPsi (sections 5.3 and 6.5). 
6.4.2 Superposition and RMS Calculations 
Superposition of subdomains and calculation rms deviations of superposed 
regions was performed using InsightIL Subsets were created for each subdomain 
(definitions are given in Table 1, section 1.3.1), with additional subsets defined for the 
p66 (A chain residues 1-560) and p51 (B chain residues 1-440) subunits, and the 
polymerase active site (p66 AspllO, Tyrl83, Metl84, Aspl85 and Aspl86) and 
NNIBP (p66 LeulOO, LyslOl, Lysl03, Vall79, Tyrl81, Tyrl88, and p51 Glul38). As 
Insightllis only capable of calculating the rms deviation of only those atoms that have 
been used as the basis of a prior superposition, the DOCK 3.5 utility program rmsd was 
used to calculate the rms deviation of the atomic positions of the polymerase active site, 
NNIBP, fingers and thumb, after the structures had been superposed using the C„ atoms 
of the p51 subunit, RNase H and connection subdomains. This required saving of the 
transformed coordinates of the fingers, thumb, polymerase active site and NNIBP 
subsets in PDB format (in Insightll), filtering using the scripts getCa, getBackbone and 
get ATOM (Appendix A4.1), followed by comparison using rmsd. 
6.5 (t)/\i/ Dihedral Angle Comparison 
The program PhiPsi was written in ANSI C and run on a Silicon Graphics 
R5000 Indy workstation. PhiPsi reads atomic coordinates from files using a reduced 
subset of the standard PDB file format, containing only ATOM records, that were 
obtained using the script ger^ TOM (Appendix A4.1.4). Two files are created by PhiPsi, 
with the (|) or \}/ angles recorded in the temperature factor field for all atoms of each 
particular residue, along with all the original coordinate and atom name data of the input 
file. The recorded angles are divided by a factor of 10 prior to writing the output files so 
that the values will fit into the standard format of the PDB temperature factor field. 
The algorithm for PhiPsi is given in Appendix A4.3. Calculation of the difference 
between torsional angles in two structures was performed using the program 
comparePDB, which is described in section 6.4.1. The resulting PDB files were 
displayed and coloured according to temperature factor (i.e. relative change in (j) or \j/) 
using InsightIL 
6.5.1 Dihedral Angle Calculation 
The angles (j)' and are defined as the torsion angle of the sequences of atoms 
C'-^ N', C„', C andN', C„', C, respectively (Figure 22). ̂ ^̂  The dihedral angles 
were calculated by PhiPsi by determining the angle between the two planes passing 
through the first three and last three atoms in the sequence of atoms defining the 
torsions (for example, the two planes for (j)' are specified by the sets of points given by 
{C-\ N', C„'} and {N', C'}, where each of C ' ^ N', C„' and C describe the Cartesian 
coordinates x,; ; and z of the atoms). The plane <P passing through any three points 
(^b ^i), fe, y2, zi) and fe, y^, z{) is described by the equation: 
ax-by-\-cz-d = 0, 
with a, b, c and d given by solving the determinant: 
(P = 
X y 
yi z, 1 
Z3 1 
= 0 
The angle 9 between the two planes (Pi and <p2 is then given by: 
cos 0 = 
aia2 +bib2 +CjC. 
The caveat to this method of calculating the torsional angles is that the angle 
Figure 22 Definition of Dihedral Angles (\> and \\f 
calculated between the two planes is an absolute value in the range of 0 to +180°, 
whereas the true dihedral angles ([) and \|/ are defined across the range of -180 to +180°. 
This should not cause any significant problems for the calculation of the difference 
between the angles by comparePDB, unless the change in conformation results in the 
reversal of the sign of the dihedral angles, in which case the reported difference will be 
less than the true value. 
CHAPTER SEVEN 
CONCLUSIONSAND 
FUTURE DIRECTIONS 
This project has investigated and established several techniques to aid the 
study of conformational change in proteins, through analysis of three dimensional X-ray 
crystal structures. The computational tools and protocols developed offer a range of 
complementary techniques to scrutinise many aspects of protein flexibility in a detailed 
and objective manner. Application of these tools to HIV-1 reverse transcriptase has 
enabled the characterisation of many aspects of the enzyme's conformational flexibility, 
ranging from large rigid body motions to rearrangements of small segments of 
polypeptide, by describing both protein backbone movement and amino acid side chain 
conformation. The contribution to ligand binding of the structural and conformational 
features of a selection of potent nonnucleoside RT inhibitors has been investigated, as 
well as the relationship between inhibitor conformation to binding pocket geometry. 
Through the application of these structure comparison methods to almost every 
currently available X-ray crystal structure of RT, this project has attempted to study 
the conformational flexibility of RT in a manner more comprehensive than previous 
studies. 
The docking studies have suggested that although the pocket adopts a 
conformation highly complementary to the bound ligand, most of the diverse NNRTIs 
studied require only minor changes in conformation to bind effectively to nonnucleoside 
inhibitor binding pocket geometries derived from other inhibitors. The docked inhibitor 
conformations all show a remarkable degree of complementarity in their three 
dimensional shapes, preserving the known "butterfly"-like conformations of most 
NNRTIs, and aligning the aromatic regions of most NNRTIs, reiterating the importance 
of Tc-stacking forces in NNRTI-NNIBP association. The observed close steric and 
electronic alignment of docked inhibitors opens the way to development of a type of 
"pharmacophore", derived from information contained within the geometry of the 
NNIBP, rather than structural similarity of the ligands. There is also some evidence that 
the flexibility of the NNIBP is limited, and that the more flexible inhibitors may be able 
to form a closer association with the enzyme. Further investigations into the correlation 
(if any) between NNRTI flexibility and experimental binding affinity will indicate 
whether there is any basis to this proposal. Avenues of further development of the 
docking process include incorporating molecular mechanical geometry optimisation of 
both the protein and inhibitor during ligand docking and improving the selectivity of the 
docking protocol. 
Difference distance matrix analysis of the apo and NNRTI bound crystal 
structures of RT has proved to be a rapid and objective method for comparison of 
conformational change in proteins. The method is capable of identifying relative 
movements of both large subdomains and smaller secondary structural regions, as well as 
the rigid areas of the protein, without the need to superpose the structures. This has 
overcome many of the deficiencies of the superposition technique, enabling regions of 
conformational flexibility of almost any size or magnitude to be characterised without 
bias. The DDM technique was used to define the rigid regions of RT, enabling the 
subsequent development of a "rigid body" superposition protocol that allows the 
alignment of RT structures of different geometry to be performed in an objective 
manner. Enhancement of the DDM method, for example by producing contoured 
surface plots of specific regions of the DDM and including side chain atoms in the 
calculations, offers great potential for detailed analysis of the flexibility of critical 
regions of the enzyme, such as the NNIBP and polymerase active site, and is currently 
being investigated. 
Application of the rigid body superposition protocol to RT - using the p51 
subunit, RNase H domain and connection subdomain as an essentially structurally 
invariant region of the protein on which to align the molecules without distortion due to 
the movement of large portions of the flexible protein - has shown that inhibitor binding 
is associated with side chain reorientation within the NNIBP and movement of the 
polymerase active site backbone. The minimal movement of the NNIBP backbone 
observed during superposition correlates with the suggestion by the docking 
experiments that the conformational flexibility of the pocket is limited. Further analysis 
in this area is needed (along with refinement of the definition of the rigid body region), 
primarily by visual inspection of the superposed coordinates and measurement of 
distances between important residues of the apo and complexed proteins, to characterise 
and quantify the conformational changes induced by inhibitor binding. 
The method of comparing the backbone dihedral angles and \|/ of two protein 
conformations has not yet been extensively applied to the RT system, but will offer 
complementary information to that gained from the DDM and superposition analyses. 
Modification of the software to enable calculation of side chain torsional angles will be 
of particular use in the analysis of the NNIBP geometry. 
The insights into the conformational flexibility of RT obtained during this 
study, particularly the relationships between NNRTI structure and conformation to 
NNIBP geometry, offer great potential for the rational design and optimisation of potent 
new NNRTIs, and elucidation of the NNRTI mechanism of action. An increasing 
appreciation of the importance of incorporating receptor flexibility into the structure 
based drug design process is being realised, creating a need for methods of studying 
induced fit effects and other conformational changes in protein-ligand complexes in 
greater detail. The comprehensive characterisation of RT flexibility, and the 
understanding of the interrelationships between inhibitor structure and conformational 
changes in different flexible regions, is still in its infancy, however, the protein structure 
comparison tools developed during this project have laid a few foundations towards the 
ultimate realisation of this goal. 
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APPENDIX ONE 
Al. l Definition of HIV-1 Reverse Transcriptase 
SecondaryStructure 
a-Helices p-Strands 
Name Residues Notes Name Residues Notes 
a l 28-43 (31 47-49 
a2 78-83 (32 60-64 
a3 112-117 3 i o - h e l i x P3 71-75 
a4 125-128 3 i o - h e l i x p4 105-110 
a5 156-174 P5 130-132 
a6 195-211 P6 142-146 
al 254-267 p7 179-183 
a8 277-281 186-191 
a9 297-311 P9 227-229 p66 only 
alO 364-383 pio 232-234 p66 only 
a l l 395-404 Pll 239-241 p66 only 
a l 2 421-428 p51 only pl2 326-333 
a l 3 474-488 p66 only P13 336-344 
a l 4 500-508 p66 only pl4 347-355 
a l 5 516-527 p66 only P15 388-391 
pl6 413-416 
P17 439-447 p66 only 
pl8 452-459 p66 only 
pl9 464-470 p66 only 
P20 492-497 p66 only 
P21 530-535 p66 only 
Assignments from Ren, etal, 1995. 109 
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Figure A2.1 DDM of Apo RT and RT-HEPT Complex 
C^-C^ difference distance matrix of RT in native form and complexed with the 
NNRTI HEPT (4) in P2j2j2j space group crystal structures (PDB entries 
1RTJ ^ ̂ ^ and 1RTI ^ respectively ). Inter-residue distances calculated using 
coordinates of C^ atoms, calculatedfor both p66 and p51 subunits (residue 
numbers are indicated on both axes). The plot is contoured in 2.5 A 
intervals: white < 2.5 A; yellow 2.5 - 5.0 A; green 5.0-7.5 A; and 
red > 7.5 A. Polypeptide segments that did not appear in both crystal 
structures, and so were not calculated, are indicated by black rectangles on the 
axes. 
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Figure A2.2 DDM of Apo RT and RT-TNK-651 Complex iP2,2,2,) 
C^-C^ dijference distance matrix of RT in native form andcomplexed with the 
NNRTI TNK-651 (6) inF2j2j2j space group crystal structures (PDB entries 
IRTJ^^^ and 1RT2 respectively). Contour levels and missing polypeptide 
segments are as described in the caption to Figure A 2.1 
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Figure A2.3 DDM of Apo RT and RT-9-C1-TIBO Complex (P2,2,2,) 
C^-C^ difference distance matrix of RT in native form and complexed with the 
NNRTI 9-Cl-TIBO (8) in P2;2,2, space group crystal structures (PDB 
entries IRTJ^^^ and 1REV^\ respectively). Contour levels and missing 
polypeptide segments areas described in the caption to Figure A2.1 
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Figure A2.4 DDM of Apo RT and RT-8-C1-TIBO Complex (C2) 
C^-C^ difference distance matrix of RT in native form and complexed with the 
NNRTI 8-Cl-TIBO (9) in C2 space group crystal structures (PDB entries 
IHMV^^^ and IHNV, respectively). Contour levels and missing 
polypeptide segments areas described in the caption to Figure A2.1 
IOC' 
150 
20C 
250 
mo 
360 
400 
450 
500 
0 
50 
100 
150 
200 
250 
yx) 
350 
430 
f ! 
S I at 1 
10C' 160 200 2S0 300 350 400 450 500 0 50 100 150 200 250 300 350 4(X) 
fingers 1  1  | palm 
, "-r̂ V'-—r-
thumb connection RNase H p51 
Figure A2.5 DDM of Apo RT and RT-Cl-a-APA Complex (Pl,!,!^) 
C^-C^ difference distance matrix of RT in native form and complexed with the 
NNRTI Cl-a-APA (12) in P2j2j2j space group crystal structures (PDB 
entries IRTJ^^^ and IVRU, ^^ respectively). Contour levels and missing 
polypeptide segments areas described in the caption to Figure A 2.1 
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Figure A2.6 DDM of Apo RT and RT-Br-a-APA Complex (C2) 
C^-C^ difference distance matrix of RT in native form and complexed with the 
NNRTI Cl-a-APA (the dibrominatedanalogue of (12)) in C2 space group 
crystal structures (PDB entries IHMV^^^ and IHNI, ^^^ respectively). 
Contour levels and missing polypeptide segments are as described in the 
caption to Figure A2.1 
APPENDIX THREE 
Tables of Superposition Data 
Notes: 
t backbone = -N-C„-CO- atoms 
} PAS = polymerase active site, p66: DUO, D185, D186, Y183, M184 
§ NNIBP = nomiucleoside inhibitor binding pocket, p66: LlOO, KlOl, K103, V179, 
Y181,Y188,p51:E138 
A3.1 Superposition of Structures RT J and VRT 
A3.1.1 Details 
PDB Entry: 
Inhibitor: 
Resolution: 
Crystal Space Group: 
IRTJ 
apo 
2.3 A 
P2^2{l^ 
IVRT 
nevirapine 
22 k 
P2i2ai 
A3.1.2 Superposition of Subdomains 
C„ atoms backbone ^ heavy atoms 
rnis atoms rms atoms rms atoms 
whole enzyme 2.156 924 2.150 3696 2.589 7606 
p51 1.150 400 1.159 1600 1.724 3308 
p66 2.583 524 2.573 2096 2.999 4298 
RNaseH 1.048 m 1.045 408 1.624 814 
connection 1.161 114 1.180 456 2.182 965 
palm 1.531 128 1.512 512 2.248 1047 
fingers 1.238 111 1.223 444 1.859 920 
thumb 0.610 69 0.663 276 1.302 552 
PAS^ 0.321 5 0.507 20 1.381 44 
NNIBP§ 0.919 7 0.901 28 2.952 66 
p51+RNase H 1.268 502 1.273 2008 1.793 4122 
p51+connection 1.203 514 1.215 2056 1.872 4273 
p51+RNase H+connection 1.288 616 1.295 2464 1.900 5087 
fingers+palm+thumb 2.859 308 2.842 1232 3.225 2519 
A3.1.3 RMS After Superposition of p51 + RNase H + Connectio 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 3.003 5 3.012 20 3.746 44 
NNIBP§ 2.360 7 2.339 28 4.453 66 
fingers 4.411 111 4.388 444 4.616 920 
thumb 3.445 69 3.452 276 3.650 552 
A3.2 Superposition of Structures RT J and RTH 
A3.2.1 Details 
IRTJ PDB Entry: 
Inhibitor: apo 
Resolution: 2.3 A 
Crystal Space Group: P2i2{lx 
IRTH 
1051U91 
2.2 A 
^̂ 212121 
A3.2.2 Superposition of Subdomains 
atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 0.974 961 0.982 3844 1.512 7872 
p51 0.668 419 0.697 1676 1.265 3443 
p66 1.087 542 1.087 2168 1.626 4429 
RNaseH 0.374 117 0.418 468 0.802 924 
connection 0.514 114 0.549 456 1.047 965 
palm 1.218 128 1.193 512 2.072 1047 
fingers 0.847 114 0.840 456 1.569 911 
thumb 0.475 69 0.484 276 1.105 552 
PAS^ 0.158 5 0.262 20 1.205 44 
NNIBP§ 1.023 7 0.969 28 3.013 66 
p51+RNaseH 0.642 536 0.670 2144 1.199 4367 
p51+connection 0.656 533 0.683 2132 1.236 4408 
p51+RNase H+connection 0.631 650 0.659 2600 1.182 5332 
fingers+palm+thumb 1.201 311 1.187 1244 1.860 2540 
A3.2.3 RMS After Si iperposition of p51 + RNase H + Connectio 
atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 3.118 5 3.075 20 3.750 44 
NNIBP§ 1.834 7 1.801 28 3.969 66 
fingers 1.363 114 1.346 456 1.917 911 
thumb 0.714 69 0.728 276 1.209 552 
A3.3 Superposition of Structures RT J and RTI 
A3.3.1 Details 
PDB Entry: 
Inhibitor: 
Resolution: 
Crystal Space Group: 
IRTJ 
apo 
2.3 A 
P2{l{li 
IRTI 
KEPT 
3.0 A 
P2x2{l, 
A3.3.2 Superposition of Subdomains 
atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 0.934 954 0.942 3816 1.533 7825 
p51 0.583 412 0.613 1648 1.270 3396 
p66 1.073 542 1.073 2168 1.665 4429 
RNaseH 0.416 1L7 0.451 468 0.862 924 
connection 0.523 114 0.567 456 1.121 965 
palm 1.376 128 1.359 512 2.213 1047 
fingers 0.899 114 0.872 456 1.735 941 
thumb 0.426 69 0.463 276 1.023 582 
FAS^ 0.134 5 0.381 20 1.350 44 
NNIBP§ 0.609 7 .0553 28 2.353 66 
pSl+RNase H 0.617 529 0.647 2116 1.228 4320 
p51+connection 0.624 526 0.654 2104 1.269 4361 
p51+RNase H+connection 0.625 643 0.656 2572 1.225 5285 
fingers+palm+thumb 1.280 311 1.269 1244 1.967 2540 
A3.3.3 RMS After Superposition of p51 + RNase H + Connectio 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 2.303 5 2.243 20 2.882 44 
NNIBP§ 0.923 7 0.890 28 2.787 66 
fingers 1.140 114 1.382 456 2.067 941 
thumb 0.887 69 0.914 276 1.255 582 
A3.4 Superposition of Structures RTJ and RTl 
A3.4.1 Crystal Structures 
PDB Entry 
Inhibitor 
Resolution 
Crystal Space Group 
A3.4.2 Superposition of Subdomains 
IRTJ 
apo 
2.3 A 
^̂ 212121 
IRTl 
MKC-442 
2.55 A 
^^2,2121 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 0.820 546 0.823 3804 1.402 7809 
p51 0.642 414 0.654 1656 1.209 3417 
p66 0.916 537 0.913 2148 1.526 4392 
RNaseH 0.254 113 0.290 452 0.684 893 
connection 0.511 114 0.528 456 1.343 965 
palm 1.242 128 1.234 512 1.960 1047 
fingers 0.886 114 0.878 456 1.605 941 
thumb 0.490 68 0.497 272 1.044 546 
PAS^ 0.101 5 0.246 20 1.079 44 
NNIBP§ 0.776 7 0.730 28 2.954 66 
p51+RNaseH 0.588 527 0.601 2108 1.123 4310 
p5l4-connection 0.622 528 0.634 2112 1.241 4382 
p51+RNase H+connection 0.578 641 0.592 2564 1.168 5275 
fingers+palm+thumb 0.129 310 1.118 1240 1.768 2534 
A3.4.3 RMS After Superposition of p51 + RNase H + Connectio 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 2.539 5 2.510 20 3.114 44 
NNIBP§ 1.271 7 1.229 28 3.770 66 
fingers 1.083 114 1.071 456 1.746 941 
thumb 0.736 68 0.746 272 1.167 546 
A3.5 Superposition of Structures RT J and RT2 
A3.5.1 Crystal Structures 
PDB Entry: IRTJ 1RT2 
Inhibitor: apo TNK-651 
Resolution: 2.3 A 2.55 A 
Crystal Space Group: P2i2i2i P2i2i2i 
A3.5.2 Superposition of Subdomains 
atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 0.920 942 0.939 3768 1.527 7748 
p51 0.775 401 0.826 1604 1.323 3325 
p66 0.957 541 0.957 2164 1.628 4423 
RNaseH 0.527 117 0.561 468 0.907 924 
connection 0.527 114 0.565 456 1.388 965 
palm 1.131 128 1.121 512 2.030 1047 
fingers 0.393 114 0.998 456 1.694 941 
thumb 1.026 68 0.461 272 1.234 546 
PAS^ 0.127 5 0.332 20 0.870 44 
NNIBP§ 0.746 7 0.765 28 2.962 66 
p51+RNase H 0.767 518 0.812 2072 1.272 4249 
p51+connection 0.745 515 0.793 2060 1.347 4290 
p51+RNase H+connection 0.741 632 0.785 2528 1.299 5214 
fingers+palm+thumb 1.118 310 1.104 1240 L860 2534 
A3.5.3 RMS After Superposition of p51 + RNase H + Connectio 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 2.302 5 2.305 20 2.785 44 
NNIBP§ 1.027 7 1.023 28 3.583 66 
fingers 1.327 114 1.302 456 1.913 941 
thumb 1.091 68 1.123 272 1.563 546 
A3.6 Superposition of Structures RT J and REV 
A3.6.1 Crystal Structures 
PDB Entry 
Inhibitor 
Resolution 
Crystal Space Group 
IRTJ 
apo 
2.3 A 
IREV 
9-Cl-TIBO 
2.6 A 
P2{iax • 
A3.6.2 Superposition of Subdomains 
atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 2.125 934 2.122 3736 2.587 7684 
p51 1.333 411 1.335 1644 1.892 3392 
p66 2.478 523 2.473 2092 2.931 4292 
RNaseH 1.100 102 1.104 408 1.627 814 
connection 1.205 114 1.223 456 2.273 965 
palm 1.526 128 1.521 512 2.307 1047 
fingers 1.186 111 1.164 444 1.914 920 
thumb 0.560 68 0.610 272 1.305 546 
PAS^ 0.262 5 0.352 20 1.614 44 
NNIBP§ 1.067 7 1.051 28 2.981 66 
p51+RNase H 1.405 513 1.406 2052 1.915 4206 
p51+connection 1.322 525 1.327 2100 1.993 4357 
p51 +RNase H+connection 1.385 627 1.389 2508 1.996 5171 
fingers+palm+thumb 2.774 307 2.761 1228 3.183 2513 
A3.6.3 RMS After Si] iperposition of p51 + RNase H + Connectio 
atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 3.377 5 3.348 20 3.976 44 
NNIBP§ 2.273 7 2.261 28 4.454 66 
fingers 4.518 111 4.501 444 4.705 920 
thumb 3.259 68 3.270 272 3.480 546 
A3.7 Superposition of Structures RT J and VRU 
A3.7.1 Crystal Structures 
PDB Entry: 
Inhibitor: 
Resolution: 
Crystal Space Group: 
IRTJ 
apo 
2.3 A 
P2i2,2i 
IVRU 
Cl-a-APA 
2.4 A 
P2i2,2i 
A3.7.2 Superposition of Subdomains 
C„ atoms backbone heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 2.278 934 2.268 3736 2.670 7677 
p51 1.409 409 1.411 1636 1.885 3373 
p66 2.658 525 2.640 2100 3.098 4304 
RNaseH 1.067 102 1.071 408 1.600 814 
connection 1.176 114 1.182 456 2.350 965 
palm 1.520 128 1.506 512 2.279 1047 
fingers 1.417 112 1.349 448 2.074 926 
thumb 0.656 69 0.679 276 1.321 552 
PAS^ 0.176 5 0.440 20 1.095 44 
NNIBP§ 1.130 7 1.150 28 2.976 66 
p51+RNase H 1.485 511 1.485 2044 1.925 4187 
p51+connection 1.416 523 1.420 2092 2.308 4338 
p51 +RNase H+connection 1.473 625 1.474 2500 2.041 5152 
fingers+palm+thumb 2.972 309 2.944 1236 3.344 2525 
A3.7.3 RMS After Superposition of p51 + RNase H + Connectio 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 3.428 5 3.403 20 4.121 44 
NNIBP§ 2.690 7 2.676 28 4.632 66 
fingers 4.525 112 4.498 448 4.753 926 
thumb 3.353 69 3.353 276 3.544 552 
A3.8 Superposition of Structures HMV and HVT 
A3.8.1 Crystal Structures 
PDB Entry 
Inhibitor 
Resolution 
Crystal Space Group 
A3.8.2 Superposition of Subdomains 
IHMV 
apo 
3.2 A 
C2 
3HVT 
nevirapine 
2.9 A 
C2 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 5.569 928 5.535 3712 5.393 7160 
p51 1.720 394 1.693 1576 2.372 3162 
p66 6.302 524 6.256 2096 6.045 3914 
RNaseH 0.868 118 0.981 472 1.529 889 
connection 2.307 114 2.245 456 2.875 865 
palm 2.038 128 2.069 512 2.692 1006 
fingers 1.688 95 1.683 380 2.922 779 
thumb 1.711 69 1.690 276 2.767 375 
PAS^ 0.144 5 0.644 20 1.413 44 
NNIBP§ 0.969 7 1.052 28 3.225 66 
p51+RNaseH 2.907 512 2.912 2048 3.281 4051 
p51+connection 2.379 508 2.356 2032 2.880 4027 
p51+RNase H+connection 2.895 626 2.889 2504 3.291 4916 
fingers+palm+thumb 7.991 292 7.939 1168 7.629 2160 
A3.8.3 RMS After Su iperposition of p51 + RNase H + Connectio 
C„ atoms backbone heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 4.233 5 4.157 20 4.726 44 
NNIBP§ 3.329 7 3.364 28 5.343 66 
fingers 8.304 95 8.273 380 8.658 779 
thumb 15.434 69 15.301 276 15.457 375 
A3.9 Superposition of Structures HMV and HNV 
A3.9.1 Crystal Structures 
PDB Entry: 
Inhibitor: 
Resolution: 
Crystal Space Group: 
A3.9.2 Superposition of Subdomains 
IHMV 
apo 
3.2 A 
C2 
IHNV 
8-Cl-TIBO 
3.0 A 
C2 
C^ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 5.115 929 5.085 3712 4.845 7300 
p51 1.720 394 1.693 1576 2.372 3162 
p66 6.443 525 6.410 2096 5.974 4052 
RNaseH 0.720 117 0.812 472 1.172 915 
connection 1.327 114 1.355 456 1.830 938 
palm 2.054 128 2.064 508 2.472 1017 
fmgers 0.847 96 0.898 384 1.777 785 
thumb 1.527 69 1.464 276 1.925 397 
PAS^ 0.520 5 0.662 16 1.043 42 
NNIBP§ 0.791 7 0.778 28 2.952 66 
pSl+RNase H 2.071 512 2.064 2048 2.557 4077 
p51+connection 1.722 508 1.706 2032 2.313 4100 
pSI+RNase H+connection 2.060 626 2.057 2504 2.524 5015 
fmgers+palm+thumb 8.279 293 8.240 1168 7.706 2199 
A3.9.3 RMS After Superposition of p51 + RNase H + Connectio 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 4.250 5 4.342 16 4.656 42 
NNIBP§ 3.218 7 3.208 28 5.218 66 
fmgers 7.013 96 6.987 384 7.161 785 
thumb 14.768 69 14.647 276 14.448 397 
A3.10 Superposition of Structures HMV and HNI 
A3.10.1 Crystal Structures 
PDB Entry 
Inhibitor 
Resolution 
Crystal Space Group 
A3.10.2 Superposition of Subdomains 
IHMV 
apo 
3.2 A 
C2 
IHNI 
Br-a-APA 
2.8 A 
C2 
atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 4.933 929 4.901 3716 4.668 7291 
p51 1.727 394 1.708 1576 2.418 3153 
p66 6.178 525 6.141 2100 5.696 4054 
RNase H 0.632 m 0.677 472 1.217 915 
connection 1.348 114 1.350 456 1.830 938 
palm 2.006 128 2.032 512 2.408 1019 
fmgers 0.885 96 0.916 384 1.773 785 
thumb 1.459 69 1.408 276 1.897 397 
PAS^ 0.544 5 0.664 20 1.259 44 
NNIBP§ 0.904 7 0.897 28 3.019 66 
p51+RNaseH 1.980 512 1.972 2048 2.535 4068 
p51+connection 1.727 508 1.715 2032 2.352 4091 
p51+RNase H+connection 2.001 626 1.995 2504 2.518 5006 
fmgers+palm+thumb 7.868 293 7.822 1172 7.309 2201 
A3.10.3 RMS After Superposition of p51 + RNase H + Connection 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 3.873 5 3.881 20 4.305 44 
NNIBP§ 3.097 7 3.141 28 5.190 66 
fmgers 5.556 96 5.535 384 5.774 785 
thumb 15.149 69 15.026 276 14.769 397 
A3.11 Superposition of Structures DLO and TVR 
A3.11.1 Crystal Structures 
PDB Entry: 
Inhibitor: 
Resolution: 
Crystal Space Group: 
A3.11.2 Superposition of Subdomains 
IDLO 
apo 
2.7 A 
C2 
ITVR 
9-Cl-TIBO 
3.0 A 
C2 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 5.417 969 5.388 3876 5.308 7567 
p51 2.070 412 2.032 1648 2.629 3272 
p66 6.742 543 6.712 2172 6.486 4190 
RNaseH 0.883 118 0.956 472 1.327 899 
connection 1.415 114 1.436 456 1.862 922 
palm 2.141 128 2.147 512 2.473 996 
fingers 1.474 114 1.442 456 2.101 893 
thumb 1.306 69 1.330 276 1.612 480 
PAS^ 0.713 5 0.956 20 1.561 44 
NNIBP§ 0.882 7 0.852 28 2.808 66 
p51+RNaseH 2.208 530 2.188 2120 2.670 4176 
p51+connection 2.116 526 2.088 2104 2.607 4199 
p51+RNase H+connection 2.280 644 2.260 2576 2.703 5098 
fingers+palm+thumb 8.608 311 8.569 1244 8.276 2369 
A3.11.3 RMS After Superposition of p51 + RNase H + Connectio 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 4.298 5 4.272 20 4.862 44 
NNIBP§ 3.472 7 3.484 28 5.234 66 
fingers 8.513 114 8.474 456 8.475 893 
thumb 14.451 69 14.371 276 13.914 480 
A3.12 Superposition of Structures DLO and UWB 
A3.12.1 Crystal Structures 
PDB Entry: 
Inhibitor: 
Resolution: 
Crystal Space Group: 
A3.12.2 Superposition of Subdomains 
IDLO 
apo 
2.7 A 
C2 
lUWB 
8-Cl-TIBO 
3.2 A 
C2 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
whole enzyme 5.375 969 5.345 3876 5.263 7546 
p51 2.077 412 2.020 1648 2.684 3270 
p66 6.686 543 6.657 2172 6.415 4176 
RNaseH 0.829 113 0.910 472 1.221 899 
connection 1.439 114 1.431 456 1.852 922 
palm 2.159 128 2.147 512 2.490 989 
fmgers 1.376 114 1.388 456 1.954 886 
thumb 1.283 69 1.275 276 1.694 480 
PAS^ 0.765 5 0.784 20 1.450 44 
NNIBP§ 0.850 7 0.874 28 2.424 59 
p51+RNaseH 2.556 530 2.226 2120 2.742 4169 
p51+connection 2.109 526 2.061 2104 2.639 4192 
p51+RNase H+connection 2.300 644 2.272 2576 2.744 5091 
fmgers+palm+thumb 8.528 311 8.489 1244 8.196 2355 
A3.12.3 RMS After Su iperposition of p51 + RNase H + Connectio 
C„ atoms backbone ^ heavy atoms 
rms atoms rms atoms rms atoms 
PAS^ 4.309 5 4.274 20 4.847 44 
NNIBP§ 3.592 7 3.544 28 4.862 59 
fmgers 7.890 114 7.861 456 7.819 886 
thumb 14.750 69 14.669 276 14.194 480 
APPENDIX FOUR 
A4.1 File Formatting, Conversion and Processing Scripts 
A4.1.1 DOCKsurfllnsight 
Usage: D0CKsurf2Insight < DOCK surface filename .ms > Insight filename. suri 
#!/bin/sh 
nawk ' 
BEGIN { 
print "DOTS" 
3itom_rei="Object name used by Insight, usually capitalised PDB filename, 
excluding extension and leading numbers'' 
} 
$7 ~ /A/ { 
printf "ATOM_REF %s :-%€!: %s\n", atom_ref, $2, $3 } 
$7 ~ /SCO/ { 
printf "%-7.6f %-7.6f %-7.6f 0,0,255,255\n", $4, $5, $6 } 
' $ 1 
A4.1.2 listRMS 
Usage: listRMS DOCK output filename [DOCK output filename...] 
#!/bin/sh 
while(test $# -gt 0); do 
infile=$l 
shift 
if [ ! -r $1 ]; then echo "ERROR: $infile does not exist or is unreadable." 
else 
nawk ' 
# contact scores 
$1 == "REMARK" && $2 == "score," && $6 == "det:" {score=$7; 
rms=$8; prev=$l} 
# Large negative scores have no space between fields 5 and 6, 
# so split if necessary $1 == "REMARK" && $2 == "score," && $5 ~ /"nodes:/ && NF==9 
{score=$6; rms=$7; prev=$l} 
$1 == "REMARK" && $2 == "score," && $5 ~ /^nodes:/ && NF==8 {split($5,new,"-"); score=sprintf("-%f",new[2]); 
rms=$6; prev=$l} 
# forcefield scores 
$1 == "ATOM" && $2 /score/ {ffscore=$2; prev=$l} 
#print scores 
$1 == "ATOM" && $1 != prev {prev=$l; printf("%5.3f %8.2f 
%9.3f\n", rms, score, ffscore)} 
' $infile I sort -n > temp.listRMS.$$ 
numstruct='cat temp.listRMS.$$ I wc -1 I sed -e 's/ //g'' 
echo "FILE: $infile - $numstruct orientations read." 
echo 
echo 'rms (A) score ffscore' 
cat temp.listRMS.$$ 
echo 
/bin/rm temp.listRMS.$$ 
fi 
done 
A4.1.3 getCa 
Usage: getCa filename [filename... 
#!/bin/sh 
ans=no 
while(test $# -gt 0); do 
infile=$l 
shift 
if [ ! -r $1 ]; then 
echo "ERROR: $infile does not exist or is unreadable." 
else 
nawk ' 
$1 == "ATOM" && $3 == "CA" {print} 
' $infile > getCa.temp.$$ 
outfile=Ca$infile 
if [ -r $outfile ] && [ $anrs != all ]; then 
echo "WARNING: $outfile already exists, overwrite? (Yes, No, 
All, Quit)" 
read ans 
case $ans in 
[Yy]*) /bin/mv getCa.temp.$$ $outfile 
echo "overwriting $outfile";; 
[Nn]*) continue;; 
[Aa]*) /bin/mv getCa.temp.$$ $outfile 
echo "overwriting $outfile" 
ans=all;; 
[Qq]*) exit;; 
*) continue;; 
esac 
else 
if [ -r $outfile ] && [ $ans = all ]; then 
echo "overwriting outfile" 
fi 
/bin/mv getCa.temp.$$ $outfile 
fi 
fi 
done 
if [ -r getCa.temp.$$ ]; then 
/bin/rm getCa.temp.$$ 
fi 
A4.1.4 getATOM 
Usage: getATOM filename [filename...] 
#!/bin/sh 
ans=no 
while(test $# -gt 0); do 
infile=$l 
shift 
if [ ! -r $1 ]; then 
echo "ERROR: $infile does not exist or is unreadable." 
else 
nawk ' 
$1 == "ATOM" {print} 
' $infile > getATOM.temp.$$ 
outfile=ATOM$infile 
if [ -r $outfile ] && [ $ans != all ]; then 
echo "WARNING: $outfile already exists, overwrite? (Yes, No, 
All, Quit)" 
read ans 
case $ans in 
[Yy]*) /bin/mv getATOM.temp.$$ $outfile 
echo "overwriting $outfile";; 
[Nn]*) continue;; 
[Aa]*) /bin/mv getATOM.temp.$$ $outfile 
echo "overwriting $outfile" 
ans=all;; 
[Qq]*) exit;; 
*) continue;; 
esac 
else 
if [ -r $outfile ] && [ $ans = all ]; then 
echo "overwriting outfile" 
fi 
/bin/mv getATOM.temp.$$ $outfile 
fi 
fi 
done 
if [ -r getATOM.temp.$$ ]; then 
/bin/rm getATOM.temp.$$ 
fi 
A4.1.5 getBackbone 
Usage: getBackbone filename [filename...] 
#!/bin/sh 
ans=no 
while(test $# -gt 0); do 
infile=$l 
shift 
if [ ! -r $1 ]; then 
echo "ERROR: $infile does not exist or is unreadable." 
else 
nawk ' 
$1 == "ATOM" && $3 == "N " {print} 
$1 == "ATOM" && $3 == "CA" {print} 
$1 == "ATOM" 5c& $3 == "C " {print} 
$1 == "ATOM" && $3 == "0 " {print} 
' $infile > getBackbone.temp.$$ 
outfile=Backbone$infile 
if [ -r $outfile ] && [ $ans != all ]; then 
echo "WARNING: $outfile already exists, overwrite? (Yes, No, 
All, Quit)" 
read ans 
case $ans in 
[Yy]*) /bin/mv getBackbone.temp.$$ $outfile 
echo "overwriting $outfile";; 
[Nn]*) continue;; 
[Aa]*) /bin/mv getBackbone.temp.$$ $outfile 
echo "overwriting $outfile" 
ans=all;; 
[Qq]*) exit;; 
*) continue;; 
esac 
else 
if [ -r $outfile ] && [ $ans = all ]; then 
echo "overwriting outfile" 
fi 
/bin/mv getBackbone.temp.$$ $outfile 
fi 
fi 
done 
if [ -r getBackbone.temp.$$ ]; then 
/bin/rm getBackbone.temp.$$ 
fi 
A4.2 >v//iD/)AfAlgorithm 
Open INPUT PDB file A 
Open INPUT PDB file B 
LOOP until end of file A 
read next atom of file A 
get coordinates of atom A 
store coordinates in arrayA at position of atom number 
IF previous atom and current atom not consecutive 
store NULL in intervening ptDsitions in arrayA 
END IF 
IF detect beginning of PDB file chain B 
record position of atom in arrayA 
END IF 
END LOOP 
LOOP until end of file B 
read next atom of file B 
IF beginning of PDB file chain B not detected 
AND arrayB position = start of chain B in file A 
LOOP until detect beginning of chain B 
read next atom of file B 
END LOOP 
ELSE IF beginning of chain B detected 
AND arrayB position < start of chain B in file A 
move to arrayB position = beginning of chain B in file A 
store NULL in intervening positions in arrayB 
ELSE 
get coordinates of atom B 
store coordinates in arrayB 
IF previous atom and current atom not consecutive 
store NULL in intervening positions in arrayB 
END IF 
END IF 
END LOOP 
•DRAW X and Y axes on screen 
DRAW grid lines at every 50 atoms on X and Y axes 
LABEL tick marks at every 50 atoms on X and Y axes 
LOOP for each atom in arrayA 
IF atomA = NULL 
DRAW rectangle on X and Y axes at atom position 
END IF 
END LOOP 
LOOP for each atom in arrayB 
IF atomB = NULL 
DRAW rectangle on X and Y axes at atom position 
END IF 
END LOOP 
LOOP (Y) for each atom in arrayA 
LOOP (X)for each atom in arrayA, position in arrayA < Y 
IF atomA(X) OR atomA(Y) OR atomB(X) OR atomB(Y) = NULL 
DRAW white square at position X,Y 
ELSE 
calculate distanceA between atomA(X) and atomA(Y) 
calculate distanceB between atomB(X) and atomB(Y) 
calculate difference between distanceA and distanceB 
IF difference < = 2 . 5 
DRAW white square at position X,Y 
ELSE IF difference > 2 . 5 AND <= 5 
DRAW yellow square at position X,Y 
ELSE IF difference > 5 AND < = 7 . 5 
DRAW green square at position X,Y 
ELSE IF difference > 7 . 5 
DRAW red square at position X,Y 
END IF 
END IF 
END LOOP 
END LOOP 
Program Size: DDM: Approximately 200 lines of C code 
winDDM: Approximately 550 lines of C++ code plus class libraries 
A4.3 PhiPsiAlgorithm 
Open INPUT PDB file 
Open OUTPUT PDB format files 
READ first residue of input file 
LOOP until end of input file 
READ next residue of input file 
IF previous two residues read are consecutive 
Get coordinates of N, Ca and C from second last residue 
Calculate coefficients for equation of plane through N,Ca,C 
Get coordinates of N from last residue 
Calculate coefficients for equation of plane through Ca,C,N 
Calculate angle between the planes 
divide angle by scaling factor 
copy scaled angle to temperature factor field 
WRITE last residue read to Psi output file 
Get coordinates of N, Ca and C from last residue 
Calculate coefficients for equation of plane through N,Ca,C 
Get coordinates C from second last residue 
Calculate coefficients for equation of plane through C,N,Ca 
Calculate angle between the planes 
divide angle by scaling factor 
copy scaled angle to temperature factor field 
WRITE second last residue read to Phi output file 
ELSE 
copy flag value to temperature factor field 
WRITE last residue read to Psi output file 
copy flag value to temperature factor field 
WRITE second last residue read to Phi output file 
END IF 
END LOOP 
Close INPUT file 
Close OUTPUT file 
Program Size: Approximately 250 lines of C code 
A4 A comparePDB Algorithm 
Open INPUT PDB file A 
Open INPUT PDB file B 
Open OUTPUT PDB format file A 
Open OUTPUT PDB format file B 
READ first residue of input file A 
READ first residue of input file B 
LOOP u n t i l end of input file A of input file B 
LOOP u n t i l current residue of inputA >= current residue of inputB 
READ next residue of inputB 
END LOOP 
LOOP u n t i l current residue of inputB >= current residue of inputA 
READ next residue of inputA 
END LOOP 
IF residueA = residueB 
IF require matching names AND names match 
OR matching names not required 
IF require matching atoms 
DELETE atoms not in both residueA and residueB 
IF require temperature factor difference 
LOOP for each atom in residue 
READ temperature factor of atomA 
multiply by scaling factorA 
READ temperature factor of atomB 
multiply by scaling factorB 
subtract temp factorB from temp factorA 
divide difference by scaling factorC 
write scaled difference to atomA 
write scaled difference to atomB 
END LOOP 
END IF 
END IF 
IF require output of entire residue 
WRITE residueA to output file A 
WRITE residueB to output file B 
ELSE IF require output of backbone only 
WRITE Ca,N,C,0 of residueA to output file A 
WRITE Ca,N,C,0 of residueB to output file B 
ELSE IF require output of trace only 
WRITE Ca of residueA to output file A 
WRITE Ca of residueB to output file B 
END IF 
END IF 
END IF 
READ next residue of inputA 
READ next residue of inputs 
END LOOP 
Close INPUT files 
Close OUTPUT files 
Program Size: Approximately 350 lines of C code 
